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ABSTRACT
The significance of semen in the transmission of genital human 
papillomavirus (HPV) infections was investigated. The suitability of 
dot blot and Southern blot hybridisation assays for use in the 
detection of HPV DNA in semen was assessed. HPV6/11 DNA was 
demonstrated by Southern blot hybridisation in semen from patients 
with intrameatal warts but was not detected in specimens from males 
attending an Assisted Conception Unit (ACU). HPV16 and 18 DNA were 
not detected by Southern blot hybridisation in either population.
Investigations were performed to identify the component of semen 
with which HPV DNA was associated. When pellet and supernatant fractions 
of HPV-positive semen were tested by Southern blot hybridisation, HPV 
positivity was predominantly associated with the cellular pellet 
suggesting that the virus was cell-associated rather than present as 
free virions. Semen specimens were fractionated on Percoll 
gradients. HPV positivity was shown to correlate with the presence of 
cellular material. Attempts to visualise HPV-infected cells using 
immunocytochemistry and in situ hybridisation were unsuccessful.
The polymerase chain reaction (PCR) was investigated for 
the detection of HPV DNA in clinical specimens. Reaction conditions 
were optimised for use of PCR in epidemiological studies. PCR was 
used to detect HPV11, 16 and 31 DNA in cervical material from patients 
attending a Family Planning Clinic (FPC). HPV16 was the most 
prevalent type, detected in 38% of specimens tested. Semen from GUM 
clinic patients and from ACU patients were tested by PCR for HPV types 
11 and 16. HPV16 was the most prevalent, found in 83% and 30% of 
specimens, respectively.
PCR was used in attempts to localise penile HPV infection by 
testing scrapes from the urethra and glans penis of GUM clinic 
patients. Neither HPV11 or HPV16 was associated particularly with 
urethral or external penile surfaces although interpretation was 
difficult due to differences in sampling method efficiencies.
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ABBREVIATIONS
ACU - Assisted Conception Unit
BPV - Bovine papillomavirus
BRL - Bethesda Research Laboratories
CDNA - complementary DNA
CIN - Cervical intrepithelial neoplasia
CIP - calf intestinal alkaline phosphotase
CMV - cytomegalovirus
CPHL - Central Public Health Laboratories
CPM - counts per minute
CRPV - Cottontail rabbit papillomavirus
DEAE - diethylaminoethane
dNTPs - deoxyribonucleotide solutions
dsDNA - double stranded DNA
DAB - 3,3 diaminobenzidine tetrahydochloride
DTT - dithiothreitol
EDTA - ethylene diamino tetracetic acid
EIA - enzyme immunoassay
ELISA - enzyme-linked immunosorbant assay
EV - Epidermidis verruciformis
FPC - Family Planning Clinic
GETL - Glucose (50mM), 10mM EDTA, 25mM Tris HC1, pH8.0, lysozyme
GUM - Genito-urinary Medicine
HPV - human papillomavirus
HSV - herpes simplex virus
IAA - iso-amyl alcohol
IVF - in vitro fertilisation
kb - kilobase
mRNA - messenger RNA
NT - nick translation
PIN - Penile intraepithelial neoplasia
PBS - phosphate buffered saline
PCR - polymerase chain reaction
PEG - polyethylene glycol
PVP - polyvinyl pyrrolidone
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ABBREVIATIONS (Continued)
rpm revolutions per minute
RT room temperature
SDS sodium dodecyl sulphate
SSC Squamous cell carcinoma
Tm melting temperature for nucleic acids
ug represents microgram (gram x 10”®)
ul represents microlitre
uM represents micromolar
UV ultraviolet
VIN Vulval intraepithelial neoplasia
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AIMS OF THE STUDY
The initial aim of this study was to determine whether human 
papillomaviruses were shed into semen, in order to assess the role of 
semen in the sexual transmission of genital HPV infections. An aim 
was also to assess the suitability of semen as a specimen for the 
determination of penile HPV infection and thus for use in prevalence 
studies. In order to achieve this, a sensitive DNA hybridisation 
system for the detection of HPV DNA in semen is required. Early 
targets of the project were to develop efficient HPV DNA probes, 
suitable sample preparation procedures and hybridisation conditions.
Should HPV DNA be detectable in human semen, further aims would 
be to determine with which component it is associated, in what form 
HPV DNA is present in semen, the number of particles (or viral DNA 
copies ) present and whether viral excretion is intermittent, 
continuous or transient.
During the course of the project, a more sensitive means for the 
detection of specific nucleic acid sequences, the Polymerase Chain 
Reaction (PCR), was described. A further aim was to develop, optimise 
and assess PCR for the detection of HPV sequences in clinical 
specimens. This technique was then available for the determination of 
the prevalence of genital HPV infection in males (as indicated by the 
presence of HPV DNA in semen and in penile scrapes) and of cervical 
infections in females in order to determine the distribution of 
infection in the general population.
12
CHAPTER 1
INTRODUCTION
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1 The Epidemiology of Squamous Cell Carcinoma of the Cervix
1.1 Cervical carcinoma- a changing pattern.
Carcinoma of the cervix is a major health problem throughout the
world. After breast cancer, it is the second most common malignancy
of females world-wide. In Africa, India and certain other Asian
countries it is the commonest malignancy of women; in Europe and North
1
America it is the fourth commonest . Whilst, generally, the mortality
associated with cervical carcinoma in developed countries decreased by
2approximately 30% between 1960 and 1980 , in England and Wales there 
was a less marked decline during this period (Table 1a) and latest 
figures show that approximately 2000 deaths a year still result from
3
it (Table 1b). Also, mortality due to cervical carcinoma in patients 
under 30 has increased since the late nineteen sixties^ (figure 1) and 
a more aggressive cancer of the cervix in which there is rapid 
progression from precancerous to invasive cancerous state may partly
5
be responsible for this trend .
1.2 Evidence For The Role Of An Infectious Agent.
The epidemiology of cervical malignancy suggests a role for an
6 35infectious agent in its aetiology ' . The first observation
suggesting involvement of a sexually transmitted infectious agent 
dates back to 1843 when Domenico Rigoni-Stern, a physician in Verona, 
Italy noted significant differences in occurrence in celibate women 
when compared to married women and widows . It has been shown that 
men whose wives have cervical carcinoma are about three times more 
likely to develop penile cancer than those with wives without cervical
Table 1
a) Trends in cervical cancer death certification rates in England and 
Wales from 1951-1984: reported deaths per million population
1951-55 56-60 61-65 66-70 71-75 76-80 81-84
20-4y 1 1 1 2 3 3 3
25-9 10 9 5 7 10 15 22
30-4 30 37 18 15 22 32 42
35-9 58 74 66 44 38 52 53
40-4 93 119 134 105 67 59 77
45-9 136 154 180 176 130 92 83
50-4 203 181 187 203 190 157 108
55-9' 254 197 178 201 198 192 143
60-4 285 246 220 192 198 213 188
65-9 304 284 232 216 192 202 191
70-4 315 313 273 246 204 199 194
All 117 112 104 98 87 84 77
Whilst generally mortalities associated with cervical carcinoma in 
developed countries decreased by approximately 30% between 1960-1980, 
mortality rates in England and Wales decreased by only 19% during this 
period. There was only a 34% reduction in mortality rates recorded 
between 1951 and 1985.
b) Cervical cancer death certifications in England and Wales for 1988
Age Reported mortalities
<1-19 0
20-24 10
25-29 23
30-34 84
35-39 113
40-44 142
45-49 118
50-54 137
55-59 154
60-64 194
65-69 ' 286
70-74 239
75-79 198
80-84 131
85-89 81
90-94 28
>95 4
All ages 1942
The actual number of registered mortalities for periods 1971-75, 
1976-80 and 1981-85 were 10,993, 10,659 and 9,764 respectively. There 
were 1,942 cervical carcinoma-associated mortalities in 1988, showing 
that the trend of approximately 2000 deaths a year continues.
15
Figure 1 Age distribution of cervical neoplasia-associated 
mortalities from 1971-1985
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While the to ta l number of m orta lities  associated w ith cervical 
neoplasia have decreased during th is  period, i t  can be seen that the 
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Data taken from OPCS Series DH1; no. 19.
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Q
cancer and that there is a similarly increased risk of women for
Q
developing cervical carcinoma if their spouse has penile carcinoma .
Furthermore, there is an increased incidence of cervical carcinoma in
women married to men whose previous spouse had genital tract 
10malignancy . These observations lend support to the hypothesis that 
a sexually transmitted infectious agent has a role in the aetiology of 
cervical carcinoma although other explanations e.g. exposure to 
carcinogens are also feasible.
1.3 Risk Factors For Cervical Neoplasia - Sexual Behaviour
Whereas in early studies, sexual variables were described in 
terms of marital status and reproductive history, more recent studies 
specifically identify the two main risk factors to be the number of
sexual partners, irrespective of marital status, and young age at
11 12 13first sexual intercourse ' no associations have been
demonstrated relating to the frequency of coitus, patterns of
menstruation, number of pregnancies, abortions or deliveries.
Associations between cervical carcinoma and multiple marriages and a
history of sexually transmitted disease (STD) have been suggested but
these are regarded as co-variables of the number of sexual partners.
Similarly a link between use of oral contraceptives, especially use
over many years, and cervical neoplasia has been suggested but has not 
10been confirmed . Again, epidemiological data relating to oral 
contraceptive use are difficult to interpret because of the large 
number of confounding variables such as age, factors relating to 
sexual behaviour and the problems of establishing appropriate control
groups. Barrier forms of contraception have been suggested to have a
35protective effect against cervical carcinoma however, and this
17
again is supportive of the theory that a sexually transmitted agent is 
involved.
For many years, cervical carcinoma research focused only on 
sexual activity of the female without considering that the male may 
play an important role in the aetiology of the disease. Indirect 
evidence was provided by studies demonstrating geographic clusters of 
penile and cervical carcinomas and by the demonstration that wives of
men previously married to women with cervical cancer were themselves
1 0at increased risk . Direct evidence came from a study by Buckley et 
53al which focused on females with only one lifetime sexual partner.
When the husbands of these women were interviewed, it was found that
the relative risk of cervical malignancy increased with the number of
sexual partners that the husband reported. The husbands of affected
women were more likely to have had sexually transmitted disease, to
have had early sexual experiences and to have had affairs during
marriage. This gave rise to the concept of the 'high risk male'.
It has been postulated that sperm alone or more specifically the
basic proteins, histones and protamines could be carcinogenic. It was
demonstrated in the early 1970's that calf thymus histones were able
54to transform BHK21 cells to a malignant state in vitro . In 1976,
Reid proposed that the basic proteins of spermatozoa, when released
onto the cervix following sexual intercourse, could alter target cells
on the cervix in such a way that could begin the process of neoplastic 
55change . Analysis of the basic protein composition of semen has
shown individual differences'^ and has given support to the concept of
the high risk male. A lower risk of cervical carcinoma in women whose
57partners have had vasectomies has also been reported . The concept 
that sperm or certain sperm products may be carcinogenic to the human
genital tract is far from proven but nonetheless cannot totally be 
disregarded.
1.4 Factors Not Related To Sexual Behaviour
Certain factors not related to sexual activity have been studied 
in investigations of the aetiology of cervical carcinoma. These 
include cigarette smoking, immunosupression, hormonal factors, 
occupation/social class and diet. Much research has gone into the 
association of smoking and cervical neoplasia. A recent study by
CQ
Brock et al found high relative risk estimates for smokers of 30 or 
more cigarettes a day compared with non-smokers. Ex-smokers, 
individuals who have smoked in the past but no longer do so, had 
varying degrees of increased risk relating to the time period since
being a.regular smoker. Nicotine and its major metabolite, cotinine,
59have been detected in cervical fluid of smokers and two biological 
mechanisms have been suggested by which smoking may be involved in the 
aetiology of cervical neoplasia; these substances may act as 
carcinogens directly on cervical cells or may produce local 
immunosupression^ facilitating proliferation of an infectious agent 
with subsequent abnormal cellular development. Immunodeficiency by 
other causes has been shown to be a significant risk factor. In renal 
transplant recipients, the incidence of cervical intraepithelial 
neoplasia (CIN), a series of progressive epithelial abnormalities 
which appear to be the precursor lesion of cervical carcinoma, is
C 1
seven times that found in a non-immunosupressed population and a
fi2study by Hughes and colleagues similarly found a six-fold increase 
in the occurrence of CIN grades II and III in patients with Hodgkin's 
disease compared with matched controls.
19
It has long been shown that cancer of the cervix is far more
common in women of lower social class than it is women of higher
classes, whether social class is measured in terms of the woman's
occupation, her husband's occupation, the type of dwelling occupied,
family income or educational status. It may be that this observation,
and observations relating to diet, can be explained in terms of other
risk factors for cervical carcinoma such as sexual behaviour (of the
woman or her consort) and/or cigarette smoking. Beral analysed
standardised mortality rates from cervical cancer and found the
highest rates to be in wives of husbands whose work entails travel
away from home and in whom sexually transmitted diseases, suggested to
be indicative of extra-marital intercourse, are relatively common, 
fi 4Robinson , however, has suggested that occupational exposure of the 
male to carcinogens might play a part in the aetiology of cervical 
cancer. She points out that the wives of men working in dirty jobs, 
perhaps with inadequate washing facilities, tend to have high 
standardised mortality rates and suggests that dust, metals, 
chemicals, tar and machine oils may be of aetiological importance.
It can be seen then that there is much evidence to suggest that a 
sexually-transmitted infectious agent is involved in the aetiology of 
cervical carcinoma. However, there is evidence to support roles for 
other risk factors and it seems likely that there are several 
interrelated enviromental factors including infectious agents whose 
accumulative effect results in development of cervical neoplasia. 
Attempts to eliminate or at least reduce the occurrence of cervical 
carcinoma are likely to depend upon the identification and prevention 
of spread of any infectious agent(s) involved.
20
1.5 Candidate Pathogens
The search for an infectious agent as a "cause" of cervical
carcinoma probably began in earnest in the 1940's when it was noted
that women with cervical carcinoma were more likely to have syphilis
1 4than the general population , but promiscuity was a confounding
variable.and when this was taken into account the association 
15disappeared . Similarly a role for Trichomonas vaginalis was
suspected at one time as trichomoniasis may be associated with
1 6cervical atypia or with invasive carcinoma , but again infection is
likely to be a covariable of promiscuity. Chlamydia trachomatis is a
1 7common cause of inflammatory cervical disease with infection often
1 8becoming chronic and persisting for many months . Several
seroepidemiological studies have shown associations between C.
19 20trachomatis and cervical dysplasia t an association which still
holds good after careful matching with controls for numbers of sexual 
21partners . Isolation of C. trachomatis from dysplasic cervical 
material has not been demonstrated and the possible involvement of C 
trachomatis still requires clarification.
1.6 Viruses In Cervical Cancer
DNA tumour viruses are thought to contribute to the development
22of 20% of cancers throughout the world . Several virus types have
23been shown to cause cancer in animals and cause-and-effeet 
associations have been suggested for certain viruses and malignancies 
of humans, the strongest association being that between hepatitis B 
virus and primary hepatocellular carcinoma 24. There is similarly
strong evidence between human T-cell lymphotropic virus type I (HTLV-
25I) and T-cell lymphomas in Southern Japanese . Epstein Barr virus
21
has been implicated in the aetiology of Burkitt's lymphoma in tropical 
African populations and nasopharyngeal carcinoma (NPC) of the 
Southern Chinese. However, although EBV infection occurs world-wide, 
the malignancies occur in well-defined geographical foci, indicating 
that other factors interact with EBV infection to produce malignancy.
The role of viruses in human genital cancer has been discussed
28since 1968, when Rawls and colleagues described higher antibody
titres to herpes simplex virus (HSV) type 2 in patients with cervical
cancer compared to matched controls. In addition, the percentage of
seroreactive women was consistently higher in the patient group than
in the control group. Although most subsequent studies confirmed
these findings, there was remarkable variation in the percentage of
seropositive patients depending on the socio-economic background of
the patient population investigated. Some studies showed that
50% or less of the patients with genital cancer had evidence of past 
29HSV exposure . More recent studies using molecular hybridisation 
techniques to detect HSV in human genital tumours showed that only a 
small proportion (approximately 17%) of cervical cancer tumours
contained HSV-related DNA sequences 30,31  ^ However, the ability of
■ao "3 "3
HSV2 and human cytomegalovirus (CMV) DNA to transform cells in
vitro to an oncogenic phenotype has been demonstrated and both HSV
•2 *3
and CMV can be shown to induce cervical tumours in mice . In vitro
transformation models have shown that following conversion of infected
cells to a transformed state, herpes virus DNA sequences may be lost
(ie deleted from the host genetic material) during cell DNA
replication. This has given rise to the concept of a 'hit and run'
30mechanism for cellular transformation. Consequently, a role as a 
co-factor in the genesis of a proportion of cervical carcinomas cannot
22
be excluded.
In contrast to HSV2, human papillomavirus DNA sequences are
found in a very high proportion, up to 90%, of all cervical cancer 
34biopsies . This has led to research interest focusing more on the 
possible association of HPV infections in the aetiology of human 
genital cancer.
1.7 Human Papillomavirus Infection and Genital Warts
Investigations into the possible involvement of papillomavirus
infections in the aetiology of human genital carcinomas were initiated
in 1972, stimulated by the observation of conversion of genital warts
(condylomata acuminata) to a malignant phenotype. In an early
experiment, published in 1974, zur Hausen and colleagues attempted
hybridisation of nucleic acid derived from human plantar wart virus
with DNA from cervical cancer biopsies and condylomata acuminata and
obtained entirely negative results. At this time it was not known
that many HPV types exist. The isolation and characterisation of
papillomavirus DNA from human genital warts proved difficult due to
insufficient material from patients and the lack of an in vitro
culture system for human papillomaviruses. In 1980, however, Gissman 
37and zur Hausen reported the isolation of sufficient DNA from one
individual genital wart to enable them to partially characterise it.
Subsequently, they were able to clone the DNA into bacterial vectors
and to characterise it further . Sufficient quantities of the viral
DNA (HPV type 6) were now available for analysis of clinical material
39from genital sites. Kryzek and his colleagues used non-stringent 
hybridisation conditions and reported that several distinct species of 
papillomaviruses could be detected in anogenital warts. Shortly after
23
this, HPV 11 was isolated from a laryngeal papilloma and was then also 
demonstrated to exist in an additional percentage of genital warts^®. 
HPV-6 and HPV-11 were shown to be closely related agents being found 
in about 60% and 30% of genital warts respectively. These studies 
showed that at least two distinct types of papillomaviruses could 
regularly infect the human genital tract.
1.8 Papillomaviruses And Cervical Cancer: Early Research
Although at this time attention was mainly focused on the
detection of HPV in genital warts, the possibility of an aetiological
role for HPV in the development of cervical neoplasia was being
considered. Cytological investigations of cervical material by
Mei sels in 1976 ^  and 1977 ^  showed characteristic features of
papillomavirus infection, particularly "koilocytotic" cells in cases
of cervical dysplasia (Figure 2). The term koilocyte was introduced
by Koss and Durfee^ to describe a cell change of unknown cause
associated with precancer. The koilocyte is now regarded as a
specific indicator of HPV infection. Papillomavirus particles were
demonstrated by electron microscopy in koilocytotic cells of
dysplastic cervical t i s s u e ^ ' A d d i t i o n a l  findings supported the
view that papillomavirus infections may be involved in the development
4 fiof cervical dysplasia. Shah and colleagues in 1980 used a group- 
specific antiserum which reacted with capsid proteins of a wide 
variety of animal and human papillomaviruses to demonstrate that 
approximately 50% of cervical dysplasias expressed papillomavirus 
antigens in superficial layers and koilocytotic cells. However, when 
material from cervical carcinoma was tested by DNA hybridisation using 
the cloned DNA of HPV-6 and HPV-11 the results were all negative
24
a) Koilocytes in histological section of biopsy specimen
The pattern seen in cervical biopsies is characterised by the 
presence of large cells with relatively small but irregular and 
hyperchromatic nuclei surrounded by clear cytoplasm. The term 
koilocytic atypia is derived from the Greek word 'koilos' meaning 
hollow or cavity, and examples of these can be seen throughout upper 
cell layers of this.section.
b) Koilocytes in cervical smears
Characteristic features of koilocytic atypia in Papanicolaou- 
stained smears are abnormal, moderately enlarged cells with 
hyperchromatic single or multiple nuclei and a distinct perinuclear 
zone either clear or more lightly stained than peripheral cytoplasm.
Figure 2
a)
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although a small number of biopsies reacted under conditions of low
stringency^. This brought about the detection of related but not
identical DNA sequences and shortly after this two new HPV types were
isolated directly from carcinoma tissue using the same procedures.
47 4ftThese are now designated HPV-16 and HPV-18 . It soon became
apparent that HPV types 16 and 18 could frequently be detected in 
material from cervical carcinomas. Subsequently, many other HPV types 
have been found associated with benign and malignant lesions of the 
genital tract (Table 2).
2 The Biology And Classification Of Human Papillomaviruses
2.1 Taxonomy
Papillomaviruses are double-stranded DNA viruses. They are
currently taxonomically classified as a genus within the family
Papovaviridae, the other genus being the polyoma virus group.
Papillomaviruses and polyomaviruses are quite dissimilar;
papillomaviruses have a larger genome (7,900 versus 5,200 base pairs),
a larger virion capsid (55 versus 44nM) and a completely different
49genomic organisation . Polyomaviruses can be passaged in tissue 
culture, transform cell lines in vitro and are oncogenic in animals of 
other species although they do not usually cause widespread disease in 
their natural hosts. Conversely, papillomaviruses cannot be 
propagated in tissue culture and are generally highly host-specific. 
Papillomavirus infections tend to be site-specific, resulting in 
benign tumours of skin and other tissues, some of which evolve into 
squamous carcinomas.
Papillomaviruses are a divergent group of evolutionarily related
26
Table 2
Human Papillomaviruses Detected in Genital Lesions
HPV type Source lesion Year Reference
6 Condylomata acuminata 1981 37,38
11 Laryngeal papilloma 1982 40
16 Cervical carcinoma 1983 47
18 Cervical carcinoma 1984 48
31 Cervical dysplasia 1986 160
33 Cervical carcinoma 1986 161
35' Endocervical adenocarcinoma 1987 162
39 Bowenoid papule 1987 163
42 Vulval papilloma 1987 163
45 . Cervical dysplasia 1987 164
51 Cervical condyloma 1988 165
27
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viruses which have similar biological properties ; however,
individual papillomaviruses vary in host specificity, in site of
predilection and degree of oncogenicity. All papillomaviruses for
whom DNA sequence data is available have a similar pattern of genomic
fiftorganisation in that potential protein coding regions , the open
reading frames (ORF's), are preserved within different papillomavirus
types (figure 3). Papillomavirus infections can be found in a very
broad range of hosts, human papillomaviruses comprising the largest
1 72(and most studied) group with more than 60 known types . Other
members of scientific importance include the rabbit, bovine, canine,
173ovine, elk, and rodent papillomaviridae .
2.2 Virion Structure
Papillomavirus particles (figure 4) are approximately 55nm in
diameter consisting of a central core of viral DNA enclosed within an
outer capsid of viral protein. The capsid consists of 72 capsomers
which are arranged in a symmetrical, 20-sided (icosahedral) pattern.
Two different families of structural protein are present; a major
protein of 54000 daltons molecular weight and a minor protein of 76000 
69daltons . Major capsid proteins of animal and human papillomavirus
types have been found to be highly cross-reactive whereas minor capsid
70proteins appear to be type-specific . However, group-and type- 
specific epitopes appear to be present on both major and minor 
proteins.
2.3 DNA Organisation
Papillomavirus DNA is a double stranded, circular molecule with 
an average molecular weight of 5x10^ daltons, corresponding to
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Figure 3
Genomic conservation among Papillomaviruses
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ORFs of human papillomavirus types 1a, 6b, and 16, bovine 
papillomavirus type 1 and cottontail rabbit showing similarities in 
arrangement. Shaded areas indicate coding regions, black regions 
represent non-coding regions. Dotted lines within ORFs represent 
first methionine codon, which could serve as a start point for 
translation.
(Adapted from Pettersson U et al. 1986; In : Papillomaviruses. Ciba 
Foundation Symposium 120. pp 23-38, J Wiley and Sons, Chichester).
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Figure 4 
Morphology of papillomaviruses
Electron micrograph of human papillomavirus particles 
demonstrating icosahedral symmetry. These were extracted from a skin 
lesion of the foot. Magnification x200000. Micrograph kindly provided 
by Dr Anne Field
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approximately 7900 base pairs. The viral DNA is complexed with 
histones (H2a, H2b, H3,H4) derived from the natural host and condensed 
into nucleosomes^'. All of the viral genetic information is coded 
for on one DNA strand, and could potentially code for 7-8 proteins^®. 
When separated from the viral nuclear proteins the DNA is super-coiled 
(form I). Cleavage of one strand of DNA by bacterial restriction 
endonuclease enzymes results in a relaxed circle (form II) while 
cleavage of both strands gives a linear molecule- form III. The three
c rj
forms can be separated by gel electrophoresis .
The DNA sequences of 12 papillomavirus types from several animal 
species has been elucidated. Alignment of sequenced papillomavirus 
DNAs has shown a highly conserved pattern of open reading frames
CO
(figure.3) . As with other DNA viruses, ORFs are classified as
"early" (E) or "late" (L) according to when transcription of the 
genomic region occurs during the process of viral replication. Early 
genes , which constitute a 69% portion of the papillomavirus genome, 
are expressed shortly after infection and prior to DNA replication. 
Products of these genes have functions controlling DNA replication and 
expression of viral DNA. In the case of tumour viruses, early gene 
products are also involved in transformation of the host cell. Late 
genes code for structural proteins of viral particles and are 
activated during the final stages of the viral cycle. There is also 
a non-coding region of approximately 1kb, the long control region 
(LCR), which contains transcriptional control signals such as RNA 
Polymerase II promoters and polyadenylation sites.
The ability of bovine papillomavirus (BPV) type 1 to transform
c 1
rodent cells and to be maintained as a plasmid has facilitated study 
of the potential functions of the early ORFs. Table 3 shows the
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functions attributed to the individual ORFs. E1, the largest ORF, is
well conserved between papillomaviruses and has been shown, at least
for BPV-1, to be involved in replication and maintenance of 100 to 200
52episomal DNA copies in rodent cell cultures . Two E2 products have 
been detected; one has been shown to transactivate a conditional 
transcriptional enhancer in the LCR affecting transcription of other 
HPV ORF. The other E2 product inhibits the transactivator. The E4 
ORF overlaps E2 in all papillomavirus genomes sequenced. The HPV1 E4 
ORF product may play a role in virus maturation and could be present
in the virion and consequently is not strictly an 'Early' gene. In
6ftBPV1 E5 appears to be a transforming gene whilst the E6 and E7
regions of HPV have attracted the most attention because of their
89transforming ability . E7 product is very similar in structure and
function to the adenovirus E1A protein which is also a potent
1 66transforming agent . It has always to be remembered of course that 
these functions have been determined in an in vitro system and it 
seems likely that in the natural infection the gene products are 
multifunctional and interactive with host factors (figure 5).
2.4 Classification
At present, 66 types of human papillomavirus have been described. 
Types are not differentiated serologically as no specific antibodies 
are available due to the lack of an in vitro culture system.
Instead, the genus is divided into genotypes depending on the homology 
( in terms of percentage cross-hybridisation) of their DNA sequence.
An arbitrary figure of 50% has been set such that if a new
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Table 3
Proposed functions of major ORF products of papillomaviruses
Open Reading Frame Function
transformation and immortalisation 
trans-activation of transcription 
maintenance of episomal copy number 
(BPV-1 and HPV8)
regulation of viral transcription 
transactivation, DNA binding 
transrepression, DNA binding 
viral DNA replication (BPV-1) 
transformation (BPV-1)
capsid proteins 
viral particle maturation
(taken from Vousden KH. 1989. Human papillomaviruses and cervical 
carcinoma. Cancer cells; 1;no. 2; 43-50)
Early proteins: 
E6 and E7
E2
E2 full length 
E2 3' portion 
E1 
E5
Late proteins: 
L1 and L2 
E4
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Figure 5
A,B; Transcription factors including nuclear factor 1 (NF1), AP1 and 
probably oct-1 bind to enhancer/promoter region of LCR. HPV-16 can 
be stimulated by progesterone similarly binding to a region of the 
LCR.
C; Two different gene products from E2 have been identified; the 3' 
terminal part and a full-length E2 protein. E2 binding sites in 
several positions within the genome activate linked promoters under 
the influence of the full-length protein whilst the effect is 
antagonised by the short E2 protein, thus providng a feedback system 
for maintenace of constant transcription levels.
D; At least two proteins derived from E1 interact to control copy 
number. A function in the 3' segment termed R (for replication) 
boosts DNA amplification whilst the 5' segment codes for a function M 
(modulator) which exerts copy number control. Their targets or 
mechanisms have not been elucidated, nor the regulation processes for 
expression of R and M
E; in vitro transformation assays have implicated the genes E5 
and E6 of BPV-1 and E6 and E7 of HPV16 in the transformation process. 
Likely mechanisms include stimulation of host chromosomal replication, 
modulation of cellular factors (similar to adenovirus E1a protein) and 
binding of the anti-oncogene RB.
F; The promoter for transcription of late regions is upstream to 
'early' promoters and consequently transcripts include the complete 
early region which are subsequently spliced out. For Late transcripts 
to be produced, stop and polyadenylation signals upstream to the L1 
region have to be disregarded. This appears to occurr in upper 
epithelial strata but not in lower strata.
(adapted from Bernard H-U. 1990. FEMS Microbiol Immunol; 64; 201-06)
Figure 5
Control of papillomavirus replication: virus and host
interactions
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papillomavirus is isolated and has a genome with 50% or greater 
homology with a virus previously isolated, it will be considered that 
type. If the homology is less than 50% it forms a new type'*®. Cross­
hybridisation between papillomaviruses of different types is variable 
with some types having no detectable homology e.g. HPV 1,2,4, and 7 
whilst others may be grouped on the basis of variable cross-reaction 
e.g. HPV 2,3,10 and 28 show 25-38% homology. Several types are 
subdivided because although showing extensive cross-hybridisation, 
they have a number of different restriction endonuclease sites, e.g.
HPV 6<\has one site for Eco R1 but HPV 6b has no site. These subtypes are 
frequently isolated and widely distributed, so are stable point 
mutations or deletions.
2.5 Viral replication
Both human and animal papillomaviruses have a predilection for 
stratified squamous epithelia and virus replication is synchronised 
with epithelial differentiation processes (Figure 6). As cells 
divide and move up through the epithelium they differentiate, 
facilitating replication of the virus. Only the upper few layers
/rc cc
contain infectious virus ' , although viral DNA can be detected in
fi7the lower layers . The dependence of papillomavirus replication upon 
cellular differentiation processes probably accounts for our inability
to culture these viruses using traditional cell monolayer systems.
X
3: Clinical manifestations of human papillomavirus infection
Table 4 lists the currently recognised HPV types and their 
clinical manifestations. Lesions caused are generally benign but some
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Figure 6
Infection of cells of the basal epithelial layer is thought to | 
occur via microfissures, abrasions or wounds. These cells are non- 
permissive for papillomavirus maturation but behave like transformed 
cells with no interruption of the differentiation processes. With the I 
onset of differentiation, vegetative viral DNA replication takes i
place, followed by viral capsid protein synthesis and virion formation i 
as the cells migrate through the strata spinosum and granulosum states 
(Orth G, Breitburd F, Favre M, Croissant 0. 1977. Cold Spring
Harbor Conf Cell Proliferation} 4; 1043-1068). Virus multiplication 
leads to alterations in the host expression of terminal j
differentiation processes, giving rise to recognisable cytological and 
ultrastructural features some of which are type-specific. These 
alterations were observed as early as the onset of vegetative viral 
DNA replication (Croissant 0, Breitburd F, Orth G. 1985. Clin 
Dermatol; 3; (4)} 43-55) and in HPV1-induced papillomas appeared 
together with the expression of the viral E4 gene product. 
Papillomaviruses no longer replicate when benign lesions become 
malignant. ,
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Table 4
Human Papillomavirus Types and their Clinical Manifestations
HPV type subtypes Clinical Manifestation
1 a-c plantar warts
2 • a-e common, plantar and palatal warts
3 a,b flat warts,juvenile warts,mild forms of EV
4 palmer and planter warts
5 a,b macular lesions of EV, squamous cell
carcinoma (SSC)
6 a-f condylomata acuminata, CIN I-III, laryngeal
papillomas
7 hand warts in butchers, meat handlers
8 macular lesions and SSC in EV
9 macular and flat lesions of EV
10 a,b flat warts
11 a,b condylomata acuminata, CIN I-III, laryngeal
papillomas
12 macular and flat lesions of EV
13 a,b Focal Epithelial Hyperplasia of oral mucosa
14 a,b macular and flat lesions of EV, SSC
15 macular and flat lesions of EV
16 condylomata acuminata,CINI-III, Bowenoid
papulosis, cancer of the penis, cervix, 
bronchus and sinuses
17 a,b macular and flat lesions of EV, SCC
18 condylomata acuminata,CIN I-III,VIN I-III,
penile and cervical carcinoma
19 macular and flat lesions of EV
20 macular and flat lesions of EV, SCC
21• flat lesions of EV
22 macular lesions of EV
23 macular and flat lesions of EV
24 macular and flat lesions of EV
25 macular and flat lesions of EV
26 cutaneous warts in immunosupressed
27 cutaneous lesions in immunosupressed
28 cutaneous flat wart lesions
29 cutaneous warts
30 SSC of the larynx, CIN I and II
31 CIN I-III, carcinoma of the cervix
32 FEH in oral mucosa, oral papillomas
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Table 4 (cont'd)
Human Papillomavirus Types and their Clinical Manifestations
HPV type subtypes Clinical Manifestation
33 Bowenoid papulosis, CIN I-III, cervical
carcinoma
34 Bowen's Disease, CIN
35 CIN I-III, cervical carcinoma
36 actinic keratosis, benign EV lesions
37 . keratoacanthoma
38 malignant melanoma
39 cervical carcinoma, CIN I-II, Bowenoid
papulosis 
PIN, CIN
multiple flat warts of the skin, SSC 
genital papillomas, Bowenoid papulosis,
CIN 
CIN
CIN, cervical carcinoma 
benign EV lesions 
macular and flat warts of EV 
SSC of the skin 
cutaneous flat warts 
macular and flat lesions of EV 
CIN I, cervical carcinoma 
CIN, cervical carcinoma 
CIN
condylomata acuminata 
Bowenoid papulosis 
CIN, cervical carcinoma
CIN, skin warts, inverted nasal papillomas 
CIN 
CIN
cutaneous warts
CIN; Cervical intraepithelial neoplasia PIN; Penile intraepithelial 
neoplasia
VIN; Vulval intraepithelial neoplasia EV; Epidermodysplasia 
verruciformis
FEH; Focal epithelial hyperplasia
(adapted from Syrjanen KJ. 1989. APMIS: 97: 957-970)
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have a more marked tendency for malignant transformation. Common hand 
warts are the most recognisable cutaneous lesions, but human 
papillomaviruses are also associated with a variety of lesions on many 
squamous epithelial surfaces including the cervix, vaginal wall, 
vulva, penis, larynx, tongue, buccal mucosa and conjunctiva.
3.1 Non-genital HPV infections
HPV infections of non-genital sites have not attracted clinical 
or research interest to the same extent as genital HPV infections as 
generally they are clinically insignificant and not a major cause of 
morbidity. However, of particular interest has been the disease 
epidermodysplasia verruciformis (EV), a rare lifelong skin disease 
which begins during infancy or childhood and is characterised by 
refractory, disseminated, flat wart-like lesions and pigmented 
macules. Approximately one-third of EV patients develop multiple skin 
carcinomas which generally arise during the third or fourth decade of 
life. EV is a multifactorial disease which involves genetic 
susceptibility, immunological incompetence and extrinsic factors, in 
addition to infection with specific HPV types. At least fifteen types 
of HPV have been found associated with benign lesions of EV patients 
but malignant lesions are usually restricted to HPV5 and, less 
frequently, HPV8.
Renal allograft recipients who have been iatrogenically 
immunosuppressed to prevent kidney transplant rejection are another 
group particularly at risk for warts and premalignant or malignant 
lesions of the skin. Forty three percent of patients surveyed from 3
14c
months to 9 years after transplantation developed warts . It is 
interesting that in recipients of bone marrow transplants in whom
39
virus infections (particularly herpesviruses) are frequent, HPV
infections are not prevalent. It seems that only long-lasting
immunosupression such as in renal transplantation favours HPV
infection. The skin cancers in kidney transplant recipients are often
multiple and usually located in light-exposed areas. The tumour
1 4-fifrequency varies with the amount of sun exposure , the highest rate
1 47reported in Caucasians living in subtropical climate (8.6%) . This
represents a 7 to 20-fold increase over the incidence in the general 
1 48population . Some patients have a widespread warts and skin
1 49cancers and present as an EV-like syndrome . However, the warts
observed in such patients are usually flat warts or common warts,
which are associated with HPV types found in the general
1 49population. Lutzner et al observed 2 immunosupressed
renal allograft recipients with skin lesions induced by HPV5.
Previously, had only been found only in EV patients. HPV5 DNA
sequences have also been detected in a carcinoma in situ and in a
1 sosquamous cell carcinoma of a renal allograph recipient . This is 
the only evidence for a role of EV-type HPVs in the cutaneous squamous 
cell carcinomas of renal allograft recipients.
EV patients and renal allograft recipients have been of 
particular interest as they'facilitate opportunities to study the 
multifactorial processes of virus-associated malignant disease.
3.2 Genital HPV infections
The most readily recognised genital lesion of HPV infection is 
the condyloma acuminata, the frank, exophytic genital wart.
Condylomata acuminata are rarely seen in infancy or in those from 5 to 
15 years of age but occur most frequently in sexually active adults. In
40
female patients the lesions often develop on the labia majora and
minora, the vagina and the perineum. In males lesions are found on
the penis, the urinary meatus, and the scrotum. Perianal lesions are
seen in both sexes. The reported incidence of condylomata acuminata,
has increased rapidly over the past 10 to 12 years, with rates per
100,000.population increasing from 84.3 in 1977 to 260.1 in 198771.
Genital HPV infections may also manifest as flat warts, bowenoid
papulosis and as other less well-characterised lesions. Many
infections in males and females are subclinical ie there is no obvious
lesion or disease. Infection may be detectable using the aceto-white
test in which application of 5% acetic acid turns infected epithelium
white. There is strong evidence to suggest that cervical
intraepithelial neoplasia (CIN) is also a manifestation of human
151papillomavirus infection . Similarly, there appears to be 
association between HPV infection and PIN (penile intraepithelial 
neoplasia ), VIN (vulval intraepithelial neoplasia) and VAIN (vaginal 
intraepithelial neoplasia)^2, 153, 154^
4: Evidence to suggest an association between HPV and cervical carcinoma
4.1 Transformation studies using HPV16 and HPV18 DNA
The oncogenic potential of HPV DNA has been studied using in
vitro transformation assays of rodent and human cell lines. The E6/E7
region of HPV16 and 18 virus has been shown to be sufficient to
transform established lines of rodent fibroblasts (NIH 3T3 cells) but
full transformation of primary rodent cells required the presence of
89an oncogene e.g. the activated ras gene (but not with activated c- 
myc). Studies of human cell transformation have shown that HPV16 and
41
HPV 18 DNA immortalised primary human epithelial cells (human foreskin
keratinocytes) whereas HPV 6 and HPV11 DNA did not^^-^^. Such
generated cell lines, unlike transformed rodent cells, are non-
tumourigenic in nude mice, although they contain and express HPV RNA
and protein. Studies have shown that in cervical tumours HPV16 or
HPV18 DNA is integrated into the host genome^^'^^ and that
integration occurs at random sites in the host genome but usually
within the E1 or E2 ORF's of the virus genome . It is thought that
integration could release E6 and E7 from normal regulation by virus-
encoded transcriptional control proteins such as E2 which are situated
103downstream of the integration point . Transcription of the E6-E7
region consistently occurs in cervical tumour cells and is possibly
91essential for the maintenance of the transformed state . Three
transcripts from this region, shown in figure 7, have been detected in
92cervical tumour tissue . It is predicted that the spliced E6 forms, 
E6 , are transcribed in HPV 16 and HPV18 but not in HPV types 6 and 11 
as these viruses lack donor/acceptor sequences in the middle of E6.
The E6/E7 genes of HPV6, an HPV type associated generally with benign
lesions, has been demonstrated to have a greatly reduced transforming
93capacity compared to that of HPV16 . It has been suggested that the
E6 transcript allows more efficient translation of E7 which is the
94major transforming gene . E7 is similar to the E1a gene of
adenovirus in that it can trans-activate the adenovirus E2 gene. E7
also has similar amino acid sequences to two transcripts of E1a which
are known to co-operate with the ras gene in the transformation of 
95primary rat cells . Several mechanisms for E6/E7-induced 
transformation have been suggested including inactivation of tumour 
supressor proteins (Rb, p53) and host cell DNA binding. Both the E7
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Figure 7
The three trancripts of HPV16 E6/E7
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 1 i I i _ i  i i i i i i
Open E6
reading | | E7
frames 97 |---------------------1
562 867
Transcripts i) I_________________________________IE6
ii) I V N_____________________ IE6* I
iii)l I--'* ''-.l________________ |E6*I
Nucleotide sequences of donor and acceptor splice sites 
donor Acceptor
(A/c AG\GTA/gAGT) ([PY]6XCAG\GG/t)
E6* I 224gag\gtatat232 399tgttaattag\gtgtattaa417
E6* II 224gag\gtatat232 516cttgttgcag\atcatcaagaacacgtag543
(modified from Smotkin et al. 1989. J Virol;63; 3; 1441-47)
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and E6 product of HPV, like adenovirus Ela, have been demonstrated to
QC
bind the product of the retinoblastoma gene (Rb) . The Rb protein is
97a tumour-suppressor gene ( an 'anti-oncogene' ), thought to be
involved in cell-signalling pathways and an important component of
cell differentiation and ceil-cycle regulation. Mutation of this gene
or removal/inactivation of the gene product by binding or complexing
with a viral product could disrupt normal control mechanisms and
result in a reduced capacity for differentiation and greater potential
for cell replication ie it will predispose the host to tumour
formation. The E7 proteins of HPV types 16 and 18 have been shown to
98have a higher affinity for Rb than HPV type 6 E7 , thus perhaps again
supporting the concept of differing malignant potentials between HPV
1 ?7types. The E6 and E7 oncoproteins are related structurally and
contain a repeated Cys-X-X-Cys motif. This sequence is
characteristic of proteins containing 'zinc fingers' which bind to 
1 58cellular DNA . The E6 protein contains four Cys-X-X-Cys motifs
while the E7 contains two. The E6 oncoproteins of HPV16 and HPV18
also bind another tumour suppressor protein, the cellular p53 
1 59protein . It has been observed that HPV-transformed keratinocytes
are resistant to the growth inhibitor, TGF-beta, and that this is
1 9ftmediated by the E7 gene . It is thought that the E7 protein 
interferes with the cells normal response to TGF-beta by eliminating 
its transcriptional inhibition of c-myc. This has led to speculation 
that the removal of transcription inhibition is due to the binding of 
E7 to the Rb protein and that one of the normal cellular functions of 
pRB may be to modulate c-myc expression.
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Table 5
Potentially oncogenic animal papillomaviruses
Host/virus benign lesion malignancy site
Cottontail rabbit 
papillomavirus1
papilloma SSC haired skin
Bovine papilloma 
virus type 411
papilloma SSC alimentary
tract
Equine veneral 
papi1lomavirus111
papilloma SSC lower genital
tract
Canine oral 
papillomavirus IV
papilloma SSC oral mucosa
mastomys natalensis keratoacanthoma 
papillomavirusv
SSC haired skin
Rhesus monkey 
papillomavirusVI
SSC lower genital 
tract
SSC : Squamous cell carcinoma 
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4.2 Papillomavirus-related malignancies in animals
In the 1930's, it was noted that Cottontail Rabbit Papilloma
Virus (CRPV) leads to benign warts in its natural host, 25% of which
became malignant after 12 months. When domestic rabbits were infected
with CRPV, there was a far higher rate of malignant conversion
within a shorter time period. This malignant change could be further
accelerated by the application of certain carcinogens such as coal 
87tar . Similar interactions between papillomaviruses and carcinogen 
have been demonstrated subsequently in other species. In Scotland 
there is an area of high incidence of bovine alimentary tract 
carcinomas which appear to be associated with bovine papillomavirus 
type 4 infection (BPV4). Although alimentary tract papillomatosis is 
widespread, the distribution of alimentary tract carcinoma is sharply 
confined to upland areas of Scotland and Northern England where 
bracken fern is prevalent and is a significant component of the cattle 
diet. Bracken is thought to contain a carcinogen which when regularly 
ingested by cattle with BPV4-associated papillomatosis of the 
alimentary canal, can lead to carcinomas of the digestive tract.
Alone, ingestion of bracken produces benign lesions but when BPV 
papillomas are concurrently present, a synergistic effect between the
DO
two results in a high rate of malignant conversion . Associations 
between papillomavirus infections and malignancies have also been 
suggested in equine, canine, rodent and non-human primate species 
(Table 5).
J
4.3 HPV-related malignancies at non-genital sites
Human papillomavirus types seem to differ in their oncogenic 
potential. This has clearly been demonstrated in HPV types associated
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with epidermodysplasia verruciformis (EV). Multiple flat warts appear
in early childhood with an average onset at. 9 years with life-long
persistance. EV-patients suffer from congenital defects in their
cell-mediated immunity which makes them susceptible to infection with
99a large number of papillomavirus types , few of which are detected
in warts from individuals not affected by EV. The DNA's of at least
fourteen 'EV-specific' HPV types have been cloned including HPV5, 8,
9, 12, 14, 15, 17, and 19-25. The viruses induce very flat warts and
macular lesions, spread over the skin of extremities, head and trunk.
Approximately 25% of EV patients develop squamous cell carcinomas on
average 20 years after onset. Only a few HPV types persist in the
malignant tumours, particularly HPV5 and HPV8. This predominant
association of EV carcinomas with HPV5 and HPV8 (and, to a lesser
extent, with some other HPV types), contrasts with the diversity of
the HPV types detected in benign lesions and suggests that specific
HPV types are a major risk factor in the development of EV
carcinomas. The delay between the onset of infection and the
development of invasive carcinomas suggests a multistage process.
These carcinomas occur predominantly on light-exposed sites and it
has been suggested that ultraviolet radiations from the sun have a
99role in malignant conversion . Thus common features exist between 
papillomavirus-associated carcinomas in humans and animals ie 
association with specific papillomavirus types, the long delay 
required for tumour development and the involvement of co-factors.
4.4 Epidemiological evidence relating to cervical malignancy
It is now well known that HPV lesions are frequently (50-80%) 
associated with CIN, carcinoma in situ (CIS) and invasive cell 
carcinomas^^. HPV6 and/or HPV11 DNA is found in the vast majority
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(greater than 90%) of condylomata acuminata (genital warts), 
approximately one third of mild cervical dysplasia (CIN1 and 2) and
7 0only rarely in more advanced dysplasias and genital cancer . HPV16 
and 18 are consistently associated with invasive cervical, vulval or
TO 7 A
penile cancers and the higher grades of dysplasia ' .  A study by
7 fiCampion et al demonstrated that progression of minor degrees of 
dyskaryosis to CIN III are more likely if associated with HPV16 rather 
than if associated with HPV6. Many other HPV types have also been 
found associated with premalignant or malignant lesions of the genital 
tract (Table 2). HPV16 and 18 DNAs have also been found as integrated 
sequences in the genome of certain cell lines (Caski, Hela and SiHa
70 7 E
cells) originally derived from cervical cancers ' .  The genomes of
HPV types 16 and 18 are found mainly as free episomes in
90 100intraepithelial neoplasias ' and as DNA sequences integrated into
101 10?the host genome in invasive cervical cancers ' . In general the
histology of genital lesion correlates well with the presence of 
specific viral types but about 10% of benign condylomas contain HPV 16
C 0
or 18 and some carcinomas contain sequences of HPV11 (Figure 8).
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Malignant conversion of benign warts has been described many times
and mixtures of viral types have also been reported in some biopsy 
57specimens . Nevertheless, the data are in some respects incomplete 
in that in many of the studies do not satisfy certain basic
on
epidemiological requirements . The main criticisms have been small 
sample numbers and a lack of adequate cross-matching of controls in 
terms of age, socio-economic class, sexual activity or other relevant 
variables. Other groups have presented data which suggests that the 
association of 'high-risk' HPV types and cervical neoplasia is far 
less clear. HPV16 and HPV18 DNA have been demonstrated in
47
77 78 79cytologically normal cervical specimens ' '  and one study showed 
that after age adjustment, there was no difference between HPV16 
detection rates in cervical material from cases of cervical cancer and 
controls®^.
Serological means of investigating the role of HPV types 16 and 
18 in the aetiology of cervical neoplasia have been hindered by the 
lack of native antigen, due in turn to the lack of an in vitro 
culture system and the presence of only extremely low numbers of 
intact particles within cervical lesions. Early serological 
approaches involved the use of antigen preparations from other more 
readily available papillomavirus types. Baird has reported use of an 
enzyme immunoassay (EIA) employing a group cross-reactive antigen
on
obtained from bovine papillomavirus type 2 . Antibodies were
detected in 95% of patients with anogenital warts, 60% of those with
CIN, 93% of those with cervical cancer and 0-7% of various control
groups. However, disrupted HPV1 and HPV2 virions were used as
antigens in EIAs to test patients with CIN, seropositivity correlated
better with a previous history of cutaneous warts than with 
1 f\lCIN . These results highlight the lack of type-specificity offered 
by this approach.
The ability to clone HPV DNA into expression vectors 
has provided another means by which type specific antigens for use in 
serological assays may be generated. Seropositivity to an L1-HPV16
fusion protein in CIN patients attending an STD clinic was only 2%
1 fifiwhen tested by Western blot whereas 47% had antibodies to an 
L2-fusion protein. Whilst L1- and L2-fusion proteins may be of value 
in type-specific prevalence studies, use as an indicator of
QO
progression to cervical malignancy is unlikely. Cason et al did
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not detect statistically significant differences between antibody 
levels to HPV16 L1 ORF product in sera from patients with CIN and from
Q 1
children. Kochel , using B-gal fusion proteins and
Western blot analysis expressed in E. coli, tested sera from women
with cervical cancer for antibodies to the E4 and E7 open reading
frames of HPV types 16 and HPV18. Antibodies to either ORF of HPV16
and/or HPV18 were found in 63% of cases compared with 6.5% and 9.8% of
1 69control groups. Jochmus-Kudielka and colleagues demonstrated that 
seropositivity to an E4-HPV16 fusion protein was common among 11-20 
year olds suggesting that this antigen is a marker for virus 
replication. The same study suggested that antibodies to an E7-HPV16 
fusion protein increased in a step-wise fashion when age-matched 
patients with CINI/II, CINIII, cervical cancer or controls were 
compared, leading to a postulation that HPV16 E7 protein may be
on
indicative of malignant progression. However, Jenison et al , also
using recombinant proteins in Western blot tests, found similar
antibody levels to HPV16 E7 (13-14%) in Sexually-Transmitted Disease
(STD) clinic patients and in hospitalised children. Anomalies between
studies probaly reflect the limitations of fusion proteins as 
1 70antigens (the lack of post-transcriptional modification, the 
binding of the viral protein to an irrelevant moiety, their fragility, 
insolubility and contamination with native E coli proteins).
Synthetic peptide antigens, predicted from DNA sequences, offer an 
alternative to fusion proteins and have been used in
seroepidemiological studies. ELISA tests for HPV16 peptides were used
171to test sera from patients with CIN . Antibodies were detected in 
upto 70% of patients but no biopsies were taken for HPV DNA typing and 
consequently interpretation as to whether the antibodies detected
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Figure 8
HPV type and oncogenic potential
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DEGREE OF ONCOGENIC CHANGE
HPV types 6, 11, 16, 18 and 31 are found to varying degrees in 
association with condylomata, CIN and cervical carcinoma. HPV types 6 
and 11 are the most prevalent type associated with benign condylomata 
but least commonly found in CIN grades II and above. Conversely, HPV 
types 16, 18 and 31 are infrequently found associated with condylomata 
and CIN I lesions but are predominant in the more severe CIN grades. 
This has given rise to the concept of varying oncogenic potential 
between HPV types.
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were type specific or cross-reactive is difficult. Antibodies to a
peptide corresponding to a region of the L1-HPV16 which was poorly
coserved among HPV types were detected in 91% of HPV16 DNA-positive
170CIN patients but in only 24% of children . Thus there is some 
serological evidence which supports an association between specific 
HPV types and cervical abnormality. However, despite the potential 
for the generation of useful reagents using recombinant DNA 
technology, full evaluation of reagents prepared in this way remains 
a problem. Interpretation of findings is difficult as the means to 
demonstrate absolute type specificity (ie lack of cross-reactivity) 
are not currently available.
5: Transmission of genital-type HPVs
There is much evidence to suggest that 'genital type' HPVs (ie 
types 6, 11, 16, 18, 31 etc. compared with skin types 1,2 5,8 etc.)
are sexually-transmitted. Genital warts have been shown to be sexually
84 1 04transmissible ' by the demonstration of a high prevalence of
benign warts in the sexual partners of patients with genital warts.
Similarly, penile intraepithelial neoplasia (PIN) was found to be
approximately 30 times more prevalent in partners of females with CIN
105than in control groups . Some studies have suggested sexual
transmission based on the demonstration of concurrent infection with
1n fi—108specific HPV types in both sexual partners . Schneider
1 0 fiet al .detected HPV DNA in penile scrapes from the sexual partners 
of females with cervical HPV infection and found viral types to be 
identical in both partners in 87% of cases. Similarly high 
correlations between types isolated from sexual partners have been 
reported^
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Whilst it seems likely that genital-type HPVs are predominantly
sexually transmitted, evidence has been accumulating which suggests
that this is not the only route. There is now strong evidence that
laryngeal papilloma in children are caused by HPV11 and it is thought
1 OQthat infection is acquired during passage through the birth canal .
Further evidence of infection via this route is provided by a report
of conjunctival infection with HPV6 in a boy born to a mother with
110genital warts at the time of birth . The route(s) via which
children acquire condylomata acuminata is far less certain. There is
much controversy as to whether the observation of condylomata
acuminata in children is a marker of sexual abuse and whilst it is
clear that some condylomata acuminata in children are sexually
transmitted ie through sexual abuse, this does not appear always to be
the case.. Warts at genital sites in children have been found to
contain HPV2 DNA (a 'skin-type' HPV) and in these cases it seems more
likely that infection has occurred by self-inoculation (by scratching
112etc.) from common warts of the hand . However, in the majority of
cases, genital HPV types, particularly types 6 and 11, are detected. 
113Roche et al examined genital wart material from five children and 
detected HPV6 in three cases, HPV6 or 11 in one case and HPV 16 in one 
case. Sexual abuse was suspected in three of the five cases but there 
was no suspicion of sexual abuse in the other two cases. It was 
suggested that the child with HPV16 infection may have been 
accidentally infected from her grandmother, who had a genital 
papilloma, and with whom she occasionally shared a bath. Again there 
is evidence that prenatal or congenital transmission can result in 
genital infection. Recurrent penile condylomata were reported in a 
child of only 17 months whose mother had histological evidence of
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cervical condylomata and it was concluded that infection had been
111congenitally transmitted . HPV DNAs (types 6 and 16) have been
114found associated with foreskins of normal newborns . HPV DNA has
also been demonstrated in amniotic fluids suggesting that an in utero
mechanism may exist (although sampling difficulties were experienced
116and contamination from other sites may have occurred) . To what
extent non-sexual transmission of genital-type HPV occurs is currently
82unknown. Jenison et al reported prevalences for HPV 6 and 16 DNA in 
oral mucosal scrapings from preschool children of 24% and 19% 
respectively which suggests that transmission congenitally, 
perinatally or perhaps via fomites frequently occurs.
Summary
Over recent years much research has been carried out into the 
association of human papillomaviruses with certain human malignancies, 
particularly cervical carcinoma. Many epidemiological studies have 
been performed to determine whether a causal role exists for certain 
HPV types and to identify co-factors. Molecular studies have 
demonstrated the ability of the papillomavirus genome to transform 
cells in vitro and thus confirm the oncogenic potential of these 
viruses. Despite the sophisticated nature of these investigations 
there are still gaps in our knowledge as to the true prevalence of 
infection in the community and the means of transmission from infected 
to uninfected individuals. Studies have been carried out to determine 
the prevalence of cervical HPV infection but little research has been 
directed towards infections of males. There is a need to establish 
the true prevalence of genital HPV infections in both sexes in order 
to re-evaluate the role of these viruses in malignant progression of
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HPV lesions, and to assess co-factors associated with the malignant 
processes. The findings of such investigations may have implications 
for subsequent attempts to form strategies for a reduction in the 
incidence of cervical malignancy. Interpretation of prevalence data 
obtained would be aided by greater information of transmission routes. 
Whilst it has become clear that there are other means of transmission, 
HPV infections of the genital tract are thought to be predominantly 
sexually transmitted and until the mechanisms and importance of this 
route have been fully elucidated, the significance of non-sexual 
routes remains difficult to assess.
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SECTION ONE
DNA HYBRIDISATION FOR THE DETECTION OF HUMAN PAPILLOMAVIRUSES IN SEMEN
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FOREWORD TO SECTION ONE
Many studies have been carried out to determine the prevalence of
HPV infection in females, particularly cervical infection. Few
studies have been directed towards infections of males. However, HPV
129infections of the genital tract appear to be sexually transmitted
and an association with benign, premalignant and malignant lesions in
116both sexes has been suggested . HPV16 and 18 DNA have been found in
1 30tissue from cases of penile cancer and condylomata acuminata of the
penis, associated with HPV types 6 and 11, are commonly observed.
Although HPV's are epitheliotropic and genital transmission is likely
to be by direct contact between infected and uninfected epithelial
surfaces, little research has been done to study the role of semen in
the transmission of HPV from male to female. Clinical studies of
males with genital warts have shown that urethral lesions are common
118and may be the sole manifestation of infection . Oriel showed that
23% of 191 men who presented at a sexually transmitted disease clinic
119with genital warts had involvement of the urethral meatus and it
has been suggested that the male urethra is a potential reservoir for 
120HPV and may be responsible for transmission from subclinical
infection. Only one study has reported attempts to detect HPV in
121semen. Ostrow et al. detected HPV DNA types 2 and 5 in the semen 
of two patients with epidermodysplasia verruciformis (a rare 
autosomal recessive condition - see page 27) and of a third patient 
with chronic lymphatic leukaemia. These HPV types are not commonly
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associated with lesions of the genital tract. These authors did not
detect any HPV DNA, using DNA probes for types 6, 11 and 16 under
conditions of low stringency, in the semen of 10 healthy donors. They
concluded, however, that semen-mediated transmission of HPV could
occur although unequivocal evidence would require a larger study.
If semen has a role in the transmission of genital HPV
infections, it may be possible for HPVs to be transmitted via
artificial insemination procedures. A study at an Artificial
Insemination by Donor (AID) centre of men presenting as semen donors
122showed that some have genital infections such as warts . There may 
be serious long term consequences to a recipient resulting from
transmission of HPV, particularly of HPV type 16 which is associated
1 26with high grade neoplastic lesions of the cervix .
The aim of this study was to determine whether HPV DNA could be 
detected in human semen in order to assess the significance of semen 
in the transmission of sexually-transmitted human papillomavirus 
infections and to determine the prevalence of genital HPV infection in 
males. Thus the first question is 'Can HPV DNA be detected in human 
semen?' In order to answer this, a sensitive DNA hybridisation system 
is required. This involves the production of efficient HPV DNA 
probes, the development of suitable sample preparation procedures and 
the establishment of appropriate hybridisation conditions. Early 
targets of the project were to achieve these.
If HPV DNA is present, it may be contained in complete virions 
which could be either cell-associated or shed into the seminal fluid, 
or it may exist within infected cells or perhaps within the
57
spermatazoa in integrated or episomal forms. Further aims of the 
study were to determine in what form HPV DNA is present in semen, 
the number of particles ( or viral DNA copies ) present and whether 
viral excretion is intermittent, continuous or transient.
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MATERIALS AND METHODS
1 Source of human papillomavirus DNA, vector DNA and bacterial cells
The genomes of HPV6, 11, 16 and 18 were the generous gifts of 
Professor H. zur Hausen and colleagues, Deutsches 
Krebsforschungszentrum, Heidelberg, Federal Republic of Germany.
The Riboprobe Gemini Transcription plasmids, pGem-1 and pGem-2 vectors 
are produced by Promega Biotec and were obtained commercially.
E.coli strain HB101 were obtained from Bethesda Research 
Laboratories Ltd. ( Cat No.8260 SA)
2 Purification of plasmid DNA
Ecoli strain HB101 cells, previously stored at -30°C (10% 
glycerol as cryoprotective agent ) were thawed and 0.1ml inoculated 
into 5ml L-broth. After incubation at 37° for 3-5 hours, 1ml of this 
was inoculated into 100ml L-broth/ampicillin (50ug/ml) and agitated 
(250rpm) overnight at 37°C. The plasmid were extracted from the 
bacterial cell culture by alkaline lysis performed as follows. The 
bacterial cell suspension was poured into 2x50ml centrifuge tubes and 
the bacteria pelleted by centrifugation for 10 minutes at 4,000rpm in 
an FSE chilspin 2 (2,750g). The supernatent was discarded leaving the 
pellet as dry as possible. -The cell pellet was resuspended in 2.5ml 
of ice-cold GETL (50mM glucose, 10mM EDTA, 25mM Tris HCL pH 8.0,
4mg/ml lysozyme) per 50ml culture and placed on ice for 30 minutes.
5ml (per 50ml culture) NaOH/SDS (0.2M sodium hydroxide, 1% SDS) were 
added to the tube, the contents were gently mixed by inversion and 
placed on ice. for 5 minutes. 3.5ml of potassium acetate solution 
(60ml 5M potassium acetate, 11.5ml glacial acetic acid and 28.5ml
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]water) were added, mixed by inversion and replaced on ice for 5 
minutes. The slurries were transferred to an Oakridge centrifuge tube 
and centrifuged at 20,000rpm (48000g)for 1 hour in the Sorval SS34 
angle rotor of a Sorval RC5C centrifuge. The supernatant was 
transferred to a sterile glass Universal container and an equal volume 
of phenol/chloroform added. After thorough mixing and centrifugation 
at 4,000rpm (2,700g) for ten minutes, the top phase was collected and 
another volume of phenol/chloroform added. Again the tube contents 
were thoroughly mixed and centrifuged as before. The top phase was 
collected and an equal volume of chloroform/iso-amyl alcohol added. 
After centrifugation the top phase was collected and to it was added 
two volumes of absolute ethanol. After thorough mixing this was left 
at room temperature for 5 minutes (or longer at 4°C) during which time 
the nucleic acid precipitated. The DNA was recovered by pelleting at 
9,000 rpm (13000g) for 30minutes in SS34 swing out rotor of the RC5C 
centrifuge. The pelleted nucleic acid was resuspended in 2ml TE and 
transferred to a 15ml glass tube. A half volume of 7.5M ammonium 
acetate and two and a half volumes ethanol were added. The tube was 
placed at -20°C for at least two hours in order to precipitate the DNA 
and then centrifuged at 9000rpm (10000g) for 30 minutes to pellet the 
DNA. This pellet was then washed with 80% ethanol, the supernatant 
discarded and the pellet dried under vacuum. The nucleic acid was 
resuspended in 0.5ml TE.
3 Preliminary restriction enzyme analysis of plasmid DNA 
Plasmid inserts were checked at this stage by restriction enzyme 
digestion. A 2ul aliquot of the preparations were digested with RNAse 
A (1 mg/ml) at 37°C for 30 minutes and then mixed with 10 x reaction 
buffer, distilled water and 10 units of the appropriate restriction
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enzyme and digested for 2 hours at 37°C. Orange G / ficoll loading 
buffer was added and the digested DNA was electrophoresed on a 
horizontal minigel using Hindlll digested lambda DNA as molecular 
weight markers.
4 Caesium chloride gradient purification
A caesium chloride solution with a refractive index of 1.4 was 
prepared by the addition of 24 grams CsCl to 19mls TE. 4ml of this 
were placed in a clear centrifuge tube (Beckman Ultra Clear). 750ul
of the extracted plasmid DNA and 60ul 10mg/ml ethidium bromide were 
added and the contents carefully mixed. Having checked the refractive 
index to be 1.39, tubes were centrifuged for 70 hours at 38000rpm 
(125,000g) in a Beckmann L8-80m centrifuge and SW55 Ti rotor. After 
centrifugation, the tubes were examined under ultraviolet light. The 
HPV/plasmid DNA band was collected and placed in a 15ml glass Corex 
tube. The volume was made up to 3ml with TE. Ethidium bromide was 
removed by 5x 1.5ml washes with amyl alcohol. After each wash, the 
top layer was removed and discarded. After the final wash, the top 
phase was removed and discarded and the volume of the lower phase made 
up to 3ml with sterile distilled water. 1.5ml 7.5M ammonium acetate 
and 9ml absolute ethanol were added, the tube contents carefully mixed 
and then placed at -20°C for 2 hours. After centrifugation at 10000g 
for 30 minutes the supernatant was discarded and the DNA dried under 
vacuum. This was resuspended in 0.5ml TE, 50ul 5M sodium chloride and 
2.5ml ethanol were added and the tube placed at -20°C for 2 hours.
The DNA was pelletted by centrifugation, washed with 70% ethanol, 
dried under vacuum and resuspended in 50ul TE. A 2ul aliquot of each 
preparation was digested with the appropriate restriction enzyme for 2 
hours at 37°C and electrophoresed on a horizontal gel together with
an undigested aliquot and Hindlll-digested lamda DNA as size markers. 
DNA concentration estimations were made from these gels.
5 Preparative agarose gels (Based on Yang, Lis and Wu )
25-1OOug HPV/plasmid were digested with 2ul 'high7 concentration 
(50 units/ul) restriction enzyme in the presence of the appropriate 
reaction buffer overnight at 37°C. The final volume was 150ul. A 2ul 
aliquot was electrophoresed and examined to ensure that digestion was 
complete. 25ul Orange G/Ficoll were added to the digest and this was 
loaded onto the slot of a 0.9% agarose gel and electrophoresed for 
approximately 2 hours. The gel was stained with ethidium bromide, 
destained with H2O and examined under long wave ultraviolet light.
The plasmid band was excised from the agarose gel and discarded. This 
created a trough into which the required HPV DNA band could be 
electrophoresed. The gel tray was replaced in the electrophoresis 
tank but the buffer level was reduced to slightly below the upper face 
of the gel. The trough created by excision of the plasmid band was 
filled with buffer. Current was reapplied to the gel tank and the HPV 
DNA band was monitored under long wave UV light as it migrated towards 
and into the trough. The buffer in the trough was collected every few 
minutes and replaced with fresh buffer. This was continued until all 
the HPV DNA band had migrated into the trough and had been collected.
6 Purification of DNA following preparative gel electrophoresis
The eluted DNA was extracted twice with an equal volume of 
phenol/chloroform and once with an equal volume of chloroform /IAA and 
precipitated with 1/10 volume 5M sodium choride and two volumes 
ethanol. After refrigeration at -20°C for 2 hours, the DNA was 
pelle ;ted by centrifugation, washed and dried under vacuum as 
described previously. The DNA was resuspended in 0.5ml TE and a 2ul
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aliquot electrophoresed on a 0.9% agarose gel.
7 Further purification of DNA for use in ligation reactions
When DNA was for use in ligation procedure,ie when subcloned into 
the pGemini vectors, further purification was performed by use of the 
Elutip system (Schleicher + Schuell, W. Germany) or Geneclean system 
(Bio 101, USA). Manufacturers instructions were followed.
8 Purification of pGemini vectors for use in ligation reactions
The pGemini 1 and 2 vectors are produced by Promega and are 
available commercially. 1ug pGeml DNA was digested with the 
appropriate restriction enzyme for 2 hours. Complete digestion was 
confirmed by electrophoresing a small aliquot on a minigel. The 
digested DNA was extracted twice with phenol/chloroform and once with 
chloroform/lAA (24:1) and precipitated by the addition of a half 
volume 7.5M ammonium acetate and 2 and a half volumes of absolute 
ethanol. The DNA was pelleted by centrifugation (BHG 
microfuge,12300g, 15 minutes), washed with 70% ethanol, dried under 
vacuum and resuspended in 43ul TE.
9 Phosphotase treatment of vector to minimise recircularisation 
during ligation
To 43ul vector DNA was added 5ul 0.01u/ul calf intestinal 
alkaline phosphatase (CIP) and 5ul 10x reaction buffer (0.5M Tris.Cl 
ph 9.0, 10mM magnesium chloride, 1mM zinc chloride, 10mM spermidine). 
This was incubated at 37°C for 30minutes after which time a further 
0.05 unit CAP was added. Incubation at 37°C was resumed for a further 
30 minutes. 45ul sterile distilled water and 5ul 10% SDS were added 
and the mixture heated at 68°C for 15 minutes. The DNA was extracted 
twice with phenol/chloroform and once with chloroform/IAA. 50ul 7.5M 
ammonium acetate and 200ul ethanol were added and precipitation
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Table 6: Preparation of Ligation Mixes for HPV DNAs
and pGemini plasmid
Ligation h20 10x pGemini HPV T4
mix Lig Bffr DNA DNA Ligas
(ul) (ul) (ul) (ul) (ul)
1 2 1 1 5 1
2 2 1 5 1
3 6 1 1 1 1
4 7 1 1 0 1
5 7 1 0 1 1
6 8 1 0 0 1
Ligation mixes for the ligation of HPV types 6, -11, -16 and -18 
DNAs and pGemini plasmid DNA were prepared as shown. 10x ligation 
buffer consisted of 0.5M Tris-HCl pH7.6, 100mM MgC^/ 100mM 
dithiothreitol, 5mM ATP and 500ug/ml BSA. pGemini DNA and HPV DNA 
were used at concentrations of 100ug/ml and 200ug/ml respectively. 
Ligation was carried out at 16°C overnight
occurred at -20°C. The DNA was pellet ed by microcentrifugation, 
washed, dried under vacuum and resuspended in 1Oul 1OMM Tris pH8.0 
Purified vector DNA and purified 'insert' HPV DNA to be cloned were 
electrophoresed in an agarose minigel to determine relative 
concentrations.
10 Ligation
Ligation mixes were prepared as in Table 6. 10x ligation buffer
consisted of 0.5M Tris-HCl pH 7.6, 100mM MgC^/ 100mM dithiothreitol, 
5mM ATP and 500ug/ml BSA. T4 DNA ligase was obtained from Gibco BRL 
(0.5-2U/ul). The ligation mixes were incubated at 16°C overnight.
11 Preparation of transformation-competent E.coli cells by the 
calcium chloride procedure
1 32Based on the method of Mandel and Higa , this method has been
5 7found to give yields of 10-10 transformants per microgram of intact 
pBR322 DNA when used with E.coli strain HB101.
An overnight culture of HB101 cells was obtained by the 
inoculation of 5ml L broth with 0.1ml E.coli suspension and incubating 
at 37°C for 18 hours. A 500ml flask containing 100ml L broth was 
inoculated with 1ml of the overnight E.coli culture and incubated at 
37°C with vigorous shaking (200rpm) until a density of approximately
n
5x10 cells/ml was obtained. The relationship between optical density 
and the number of viable bacteria per millilitre of culture for E.coli 
strain HB101 is
1 OD^5q=0.5( 5x 107 cells/ml) 
and the correct density was obtained in 2-3 hours. The culture 
was chilled on ice for 10 minutes and centrifuged at 4000g for 5 
minutes at 4°C. The supernatant was discarded and the cells 
resuspended in the 50ml ice-cold, sterile solution of 50mM calcium
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chloride and 10mM Tris( pH 8.0). The cell suspension was placed in an
ice-bath for 15 minutes and then centrifuged at 4000g for 5 minutes at
4°C. The supernatant was discarded and the cells resuspended in 6.6ml
ice-cold, sterile solution of 50mM calcium chloride and Tris (pH 8.0).
The suspension was dispensed into 0.2ml aliquots and refrigerated at
4°C overnight as this has been found to increase the transformation
131efficiency fourfold to sixfold .
12 Transformation
Two 200ul aliquots of calcium chloride-treated cells for each 
ligation mix, and an additional two for transformation controls, were 
placed on ice. 1ul and 5ul aliquots of each ligation mix were added 
to an aliquot of competent cells and gently mixed for 5 seconds. A 
transformation control of 0.01ug/ml pGeml DNA was treated similarly. 
These were incubated on ice for 30 minutes, heat shocked at 42°C for 
45 seconds and replaced on ice for two minutes. 900ul L-broth 
containing 0.2% glucose and 1OmM magnesium chloride, 1OmM magnesium 
sulphate were added to each tube and these were placed at 37°C with 
vigorous agitation for 1 hour. 100ul of each were spread onto an 
L-ampicillin agar plate. The remaining 900ul was centrifuged briefly, 
the E.coli cell pellet resuspended in 100ul L-broth and plated onto 
L-ampicillin plates. The agar plates were incubated at 37°C overnight 
and examined for ampicillin-resistant colonies.
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13 Analysis of colonies for HPV/pGem recombinants
Colonies were picked from the L-agar plates, inoculated into 5ml 
L-ampicillin broths and incubated overnight at 37°C with vigorous 
shaking. 1.5ml of each culture was transferred to an eppendorf tube 
and centrifuged for 1 minute. The supernatant was removed by 
aspiration leaving the pellet as dry as possible. The pellet was 
resuspended in 100ul GETL by vortexing and left at room temperature 
for 5 minutes. 200ul sodium hydroxide/SDS were added, the tube 
contents were mixed by inversion and placed on ice for 5 minutes.
150ul ice-cold potassium acetate were added, mixed by inversion and 
replaced on ice for a further 5 minutes. The tubes were then 
centrifuged for 5 minutes and the supernatant transferred to a clean 
tube. Nucleic acid was extracted twice with an equal volume of 
phenol/.chloroform and once with an equal volume of chloroform/lAA.
Two volumes of ethanol were added, the tubes vortexed and left at room 
temperature for 2 minutes and then centrifuged for 5 minutes. The 
supernatant was removed and 1ml 70% ethanol added to the pellet. The 
tubes were inverted to wash the pellet and then centrifuged for 5 
minutes. The supernatant was removed and the pellet ed nucleic acid 
dried under vacuum. The pellet was resuspended in 30ul TE. 10ul of 
each was transferred to a microfuge tube and 3ul orange G/ficoll 
loading buffer were added. These were electrophoresed in a 0.9% 
agarose gel, the nucleic acid stained with ethidium bromide and the 
gel photographed. Preparations showing DNA bands of the appropriate 
size (HPV insert + vector approximately 10.8kb) were selected. A 
further 1Oul of extracted nucleic acid was taken and RNAse A was added 
to a final concentration of 20ug/ml. 1.5ul restriction enzyme buffer 
and 1ul of restiction enzyme were added followed by incubation at 37°C
for 1 hour. The results of the digest were analysed by 
electrophoresis through a 0.9% agarose gel.
14 Extraction of HPV/pGem DNA from 100ml E.coli cell cultures
HPV/pGem recombinant DNAs were extracted using the procedures 
recommended by the manufacturer (Promega Biotec).
Transfected E.Coli were cultured overnight in 100ml of L- 
broth/ampicillin at 37°C with agitation. The cells were pelleted by 
centrifugation at 3000g for 15 minutes at 4°C and the pellet 
resuspended in 2ml freshly prepared STE buffer (25mM Tris-HCl, pH7.5,
1OmM EDTA, 15% sucrose and 2mg/ml lysozyme). The cells were 
resuspended by gentle pipetting up and down with a 10ml pipette and 
then placed on ice water for 20 minutes. This was then carefully 
mixed with 4ml 0.2M sodium hydroxide, 1% SDS and replaced in ice 
water for 20 minutes. After centrifugation at 15000 rpm (26,000g) in 
the SS34 rotor of the Sorvall RC5 centrifuge for 15 minutes the 
supernatant was transferred to another tube and 20ul RNAse A (1 mg/ml) 
added. This was incubated at 37°C for 20 minutes. Two 
phenol/chloroform extractions were performed followed by DNA 
precipitation with two volumes of ethanol. The DNA was pelleted by 
centrifugation at 9000rpm (13000g) in the SS34 rotor of a Beckman RC5 
centrifuge for 30 minutes. The pellet was resuspended in 0.5ml 
sterile distilled water and mixed with 125ul 4M sodium chloride,
725ul 13% polyethylene glycol were added and the tube incubated in ice 
water for 1 hour. After centrifugation at 9000rpm (SS34 rotor, 
Sorvall RC5) for 15 minutes the supernatant was removed and the pellet 
washed with 70% ethanol. The DNA was dried under vacuum and 
resuspended in 0.5ml TE. DNA yield and purity were determined by
reading absorbance at 260/280nm using a Beckman DU6 spectrophotometer.
15 Excision of HPV DNA from vector sequences
Restriction enzyme digestion of HPV/pGem DNA and separation of 
HPV DNA from vector sequences by preparative gel electrophoresis were 
as described earlier (method 5)
16 Restriction enzyme mapping of HPV/pGem clones to determine 
orientation of insert
Recloning by the method described is non-directional ie. two
insert orientations are possible. The orientation of the HPV insert
within the vector was determined by restriction enzyme digestion of
HPV6b and HPV 18 with Bam H1 and of HPV11 and 16 with EcoRl.
1ug HPV/pGem construct was digested for 2 hours at 37°C with 10
units of restriction enzyme in a total volume of 20ul. After addition
of 3 ul orange G/ficoll, the preparation was electrophoresed in a 0.9%
agarose gel. DNA bands were stained with ethidium bromide and
photographed. Band sizes were deduced by comparison with those of
Hind Ill-digested lambda DNA electrophoresed in parallel.
■ao
17 Preparation of P-labelled HPV DNA probes
32P-labelled probes were generated using the random priming 
procedure (Oligolabelling kit, Pharmacia or Multiprime labelling kit, 
Amersham International). Reaction mixes consisted of :-
xul HPV DNA, (50ng) previously heated to 95°C for 5 minutes
and then on ice for two minutes.
5ul 32P-dCTP (50uCi, 3000 Ci/mmol)
1Oul Reagent mix
Distilled water to a final volume of 49ul.
1ul Klenow fragment
These were incubated at 37°C for 1 hour. Unincorporated labelled
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nucleotides were removed by passing the reaction mix through a
■32
Sephadex G-50 column (NICK column, Pharmacia). The P-labelled probe
was eluted in a 400 volume of TE.
DEAE binding assay: 1ul radiolabelled probe was diluted 1:10 by the 
addition of 9ul TE and 2ul of this was then spotted onto two 2.5cm 
squares of DEAE paper. One of the two DEAE square was washed as 
follows:
. 5 x 5  minutes in 5% sodium hydrogen phoshate 
1 x 1 minute in sterile distilled water
1 x 1 minute in methylated spirit
The washed square was allowed to air dry and then both this and 
the unwashed square were counted using a Beckman LS 1801 scintillation 
counter. The fraction of input radioactivity that had been 
incorporated (value F) was calculated by dividing the DEAE-bound 
counts by the total input counts. Specific activities were calculated 
from the counts obtained using the following formula:
SA = (uCi)(2.2 x 109)(F)
Di+[(1.3 x 103)(F)(uCi/S)]
Where SA = Specific activity of DNA (dpm/ug)
uCi = uCi of dCTP in reaction
F = Fraction of input label incorporated into DNA
D^ = Mass of input DNA template (in ng)
S = Specific activity of dCTP (in Ci/mmol=uCi/nmol)
Radiolabelled DNA probes were stored at 4°C until required. 
Immediately prior to use, probes were denatured at 95°C for 10 
minutes.
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18 DNA Extraction from semen for evaluation of proteinase K digestion
Semen specimens, previously stored at -70°C, were thawed and a 
0.4ml aliquot was taken. To this, 40ul of 10% SDS and 1Oul proteinase 
K were added and the tubes incubated at 37°C overnight. DNA was 
obtained by two phenol/chloroform extractions followed by one 
chloroform/iso-amyl alcohol extraction and precipitation with 40ul 5M 
sodium chloride and 1ml ethanol at -20°C overnight. The DNA was 
pelleted by microcentrifugation, washed with 70% ethanol, dried under 
vacuum and then resuspended in 200ul of TE. DNA determinations were 
performed using a Hoefer Scientific Instruments TKO 100 Fluorometer 
(marketed by Biotech Instruments limited).
19 Dot blot preparation of semen DNA
The DNA was denatured by the addition of 50ul 1.5M sodium
chloride and 0.5M sodium hydroxide and left to stand at room 
temperature for 1 hour. The extracted DNA was divided into two equal 
volumes and then drawn under vacuum onto two Hybond-N nylon membranes 
prepared in parallel using "minifold" dot-blotting apparatus. The DNA 
'dots' were then neutralised by the addition of 200ul of 1.5M NaCl, 
Q.5M tris-HCl(pH 7.2) and 1mM sodium EDTA. This was drawn onto the 
membrane under vacuum. When there was no residual volume in the wells
of the minifold apparatus the nylon membranes were carefully removed,
placed in an envelope of 3MM paper and dried at 37°C for 1 hour. When 
totally dry the membranes were wrapped in 'clingfilm' and exposed to 
ultra-violet light on a transilluminator for 10 seconds in order to 
cross-link the DNA to the nylon membrane. After removal of the 
"clingfilm" the blots were ready for hybridisation.
20 Hybridisation and wash procedures
Prehybridisation steps and hybridisation steps were carried out
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using Hybaid hybridisation bags and apparatus. The 
prehybridisation/hybridisation buffer consisted of 6xSSC,
5xDenhardt's solution and 0.5%SDS. For prehybridisation, 100ul of 
20mg/ml denatured salmon sperm DNA were added per 10ml 
prehybridisation buffer giving a final concentration of 0.4mg/ml. 
Prehybridisation was at 65°C for a minimum of three hours. DNA probes 
for HPV types 11, 16 and 18 were prepared by random primer labelling 
using a Pharmacia kit. 50ng of each DNA type were labelled and the
Q
specific activity of the probes was approximately 5x10 dpm/ug. The 
probes were denatured at 95°C for 10minutes. Hybridisation occurred 
at 65°C for 16 hours. After hybridisation the filters were washed at 
65°C successively with 2XSSC for 30 minutes, 0.1X SSC+0.1% SDS for 30 
minutes and 0.1XSSC for 10 minutes. The filters were exposed against 
Hyperfilm MP overnight.
21 Semen DNA extraction procedure for Southern blot hybridisation 
analysis
Nucleic acid was extracted by proteinase K /SDS digestion 
followed by two phenol chloroform extractions as described previously 
( method 18). RNA was removed by digestion with RNAse A for 15 
minutes at 37°C. The RNAse was destroyed by the addition of 1Oul 
20mg/ml proteinase K and 40ul 10% SDS to the specimen followed by 
incubation at 37°C for 30 minutes. The DNA was re-extracted with an 
equal volume of phenol/chloroform followed by extraction with 
chloroform/iso-amyl alcohol and precipitated with 40ul 5M sodium 
chloride and 1ml absolute ethanol at -20°C overnight. DNA was 
pelleted by microcentrifugation for 15 minutes. The pellet was washed 
with 70% ethanol and centrifuged again for 15 minutes. The 
supernatant was discarded and the pellet dried under vacuum. The
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extracted DNA was resuspended in 50ul TE.
22 Electrophoresis and Southern blotting
5ml ficoll/orange G was added to the extracted DNA preparations. 
These were then loaded into the wells of a 0.9% horizontal agarose 
gels. The gels were run under a current of 100mA for approximately 4 
hours or at 30mA overnight. After electrophoresis, the gel was 
agitated in a DNA denaturing solution (1.5M sodium chloride, 0.5M 
sodium hydroxide) for 1 hour. The gel was then neutralised by 
agitation in 1.5M sodium chloride, 0.5M Tris-HCl,pH 7.2 and 0.001M 
sodium EDTA for 30minutes. Excess liquid was blotted from the gel 
with tissues. A piece of Hybond-N nylon membrane was cut to the exact 
size of the gel. The membrane was wet with distilled water then 
placed in 2X SSC. The Southern blot transfer apparatus was assembled 
with 10X SSC in the buffer reservoir. The gel was placed on the 
central bridge of the transfer tray in contact with the 3MM filter 
paper wick, ensuring that there were no air bubbles between them. The
nylon membrane was placed exactly on top of the gel. Air bubbles
between the gel and the membrane were removed. A stack of absorbant 
tissues cut to the exact size of the gel was.placed on top of the
nylon membrane and gel again without trapping air bubbles. A perspex
block and a lead weight were placed on top of the stack of tissues to 
provide evenly distributed compression. Transfer proceeded overnight 
at room temperature after which time the absorbant stack was 
discarded. Using the gel as a template the position of the wells were 
marked on the nylon membrane. The membrane was then seperated from 
the gel and rinsed in 2X SSC. The membrane was placed to dry at 37°C 
for 1-2-hours. When dry, the membrane was wrapped in "clingfilm" and 
exposed to UV irradiation for 15 seconds on a transilluminator.
23 Hybridisation
The membrane was prehybridised under the conditions described
previously (method 20), followed by hybridisation with an HPV DNA
32probe labelled with P by random primer extension to a specific
O
activity of 5x10 dpm/ug using the Pharmacia kit. Hybridisation 
occurred at 65°C overnight after which the membrane was washed at 65°C 
successively with 2XSSC for 30 minutes, 0.1X SSC+0.1% SDS for 30 
minutes and 0.1XSSC for 10 minutes. The membrane was exposed to X-ray 
film overnight.
24 Restriction enzymic digestion from semen pellet and supernatant 
fractions
An 800ul aliquot of semen specimens was microfuged (6,500 rpm, 
3000g) for 30 seconds to separate the semen into a spermatozoa/cell 
pellet and a seminal fluid supernatant. The pellet was resuspended in 
1ml PBS and centrifuged for 30 seconds. This washing procedure was 
repeated twice after which a 1Oul aliquot was examined by light 
microscopy. The pellet was resuspended in 400ul TE. DNA was 
extracted from this and the seminal fluid fraction as described 
previously. The extracted DNA was digested simultaneously with BamHI 
and EcoRI restriction enzymes in order to determine the HPV DNA type 
present. The digests were electrophoresed on 0.9% agarose and 
Southern blotted overnight onto a nylon membrane. These were then 
hybridised with specific HPV DNA probes as described previously.
25 Electron microscopy
For examination by electron microscopy, 0.5ml aliquots of HPV- 
positive semen were centrifuged at 8000rpm for 1 hour in a Beckman L8- 
80 centrifuge. The supernatent fraction was then centrifuged for 1 
hour at 30000rpm in a Beckman L8-80 centrifuge. The pellets from the
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high speed and low speed centrifugation run were resuspended in 
phosphate buffered saline, stained with 3% phosphotungstic acid and 
examined in a Jeol 1200X electron microscope.
26 Separation of spermatozoan and cellular DNA by selective 
proteinase K digestion
0.5ml semen was diluted with 1ml PBS and allowed to stand at room 
temperature for 30 minutes. This was gently vortexed and 
microcentrifgued for 1 minute to pellet spermatozoa and cells. 5ul of 
pellet was examined by light microscopy. The remainder was 
resuspended in 200ul digestion buffer consisting of 1OmM Tris.HCl, pH 
8.0, 1OmM EDTA, 50mM sodium chloride and 2% SDS. Proteinase K was 
added to give a final concentration of 150ug/ml and digestion was 
allowed to occur at 37°C for 1 hour. The digests were microfuged for 
1 minute to pellet spermatozoa heads. The supernatant was retained 
for DNA extraction (preparation 1). The pellets were washed twice 
with 0.5ml digestion buffer and finally resuspended in 0.5ml digestion 
buffer containing 20ul 1M DTT ( prepared in 1OmM sodium acetate, pH 
5.2). After digestion for 2 hours at 56°C, DNA was extracted from 
both preparations as described previously.
27 Percoll fractionation
1 3 4This was based on the method described by Bolton et al for the 
preparation of spermatozoa for use in in vitro fertilisation (IVF) 
purposes.
Preparation of self-forming gradient: A 60% (v/v) solution of percoll 
in 0.15M sodium chloride was prepared and 10ml volumes dispensed into 
12ml polycarbonate centrifuge tubes (DuPont). Density gradients were 
established by centrifugation at 22000 rpm (30,000g) for 15 minutes 
in a Beckman 50Ti fixed angle rotor of the Beckman L8-80M centrifuge.
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Gradients prepared in this way could be stored at 4°C for up to 14 
days.
Fractionation: Gradients were removed from the 4°C refrigerator and
allowed to warm to room temperature. 1ml whole, undiluted semen was 
carefully layered onto the gradient column and centrifuged at 1300 rpm 
in an MSE chillspin centrifuge (400g) for 20 minutes at room 
temperature.
Fraction collection: 1ml fractions were carefully collected from the
top of the gradient using a P1000 Gilson pipette. The optical density 
of each fraction was determined by refractometry and the density 
calculated.
Percoll removal/DNA extraction: The uppermost fraction, seminal fluid
not having entered the gradient, did not require processing for the 
removal of Percoll. All gradient fractions below this were diluted 
with 5ml saline and centrifuged for 5 minutes at 200g in an MSE 
Chillspin centrifuge at room temperature. Cellular pellets were 
collected and the washing procedure repeated twice after which an 
aliquot was removed for examination under light microscopy. The 
pellets were resuspended in 1ml PBS and then divided into two 
aliquots. One aliquot was stored at 4°C for analysis by 
immunocytochemistry and in situ hybridisation. From the second 
aliquot, DNA was extracted from cellular material present using 
procedures described earlier. This was was then electrophoresed, 
Southern blotted and hybridised as described earlier.
Mock specimen: In order to determine in which fraction epithelial 
cells would band, one semen specimen previously found to be HPV- 
negative was seeded with Caski cells and processed in parallel with 
the test.specimens.
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28 Preparation of slides for in situ hybridisation and 
immunocytochemistry
Cells pelleted from Percoll gradient fractions had been stored at 
4°C for in situ and immunocytochemistry investigations. Those found 
by light microscopy to contain large numbers of epithelial cells were 
microfuged and the pellet resuspended in 100ul PBS.
29 In situ hybridisation
Cell processing and pre-treatment; 5ul aliqouts of washed cell 
preparation were spotted onto slides treated with 3-
aminopropyltriethoxysilane (Sigma), air-dried and fixed with Carnoy's 
fluid for 10 minutes. They were either pretreated for hybridisation 
or stored at -30°C.
Prior to'hybridisation, the cell spots were washed in alcohol, 
rehydrated and treated sequentially with 0.2N hydrochloric acid,
5ug/ml proteinase K in 50mM Tris-HCl pH 7.6 and 5mM EDTA, 0.2% glycine 
in PBS, 4% paraformaldehyde in PBS and 0.2% glycine in PBS before 
dehydration and air-drying.
Preparation of biotinylated HPV DNA probes: DNAs of HPV types 6, 11
and 16 were obtained by excision from HPV/pGemini clones as described 
earlier ( methods 1 - 6). DNAs were labelled with biotin-11-UTP 
(Gibco, BRL) by nick-translation (Kit by Gibco BRL). Unincorporated 
biotin was removed by the spin column method using Nick columns.
Hybridisation mixture (45% deionised formamide, pH 6.8, 2.5% 
polyethylene glycol 6000, 830ug/ml salmon sperm DNA and DNA probe at 
1ng/ul) was placed on cell spots, covered with a cover slip and sealed 
with cow gum (Cow proofings ltd).
The spots were heated at 95°C for 10 minutes to denature probe
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and target DNA, and hybridised overnight at 42°C in a moist chamber. 
After removing the cover slips under 2 x SSC, the spots were washed 
sequentially with 2 x SSC, twice with 50% formamide in 0.1 x SSC at 
42°C for 15 minutes (for high stringency wash), 2 x SSC, 0.1% Triton 
X-100 in PBS and PBS. The spots were then covered with streptavidin- 
alkaline phosphate conjugate (Gibco BRL) at a dilution of 1:200 in 5mM 
EDTA, 0.5% Triton X-100, 0.1% BSA in PBS for 30 minutes at room 
temperature. Further washes and detection were according to the 
Blugene protocol (Gibco BRL). Slides were examined by light 
microscopy at low magnification.
30 Immunocytochemistry
Detection of papillomavirus antigens was attempted using a slight 
modification of the Dakopatts Dako PAP kit procedure (Dako Corporation 
kit K521). The modification involved the use of DAB (3,3 
diaminobenzidine tetrahydrochloride) as substrate rather than AEC (3- 
amino-9-ethylcarbazole).
5ul aliquots of washed cell preparation were spotted onto glass 
slides, air dried and fixed for 1 minute in acetone-methanol (1:1). 
Cell spots were covered with 3% hydrogen peroxide
and left at room temperature for 5 minutes. The slides were rinsed 
with distilled water from a wash bottle and placed in buffer ( 0.05M 
Tris pH 7.6 containing 2.5% bovine albumin and 0.015M sodium azide) 
for 5 minutes. The spots were covered with blocking serum (normal 
swine serum prediluted in 0.05M Tris, pH 7.6) for 20 minutes at room 
temperature. Excess serum was tapped from the slide and sufficient 
anit-papillomavirus antiserum (rabbit anti-papillomavirus serum 
diluted in 0.05M Tris pH7.6, 2.5% BSA, 0.015 M sodium azide) placed on
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the slide to cover all cell spots. In order to control the 
specificity of reaction, cell spots were tested in parallel with non- 
immune rabbit serum. Test and control slides were left at 4°C 
overnight after which they were gently rinsed with Tris buffer from a 
wash bottle and placed in a bath of Tris buffer for 15 minutes. Cell 
spots were then covered with the 'link' antibody ( swine anti-rabbit 
Ig antiserum in 0.05M Tris pH 7.6) and incubated for 20 minutes at 
room temperature. Excess serum was rinsed from the slide with Tris 
buffer and the slide placed in a Tris buffer bath for 20 minutes. The 
spots were covered with PAP complex ( soluble horseradish peroxidase - 
rabbit antihorseradish peroxidase) for 20 minutes at room temperature. 
The slides were rinsed gently with Tris buffer and placed in a Tris 
buffer bath for 5-20 minutes. DAB substrate ( 6mg 3,3 
diaminobenzidine terahydrochloride in 9.9ml 0.05M Tris buffer, pH7.6,
+ 0.1ml 3% hydrogen peroxide) was placed onto each specimen and 
incubated at room temperatub for 5-15 minutes. After rinsing with 
water, the slides were counterstained with Giemsa stain for 1 hour at 
room temperature and examined under low power.
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CHAPTER 4
RESULTS
Summary DNA sequences for HPV types 6, 11, 16 and 18 were received
from the laboratory of Professor H zur Hausen. The HPV sequences were
excised from plasmid vectors, characterised by restriction enzyme
‘2 2digestion analysis and cloned into pGemini vectors. P-labelled 
probes were generated from purified HPV DNA by random priming.
Procedures for the extraction of DNA from semen samples were 
considered. Results obtained demonstrated that the addition of 1Oul 
20mg/ml proteinase K + 1% SDS to 400ul semen samples gave optimal DNA 
yields and was used for subsequent DNA extractions.
Detection of HPV DNA in semen was attempted using dot blot 
hybridisation but problems with non-specific hybridisation were 
experienced and Southern blot hybridisation was subsequently employed. 
The sensitivity of this procedure was investigated and it was 
established that Southern blot hybridisation could detect 
approximately 10^ genome copies per 0.4ml sample. Semen specimens 
from patients attending an Assisted Conception Unit and a GUM clinic 
were tested for HPV DNA by Southern blot hybridisation. All specimens 
from the ACU patients were negative but HPV6/11 DNA was detected in 8 
of 20 specimens from GUM clinic patients.
Attempts were made to localise HPV DNA within semen components 
using selective digestion and 'Percoll' fractionation procedures. 
Results obtained suggested that the HPV DNA was associated with the 
seminal fluid fraction, perhaps with epithelial cells, but not with 
the spermatozoa. Use of in situ hybridisation and immunocytochemistry 
for localisation of HPV DNA within semen components were unsuccessful.
80
/1: PREPARATION OF HPV DNA PROBES FOR USE IN DOT BLOT AND SOUTHERN BLOT 
HYBRIDISATIONS
1.1 Recloning of HPV DNA into pGemini Vectors
DNA clones of HPV types 6,11,16 and 18 were received from Dr H zur 
Hausen. HPV6b DNA was received as a 7902 bp insert in the Eco RI site 
of plasmid pBR322 representing the full-length genome. HPV11 and 
HPV16 DNAs were received as full-length fragments cloned into the Bam 
HI site of plasmid pAT 153, and were 7931 bp and 7904 bp respectively. 
HPV 18 DNA was a full-length fragment of 7.8kb cloned into the Eco RI 
of plasmid pBR322. The HPV DNA inserts were excised from the plasmids 
using either Bam H1 or Eco R1 restriction enzymes and purified by 
electrophoresis in low gel-temperature agarose. Digestion of the 
inserts with the restriction enzyme Pst1 gave characteristic band 
patterns (Figure 9). The purified fragments were ligated into a 
pGemini vector digested with the appropriate restriction enzyme and 
transfected into competent HB101 strain E. Coli. Plasmid DNA from 
resulting bacterial colonies was analysed by restriction enzyme 
digestion and sizing of the resulting fragments by gel electrophoresis 
(Figure 10).
Yields of HPV DNA from'10ml culture of E. Coli containing 
HPV/pGemini plasmid constructs were compared with yields from an equal 
volume of E.Coli containing HPV/pATl53 or HPV/pBR322 constructs. 
Generally, yields from pGemini constructs were twice that from pBR322 
or pAT153 constructs.
Two orientations were possible and again this was determined by 
restriction enzyme digestion (figure 11). Transfected E. Coli were 
cultured in 100ml broths and HPV/pGEM constructs obtained by the
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Figure 9
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Figure 9 : PstI Restriction enzyme digests of HPV 6, 11, 16 and 18 DNA
Approximately 1ug of HPV insert was purified following excision from 
pAT153 or pBR322 vector and digested with 20U PstI. Following 
electrophoresis on a 0.9% agarose gel, DNA bands were visualised by staining 
with ethidium bromide. Lanes 2, 4, 6, and 8 show digests of HPV18,
-16, -11 and -6 DNA respectively. Lanes 1, 3, 5, 7 and 9 contain Hind 
III digests of phage lambda DNA as molecular weight markers giving 
band sizes of 23.1, 9.4, 6.5, 4.4 (barely visible), 2.3 and 2.0 kb 
pairs.
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Figure 10
Figure 10a
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Figure 10a :'Mini-lysis' preparations from colonies obtained following 
re-cloning of HPV DNA into pGemini vector
Lane 1 contains pGem DNA as a size marker; Lane 2 contains an 
HPV11/pGemini construct size marker; Lanes 3-10 contain nucleic acid 
extracted from colonies selected for ampicillin resistance following 
ligation of HPV16 and pGemini DNA and transformation of HB101 E. coli 
cells. Lanes 5 and 8 contain DNA of the correct size for HPV/pGemini 
constructs whilst lanes 3, 4, 6, 7, 9 and 10 contain only 
recircularised pGemini DNA.
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Figure 10b
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Figure 10b: Plasmid preparations found to be of correct size for HPV/pGemini
construct on 'mini-lysis' screening are further analysed by digestion with 
appropriate restriction enzyme. Here, two preparations indicated to be 
HPV16/pGemini constructs were digested with Bam HI enzyme and electrophoresed 
along with undigested preparations. Lane 1 contains pGem vector as size 
marker. Lane 2-5 contain two potential HPVl6/pGem constructs undigested 
(lanes 2 and 4) and digested with Bam HI (lanes 3 and 5). Lane 6 contains 
HPV16 DNA as size marker. Digestion of the plasmid preparations with Bam HI 
yields two bands of 2.8kb (pGemini) and 7.9kb (HPV16) approximately.
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Figure 11: Determination of the orientation of HPV inserts in pGem vector
A: The procedure used for the re-cloning of HPV DNAs into
pGemini vectors is non-directional ie two insert orientations 
are possible. HPV6 DNA was cloned into the Eco RI site of 
pGem-2 plasmid and the insert orientation was determined by 
digestion of this construct (pGHPV6) with BamHI restriction 
enzyme. HPV6 DNA and pGem-2 both contain a single BamHI site.
B: The two possible insert orientations are shown. Digestion of
HPV6 DNA gives fragments A and B which 2.53kb and 5.37kb 
respectively.
C: When pGHPV6 construct is digested with BamHI, two fragments
8.24kb and 2.53kb are obtained showing that the insert 
orientation is as in Bii
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Table 7
Comparison of specific activities obtained for DNA labelled bv nick 
translation or random priming techniques
Quantity of Total percentage Specific
DNA counts3 incorporation activity*3
Nick
Translation
50ng
1ug
1.4 x 10
3.8 x 10
21
575
2.6 x 108
3.8 x 10
Random
Priming
50ng
1ug
3.3 x 10
3.9 x 10
49!
585
5.8 x 10
3.8 x 10
8
a: Total counts in counts per minute (cpm)
k; Specific activity expressed in disintegrations per minute per 
microgram DNA (dpm/ug).
50ng and 1ug quantities of purified HPV-11 DNA were labelled with 
^P-dCTP by nick translation (BRL kit) and random priming Pharmacia 
Oligolabelling kit). Labelling reactions were carried out for 1 hour 
at 15°C and 37°C respectively. The results demonstrate that higher 
specificities could be obtained using the random priming procedure to 
label smaller quantities (50ng) of DNA. A specific activity of 5.8 
x108 dpm/ug was obtained on this occasion. Higher specific activities 
could be obtained by using random priming to label DNA quantities less 
than 50ng, by extending the reaction incubation period and/or by using 
two P-labelled nucleotides. However, probes with specific 
activities >2x10  ^dpm/ug undergo rapid biological degradation and must 
be used within a short time of preparation. Probes with specific 
activities of approximately 5x108 dpm/ug can be produced reliably and 
are adequate for most applications.
alkaline lysis method. HPV inserts were excised and separated from
the vector by electrophoresis in low gel-temperature agarose. For use
32in DNA hybridisations, P-labelled probes were generated by random 
primimg. Initially, probes had been generated by nick translation but 
it was found that probes of higher specific activity could be produced 
achieved by random priming (Table 7).
2: OPTIMISATION OF EXTRACTION PROCEDURE FOR DNA IN HUMAN SEMEN
2.1 Use of proteinase K for enzymic digestion of semen protein
Six semen specimens were taken and to two 0.4ml aliquots of each 
were added either 40ul 10% SDS or 40ul 10% SDS + 100ul 200mg/ml 
proteinase K (final concentrations 13.5mg/ml proteinase K and 1% SDS. 
These were incubated at 37°C overnight after which protein 
determinations were performed using the Bio-Rad Lowry reagent to 
assess residual protein levels. DNA was extracted from the remainder 
of the digests by two phenol chloroform extractions and one chloroform 
/isoamyl alcohol extractions and precipitated as described (method 
18). DNA concentrations were determined by fluorometry. The results 
(table 8) demonstrate the effect of proteinase K digestion on DNA 
yields from semen specimens. As would be expected, digestion with 
proteinase K results in greatly reduced protein levels and 
significantly increased DNA yields. The DNA yields from specimens 
digested with proteinase K (average yield 50ug) were six times higher 
than those from undigested specimens (average yield 8.4ug). DNA 
yields from the six specimens tested varied quite considerably within 
a range of 16.32ug to 107.4ug. As a corresponding range of DNA yields 
was obtained for undigested semen (ie 2.8 to 22.72ug) this suggests
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Table 8
Use of proteinase K for enzymic digestion of semen protein
A B C
Untreated SDS only Proteinase k digested
Protein DNA Protein DNA Protein DNA
Semen No. ( Abs ) (ug) (Abs ) (ug) ( Abs ) (ug)
1 0.75 2.80 0.812 2.0 0.095 16.32
2 1 .02 5.12 0.96 6.9 0.125 68.48
3 1.15 6.40 NT NT 0.085 23.00
4 0.985 6.80 NT NT 0.15 107.40
5 1.14 22.72 1.13 1 1 .2 0.17 47.68
6 0.95 6.72 0.97 7.3 0.13 36.80
Comparison of protein and DNA yields from 0.4ml semen afterv 
treatment with proteinase k + 1% SDS (column C), SDS only (column B) 
j and after no treatment (column A) demonstrates the efficiency of 
; proteinase k in disrupting protein and consequently in liberating DNA.
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Table 9
To establish the quantity of Proteinase K required 
for optimal DNA yield.
DNA yield (up) Volume of proteinase K added.
Semen No. 5ul 1 Oul 20ul 50ul
7 16.0 13.3 13.6 14.1
8 74.1 71 .4 72.3 69.1
9 56.8 65.0 53.8 56.3
10 129.0 134.0 132.0 132.0
11 72.5 76.8 70.0 54.2
12 68.5 68.0 48.3 40.2
In order to establish the quantity of proteinase k required for optimal 
DNA yield, 0.4ml aliquots of 6 semen specimens were treated with 5, 10, 20 
or 50ul proteinase k, equivalent to concentrations of 0.625, 1.3, 2.6 and 
6.25mg/ml. The results show that addition of proteinase k to concentrations i 
greater than 0.625mg/ml has no effect on DNA yield suggesting that complete 
protein digestion occurs at this concentration.
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that variation is related to the specimen and is not related to the 
digestion/extraction procedure.
2.1 To establish the quantity of proteinase K required for optimal 
DNA yield
The concentration of proteinase K used in the previous study was 
13.5mg/ml which was assumed to be an excess to ensure that protein 
digestion proceeded to completion. Here, six further semen specimens 
were incubated with a range of concentrations of proteinase K in order 
to establish the quantity required for optimal DNA yield. The volumes 
of proteinase K added to 0.4ml aliquots of semen were 5, 10, 20 and 
50ul giving concentrations of 0.625, 1.25, 3.125 and 6.25mg/ml. 
Incubation was at 37°C overnight and DNA extraction and precipitation 
were as described previously. The results (Table 9) suggest that DNA 
yields from the specimens tested were very similar regardless of the 
amount of proteinase K added ie concentrations of proteinase K between 
0.625mg/ml and 6.25mg/ml gave similar DNA yields for each specimen.
The yields obtained are very similar to those obtained in test 1 when 
100ul of proteinase K were added to the specimens and greater than 
those obtained when the specimens were untreated. This suggests that 
complete protein digestion is achieved by the addition of 5ul of 
20mg/ml proteinase K to a 0.4ml aliqout of semen and incubated at 
37°C overnight.
On the basis of these results it was decided that 10ul of 20mg/ml 
proteinase K would be added to 0.4ml of semen specimens for routine 
extraction and screening. This volume was selected to ensure that an 
excess of proteinase K would be present even if the protein content of 
particular semen specimens exceded that seen in preliminary tests.
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3: SCREENING HUMAN SEMEN FOR HPV DNA BY DOT BLOT HYBRIDISATION
3.1 Source of specimens
153 semen specimens were obtained from those submitted to King's 
College Assisted Conception Unit (ACU) for investigations of 
infertility. The identities of donors were unknown.
DNA was extracted from 153 semen specimens (method 18), dot 
blotted onto a nylon membrane and hybridised with DNA probes for HPV 
types 6, 11 and 16 (methods 19, 20). The autoradiographs showed a 
high proportion of the specimens to be positive. However the same 
specimens seemed to be positive for both HPV types 11 and 16 
suggesting that the probe binding may be non-specific (Figure 12).
The membranes were rewashed under conditions of greater stringency and 
re-exposed against Hyperfilm MP with intensifier screens at -70°C for 
3 days. After re-washing, fewer positive reactions could be seen but 
all gave positive reactions with both HPV11 or HPV16 perhaps 
suggesting non-specificity. Specimens giving positive reactions in 
the dot blot hybridisation were negative when tested by Southern blot 
hybridisation.
4: DETERMINATION OF THE SENSITIVITY OF SOUTHERN BLOT HYBRIDISATION FOR 
THE DETECTION OF HPV DNA IN SEMEN
Twelve aliquots of semen were seeded with HPV DNA at a given 
concentration either before or after specimen DNA had been extracted. 
DNA was electrophoresed and transferred to a nylon membrane by 
Southern blot. The membranes were hybridised with an HPV 11 DNA probe 
as described and autoradiographed overnight.
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Figure 12: Non-specific binding of probe sequences in dot blot
hybridisation
DNA was extracted from semen specimens, dotted onto a nylon 
membrane under vacuum, prehybridised in 6 x SSC, 5 x Denhardts, 0.5% 
SDS and 200ug/ml salmon sperm DNA and hybridised with ^2P-labelled 
probes for HPV6/11, 16 or 18 at 65°C overnight. The membrane was 
washed successively with 2 x SSC, 0.1 X SSC + SDS and 0.1 x SSC at5 
65°C. Autoradiography was performed at -70°C. Upper and lower 
photographs are of autoradiographs obtained for HPV11 and HPV16 probes 
respectively. Similar patterns of positivity were obtained with both 
probes. Signals were of such intensity that they were detectable 
after only a few hours (approximately 8hrs) exposure after which time 
specific HPV DNA controls were only barely visible (upper photograph; 
HPV11 DNA in row G, column 1.
Lower; HPV16 DNA in Row G, column 3). Positive signals obtained were 
considered non-specific as rewashing the membranes with 0.1x SSC at 
68°C had little effect and attempts to confirm these results by 
Southern blot hybridisation were unsuccessful.
Figure 12
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4.1 Test specimens seeded before extraction
Ten-fold dilutions of HPV 11 DNA were prepared to give 10ng,
1ng, 100pg, 1pg and 0.1pg per microlitre. These were then seeded into
0.4ml aliquots of semen which were mixed and allowed to stand at room
temperature for 10 minutes. A negative control (ie no HPV DNA seeded)
was also included. Total DNA was extracted, electrophoresed,
transferred to a nylon membrane by Southern blot and hybridised with a 
o2
P-labelled DNA probe for HPV 11. Figure 13 shows the autoradiograph 
obtained. No HPV DNA was -detectable in semen aliquots seeded with 
100fg-1ng HPV DNA prior to extraction. The semen aliquot seeded with 
1Ong HPV DNA gave a positive signal but this was visible as an 
indistinct smear of low-molecular weight DNA rather than a precise 
band, suggesting that the HPV DNA had been degraded. The minimum 
detectable quantity of HPV DNA seeded into TE buffer prior to 
extraction was 100pg.
4.2 Test specimens seeded after DNA extraction
The DNA extracted from six (unseeded) semen specimens were seeded 
with 10ng, 1ng, 100pg, 10pg, 1pg and Opg HPV11 DNA. This was 
electrophOsed, Southern blotted onto a nylon membrane and hybridised 
with an HPV11 DNA probe. Figure 13 shows results obtained. The 
minimum detectable quantity of HPV11 DNA seeded into nucleic acid 
extracted from semen was 10pg. In order to establish the effect of 
the presence of semen nucleic acid on the sensitivity of the Southern 
transfer and hybridisation procedure, 100, 10 and 1pg quantites of 
HPV11 DNA were seeded into TE buffer, electrophoresed, transfered and 
hybridised. One picogram of HPV11 DNA could be detected, suggesting 
that a slight decrease in sensitivity occurs due to the presence of 
unrelated sequences extracted from the specimen.
Figure 13; Determination of sensitivity of Southern blot
hybridisation
Specimens seeded before extraction Specimens seeded after extraction
DNA In Semen In TE DNA In Semen In TE
10ng ++ (degraded) 1 Ong +++
1ng - + + 1ng ++
100pg - + 100pg ++ +
10pg - + 10pg + +
ipg - - ipg - ±
lOOfg -
No DNA - 1 No DNA -
Figure 13
Determination of the Sensitivity of Southern Blot Hybridisation 
for the Detection of HPV DNA in Semen
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Figure 13: Determination of the sensitivity of Southern blot
hybridisation: Quantities of HPV 11 DNA were seeded into semen
before and after DNA extraction. The preparations were 
electrophoresed, transferred to nylon and hybridised with a 32P- 
labelled probe.
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5: SCREENING HUMAN SEMEN FOR HPV DNA BY SOUTHERN BLOT HYBRIDISATION
Semen specimens were obtained from two sources; those submitted 
to King's ACU for investigations of infertility and those from males 
attending the Department of Genito-urinary Medicine (GUM) at Leeds 
General Infirmary. Of the GUM patients, 20 were patients with 
intrameatal warts, 7 with non-intrameatal genital warts and two were 
being treated for genital infections other than genital warts.
5.1 Semen from males attending an infertility clinic
DNA was extracted from 70 semen specimens from King's College ACU 
and electrophoresed in a 0.9% agarose gel. The DNA was passively 
transferred to a nylon membrane by Southern blot and hybridised with 
^P-labelled HPV DNA probes. All were negative for HPV types 6, 11,
16 and 18 by this method.
5.2 Males attending GUM Clinic
Twenty nine semen from males attending Leeds General Infirmary 
GUM clinic were tested as described. HPV DNA results are shown in 
Table 10. Nine of the 29 specimens tested were found to be positive 
when hybridised with a pooled HPV 6/11 DNA probe. Eight of these were 
among 20 specimens from males with intrameatal warts and one of seven 
specimens from males with non-intrameatal penile warts was positive. 
Two specimens from males with no penile warts were both negative for 
HPV 6/11 DNA. None of the 29 specimens were positive by this method 
for HPV types 16 and 18. Figures 14 and 16 show the signals obtained 
from five of the positive specimens. With the exception of specimen 
16, ( Lane 1, figure 16c), autoradiograph signals were less intense 
than those from the 100pg HPV11 control.
5.3 Further tests
Sufficient specimen was available for further investigation of
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Table 10: Detection of HPV DNA in semen from males 
attending a GUM clinic
Specimen No. Clinical symptoms HPV+ 6, 11, 16, 18
1 intrameatal warts -
2 intrameatal warts + - + -
3 intrameatal warts + - + - -
4 intrameatal warts + + + - -
5 intrameatal warts -
6 intrameatal warts -
7 intrameatal warts -
8 intrameatal warts + / * +/ + - -
9 intrameatal warts -
10 intrameatal warts -
11 intrameatal warts -
12 intrameatal warts + / * + / + - -
13 intrameatal warts -
14 intrameatal warts -
15 intrameatal warts -
16 intrameatal warts + + + + - -
17 intrameatal warts + - + - -
18 intrameatal warts -
19 penile warts -
20 penile warts -
21 intrameatal warts + / * +/ + - -
22 intrameatal warts -
23 penile warts -
24 penile warts -
25 no warts -
26 no warts -
27 penile warts -
28 penile warts + / * + / + - -
29 penile warts -
'fc
Insufficient specimen available to differentiate between HPV6 and 
HPV11
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Table 10b (summary)
GU Med Clinic Southern Blot
population HPV6/11 HPV1 6_______HPV+
Group A
Intrameatal warts 8(40%) 0 8(40%)
(n=20)
Group B 
Penile warts 
(n=7)
Group C 
No warts 
(n=2)
Infertility clinic 
population
(n=70) 0 0 0
1(14%) 1(14%)
Group A: 20 specimens from patients attending for treatment of 
intrameatal penile warts 
Group B: 7 patients attending for treatment of non-intrameatal penile 
warts
Group C: 2 patients attending for treatment of GU infections other 
than penile warts
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Figure 14
Figure 14: Semen DNA from patients with penile intrameatal warts
Autoradiograph of semen DNA from patients with intrameatal penile warts 
probed with ^P-labelled HPV6/11 probe:
Lane 1 contains linear HPV11 DNA control (100pg). Lane 2 contains linear
HPV16 DNA control. Lanes 3-7 show undigested extracted DNA from 5 specimens. 
Specimens 2,3 and 4 (Lanes 4,5 and 6) are positive, but give less intense 
signals than the 100pg HPV 11 DNA control. The bands have electrophoresed a 
shorter distance than the linear control suggesting that this form of viral
DNA is open circular (form II). Specimens 5-15 and HPV18 DNA control were
also run on this gel but are not shown.
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Figure 15
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Figure 15: Restriction enzymic digestion of HPV DNA from semen
Autoradiograph of Bam Hl/Eco Rl-digested DNA from the semen of two 
patients with penile intrameatal warts. Semen pellets and supernatant DNA 
were extracted seperately and digested with Bam HI and Eco R I . Lane 2 
contains an HPV11 digest marker. Lanes 3 and 4 contain supernatant and 
pellet fractions of semen specimen 3. Lanes 5 and 6 contain supernatant and 
pellet fractions of specimen 4. Lane 7 contains an HPV6 DNA digest size 
marker. For both specimens the HPV DNA was predominantly associated with 
the pellet fraction. A linear 7.9kb band is visible in both semen 3 lanes 
suggesting that HPV11 DNA is present. Two bands of 5.4kb and 2.5kb can be 
seen in the pellet of semen 4 indicating HPV 6 DNA is present. There is an 
additional faint band of 7.9kb which may indicate the presence also of HPV11 
or may be due to incomplete digestion. Insufficient sample was available 
for confirmation.
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Figure 16
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Figure 16 : Autoradiographs of semen specimens 16-29 (see table 10) from
males attending a Genitourinary Medicine clinic. Specimens have been 
centrifuged and the nucleic acid extracted separately from semen pellet and 
supernatant fractions. These were digested simultaneously with Bam HI and 
Eco RI, electrophoresed and Southern blotted. Undigested HPV 6,-11 and 16 
controls were included. Hybridisation conditions were as described 
previously.
a) Pellet fractions hybridised with a pooled HPV11 and HPV16 probe. 
Specimen 17 (lane 2) is positive; specimens 16, 21 and 28 (lanes 1, 6 
and 13) were confirmed weakly positive on re-test. Single bands of 
similar size to HPV DNA controls were detected although smears of 
positivity were also seen.
b) Supernatant fractions hybridised with pooled HPV11 and 16 probe. 
Specimen 16 is positive but the signal is visible as two bands rather 
than a single band, showing that the HPV type present is not HPV11.
The digest map is not compatable with that of HPV16 which gives bands 
of 6.8, 0.7 and 0.6kb.
c) Same blot of extracted supernatant DNA after the pooled HPV11 and 
16 probe had been stripped and the blot rehybridised with a pooled 
HPV6/11 probe. Positive signal for specimen 16 (lane 1) is of greater 
intensity than with the HPV11/16 probe suggesting that the HPV DNA 
present may be type 6.
Figure 16
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five of the 9 specimens positive for HPV6/11. In order to determine 
whether HPV DNA was associated with the cellular or seminal fluid 
component, an aliquot of each specimen was spun in a microfuge for 30 
seconds to pellet the spermatozoa and cellular material. To 
differentiate between HPV6 and HPV11, DNA extracted from the 
supernatants and pellets were digested with Bam HI and Eco RI 
restriction enzymes. Figures 15 and 16 show the digestion patterns of 
four HPV positive specimens (specimens 3, 4, 16 and 17). In four of 
the five specimens, the HPV DNA was present almost exclusively in the 
pellet fraction. The exception was specimen 16 which was positive for 
HPV 6 DNA almost exclusively in the supernatant fraction. Specimens 
four and 17 appear to contain only HPV type 11 and specimen three may 
contain both HPV 6 and HPV 11. However, further restriction enzyme 
mapping would be required to show this conclusively. This was riot 
possible due to inadequate quantities of specimen.
HPV-positive semen specimens were examined by direct electron 
microscopy but no virus-like structures were visible in either the 
pellet or the supernatant fraction.
5.4 Investigation to determine with which component of semen the DNA 
was associated
Semen specimens found to be positive by Southern blot 
hybridisation were investigated to determine the component of semen 
with which the HPV DNA is associated. In order to do this, it was 
necessary to separate the components of semen, particularly epithelial 
cells from spermatozoa. Two methods were investigated; separation by 
selective digestion and fractionation on a 'Percoll' gradient, 
i) Selective digestion
Spermatozoa DNA and cellular DNA might be obtained separately by
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selective enzymic digestion as described for forensic purposes by von 
135Beroldmgen . This method is based on the insensitivity of 
spermatozoa to digestion with in the absence of a reducing agent. 
Digestion with proteinase K for a short period (1 hour) in the absence 
of dithiothreitol (DTT), a reducing agent, is insufficient to disrupt 
the spermatozoa heads but sufficient to liberate DNA from epithelial 
cells present in semen. Thus digestion under these conditions 
followed by microcentrifugation allows separation of cellular and 
spermatozoan DNA.
Semen specimens were diluted with PBS and, after a short 
incubation at room temperature, microcentrifuged to pellet cellular 
material. The pellet was digested with proteinase K for 1 hour, 
microcentrifuged briefly and the supernatant removed for DNA 
extraction (preparation 1). The pellet was washed twice and a small 
aliquot was removed for examination by light microscopy. Following 
further digestion with proteinase K this time in the presence of DTT,
DNA was extracted from this (preparation 2) and from preparation 1 and 
Southern blot hybridisation was carried out.
Compared to epithelial cells, spermatazoa 'heads' are relatively 
insensitive to digestion with proteinase K in the absence of DTT.
Figure 17' shows light microscopy preparations of semen before and 
after digestion for 1 hour in the absence of DTT. Cellular material 
has been disrupted and spermatazoa tails have been digested but 
spermatazoa heads generally remain in tact. Thus it is possible to 
obtain seperate preparations of cellular and spermatazoa DNA.
Southern blot hybridisation of both preparations 1 and 2 with probes for 
HPV11 showed that HPV DNA was restricted to preparation 1, suggesting 
that HPV .DNA is associated with a cellular component of semen and
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Figure 17: Semen before and after selective digestion with proteinase
k in the absence of DTT. Smears of HPV-DNA positive semen specimens 
were stained by Giemsa's method and examined under low power light 
microscopy. An aliqout of specimen was then digested with proteinase 
k in the absence of DTT for 1 hour. A smear was prepared from this 
which was stained by Giemsa and examined under low power microscopy.
a) Giemsa-stained smear of semen before digestion. Spermatozoa heads 
have taken up the stain and are clearly visible. Spermatozoa tails do 
not stain but are visible as 'ghosts'. Nuclear staining of cells 
occurs but the cytoplasm is refractive to staining.
b) After digestion with proteinase k for 1 hour in the absence of 
DTT, semen specimens are centrifuged and a smear made of the pellet. 
The pellet consists of spermatozoa heads as protein other than that of 
spermatozoa heads has been completely digested. This facilitates the 
separation of spermatozoan DNA and the DNA of other cellular 
components of semen. In this case, digestion may have been allowed 
to proceed too far as some spermatozoa heads are undergoing lysis.
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not the spermatazoa.
ii) Percoll fractionation: Three HPV DNA-positive semen specimens
were available for test by this method. 1ml semen was fractionated 
in self-forming Percoll gradients generated from 60% (v/v) Percoll 
solution. Fractions were collected and the refractive indexes were 
read. Initially fraction collection was attempted using a Hoeffler 
fraction collector but this was unsatisfactory as coarse material 
pelleted through the PVP during centrifugation and tended to leak into 
fractions as they were collected. Subsequently, 1ml fractions were 
carefully collected from the top of the gradient using a Gilson P1000 
pipette. Percoll removed and cellular material obtained by 
centrifugation. DNA was extracted from an aliquot of each fraction - 
pellet and tested for HPV DNA by Southern blot hybridisation.
Cellular material from fractions found to contain HPV DNA was tested 
by in situ hybridisation and by immunocytochemistry.
Examination of fractions by light microscopy revealed that 
epithelial cells tend to predominate in the uppermost fractions whilst 
spermatazoa were present in almost all fractions. Figure 18 shows 
results of Southern blot hybridisation of HPV DNA probes with DNA 
extracted from Percoll gradient fractions. HPV DNA was detected in 
fractions 1 and 2 of the gradients, specific gravities of 1.045 and 
1.055g/ml respectively. HPV DNA from Caski cells seeded into HPV- 
negative semen was also detected in fractions with similar specific 
gravities. These results further suggest that HPV DNA is associated 
with a cellular component other than spermatazoa. Autoradiographic 
signals from fractions of test specimens were weak and it would appear 
that some losses of HPV DNA have occurred during processing. The 
smearing of autoradiographic signals suggests that degradation of HPV
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DNA has occurred.
In situ hybridisation: Cellular material pelleted from Percoll
gradient fractions were spotted onto slides and tested by in situ 
hybridisation using genomic probes for HPV types 6/11, 16, 18 and 31. 
He a cells seeded into semen were used as a positive control 
preparation. HPV DNA could not be shown to be present in epithelial 
cells or spermatozoa by this method.
Immunocytochemistry: The Dakopap kit for the detection of 
papillomavirus antigens was used in an attempt to demonstrate the 
presence of HPV-related antigens in epithelial cells present in semen. 
No significant differences were demonstrated between cells tested 
using a papillomavirus-specific antibody and those tested using a non- 
immune serum.
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Figure 18
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Figure 18: Southern blot of percoll-fractionated HPV-positive semen
An HPV11-positive semen was fractionated on a percoll gradient, 
the DNA extracted from each fraction, Southern blotted and hybridised 
with an HPV11 probe. Fractions 1 and 2, buoyant densities 
respectively, were positive.
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CHAPTER 5
DISCUSSION
The aim of this study was to determine whether HPV DNA could be 
detected in human semen from males with and without clinically 
apparent genital warts. Before this could be achieved, it was 
necessary to establish procedures for the extraction of DNA from human 
semen and to investigate suitable hybridisation systems.
As no information was available as to the component of human 
semen with which HPV DNA is likely to be associated, it was necessary 
to extract DNA from whole semen rather than extracting either the 
semen pellet fraction or the seminal plasma fraction alone. The 
volume of semen tested should be large enough to give a suitable yield 
of DNA for use in dot blot and Southern blot hybridisations but, as 
large numbers of specimens may need to be screened, the sample volume 
must be one which can be easily handled during extraction procedures.
A starting point for acheiving a suitable extraction procedure is to 
add proteinase K and SDS directly to whole semen and then extract and 
purify the DNA using standard procedures. A protocol for DNA 
extraction from semen was established. Four hundred microlitre 
quantities can be extracted conveniently in Eppendorf tubes allowing 
fairly large numbers of semen to be processed at one time. Digestion 
with proteinase K at a concentration of 0.5mg/ml yields on average 
approximately 50ug DNA.
Dot blot hybridisation was found to be unsuitable for the
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detection of DNA sequences in extracted semen DNA due to a problem of 
the non-specific binding of probe DNA to the extracted material. This 
non-specificity may be masking true positives, although, when 
specimens giving apparently positive results were re-tested by 
Southern blot hybridisation, no positives were found. Non-specific 
binding may be avoidable by the use of 50% formamide hybridisation 
conditions as described for the detection of bovine herpes virus I
1 O C
(BHV-I) in semen rather than aqueous conditions. However,
Southern blot hybridisation has been employed in studies for the 
detection of HPV D N A ^  and hepatitis B virus DNA 137,138 
semen and no problems of non-specificity were described. This 
suggested that Southern blot hybridisation may also be suitable for 
investigations into the prevalence of HPV in semen.
It was first necessary to determine the limits of sensitivity of 
the Southern blot hybridisation when used for the detection of HPV DNA 
in semen. It was necessary to consider loss of DNA during the 
extraction procedure and Southern transfer procedure as well as the 
inherent limit of sensitivity of the hybridisation procedures used.
In order to do this, dilutions of HPV 11 DNA from 1pg to 10ng were 
added either to aliquots of semen before DNA extraction or to 
extracted semen DNA. These were then electrophoresed, blotted and 
hybridised with an HPV 11 DNA probe. HPV DNA added to semen prior to 
extraction was detected in only one aliquot, that seeded with the 
highest concentration of HPV DNA (10ng). The autoradiograph showed 
the HPV DNA to have been degraded. HPV DNA was demonstrable in all TE 
buffer controls similarly seeded with HPV DNA. This shows that the
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Figure 19
Calculation of viral copy number using Avagadro's number
The viral genome is 8 kilobases long,
c
equivalent to 8 x 6.5 x 10 daltons
2 x 108 daltons.
Avogadros # : number of molecules in a mole
= 6.0 x 1023 molecules.
therefore,
5.2 x 108g = 6.0 x 1023 molecule
1 genome molecule = 5.2 x 108
6.0 x 1023
= 8.67x 10_18g
= 8.67 attogram 
therefore, 10pg = 10 x 10~^2
8.67x IQ"18
= 1.15 x 108 copies
degradation of the HPV DNA was due to a component of semen, presumably 
nucleases, rather than to the extraction or blotting procedures 
employed. The TE controls also showed that the limit of detection of 
the extraction and Southern blot procedure was approximately 10pg 
viral DNA. HPV DNA seeded into extracted semen DNA is not degraded 
and the limit of detection appears to be 1-1Opg. It appears that 
there may be a slight masking effect caused by the presence of 
cellular DNA as the TE control seeded with 1pg HPV DNA could be seen 
more clearly than the 1pg DNA seeded into extracted semen DNA.
Using Avogadros number (figure 19 ), it can be calculated that 
10pg HPV DNA is equivalent to approximately 10® copies. Thus the DNA 
extraction procedure and Southern hybridisation method employed could 
detect 10® viral genome copies or, as 0.4ml semen is tested, in excess 
of 2.5x10 HPV DNA copies/ml semen would have to be present to be 
detected by this method.
Using Southern blot hybridisation, HPV 6/11 DNA was detected in 8 
of 20 semen specimens from patients with intrameatal warts and in one 
of seven patients with non-intrameatal penile warts. These results 
demonstrate the presence of genital types of HPV DNA in human semen,
1 P i
an observation not previously reported. Ostrow et al reported 
detection of HPV DNA types 2 and 5 in the semen of two patients with 
the rare autosomal recessive condition epidermodysplasia verruciformis 
and of a third patient with chronic lymphatic leukaemia but these HPV 
types are not commonly associated with lesions of the genital tract. 
These authors did not detect any HPV DNA, using an HPV 6 probe under 
conditions of low stringency, in the semen of 10 healthy donors. The
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findings here support the suggestion made by Ostrow that semen could
be a vehicle for HPV transmission. The results also show that HPV 6
and 11 DNA in the semen specimens was predominantly in the pellet
fraction ( although one specimen [figure 16, specimen 16] containing
HPV6 was detected predominantly in the supernatant fraction)
suggesting that the DNA is associated with cellular material rather
than present in free virions shed into the supernatant. Ostrow's
group found HPV associated with the supernatant fraction of the semen.
This may reflect differences in virion production of the lesions
caused by different HPV types or may be a result of an altered host
response in patients with underlying disease. Lesions of the skin
associated with HPV types 2 or 5 often contain very large numbers of 
1 39virions whereas genital lesions associated with types 6 and 11 
usually contain comparatively few. Thus it appears that the 'genital' 
HPV types are more cell-associated and rely less on production of a 
large number of free virions for transmission. However, only six 
specimens were examined in this way and confirmation with other 
specimens would be advantageous.
It is interesting to note that although HPV6/11 was detected in 
40% of semen specimens from males with intrameatal penile warts,
HPV16 DNA was not detected. This observation perhaps correlates with 
what is known about the lesions associated with the different HPV 
types; HPV types 6 and 11 are most commonly associated with 
condylomatous lesions ie the classic, exophytic wart whereas HPV16 is 
most frequently found in the flat pigmented lesions or in clinically 
inapparent lesions^ ^  (requiring the application of dilute acetic acid
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to render them visible). It seems likely that cell shedding will
occur more readily from HPV6- or HPV11-associated lesions than from
HPV16-associated lesions and this may account for the absence (or
smaller quantities) of HPV16 DNA in semen. It could of course be due
to patient selection as males with intrameatal penile warts have, by
definition, condylomatous lesions of the distal urethra and HPV16 is
141rarely detected m  condylomata acuminata although infection with 
types 6/11, 16 and/or 18 occur140. Alternatively, this observation 
may indicate that urethral HPV16 lesions are less common than urethral 
lesions of HPV6/11. This is hard to establish by clinical examination 
as detection of intraurethral condylomata beyond the very distal 
region of the urethra is difficult whilst detection of the flat and 
less obvious lesions is virtually impossible. No data is currently 
available regarding the prevalence of urethral HPV16 infections as 
indicated by DNA hybridisation studies.
Attempts have been made to determine the semen component with 
which HPV DNA is associated. As mentioned earlier, when semen 
specimens were centrifuged and the pellet and supernatant tested 
separately by Southern blot hybridisation, HPV DNA was demonstrated to 
be predominantly associated with the cellular pellet fraction. In 
order to determine with which component, ie epithelial cells or 
spermatozoa, HPV DNA was associated, semen specimens were subjected 
to a limited digestion procedure which allowed separation of 
spermatozoan from cellular DNA. HPV DNA was shown to be associated 
with cellular rather than the spermatozoan component. Further to 
this, HPV-positive specimens were fractionated on Percoll gradients
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and the fractions tested by Southern blot hybridisation, by in situ
hybridisation and by immunocytochemistry. Southern blot hybridisation
again suggested that the HPV DNA was associated with cells present in
the semen and not the spermatozoa. In situ hybridisation and
immunocytochemistry gave negative results which is not surprising
given the relative insensitivities of the two techniques.
Immunocytochemistry using a cross-reactive polyclonal antiserum is
known to give positive reactions in only 50% of tissue shown to be
1 42containing HPV DNA . In situ hybridisation is useful for localising 
HPV DNA in cells where the copy number is high but as no data is 
available as to the number of cells excreted into semen, the 
percentage likely to be HPV DNA positive or the number of copies of 
HPV DNA per cell, it is difficult to interpret this result. If 
sufficient material had been available it perhaps would have been 
worthwhile to repeat the in situ hybridisation procedure with larger 
volumes of semen in order to increase the number of cells examined and 
thus increase the sensitivity of the procedure.
There still remains a need for studies to determine the 
prevalence of genital HPV infections in males in order to assess the 
significance of the male genital tract as a reservoir for infection. 
HPV DNA was detected by Southern blot hybridisation in only 40% of 
semen specimens from males with evidence of current urethral HPV 
infection and in these the quantities of HPV DNA present were very 
low. Semen specimens tested from males attending an infertility 
clinic were all found to be negative for HPV DNA by Southern blot 
hybridisation. This may suggest that shedding of HPV into semen
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occurs infrequently and consequently is of little significance in the 
transmission of genital HPV infections. Transmission from infected 
individuals may be mainly by direct contact between infected epithlia 
of external penile surfaces and uninfected epithelia of the female or 
by non-sexual routes. However, 1-1Opg HPV DNA, equivalent to 2.5 x 
10  ^copies per millilitre of semen must be present to give a positive 
result by Southern blot hybridisation. In order to determine whether 
semen of infected individuals contains HPV DNA at levels below these, 
a more sensitive technique is required. The recently described 
Polymerase Chain Reaction (PCR)^^ may offer the required sensitivity 
and has been investigated in the following section.
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SECTION TWO
DEVELOPMENT OF A POLYMERASE CHAIN REACTION PROCEDURE 
FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS DNA
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CHAPTER 6
INTRODUCTION
THE POLYMERASE CHAIN REACTION AS A RESEARCH AND DIAGNOSTIC TOOL
The polymerase chain reaction (PCR) is an in vitro method for 
primer-mediated enzymatic amplification of specific target nucleic 
acid sequences. It allows the detection of DNA and RNA in clinical 
material when present in quantities well below those detectable using 
other nucleic acid detection systems such as dot blot and Southern 
blot hybridisation. Single gene copies can be detected and amplified 
to produce sufficient quantities of the target DNA sequence for 
detailed analysis. PCR was brought to the attention of molecular 
biologists in 1985 when researchers from the Cetus Corporation 
described a rapid prenatal test for sickle cell anaemia . This test 
was based upon the ability of PCR technology to identify a single base 
mutation in the human B-globin gene using entire foetal genomic DNA 
and demonstrated both the remarkable sensitivity and highly specific 
nature of the procedure. PCR rapidly found applications in widely 
divergent scientific fields particularly in the study of genetically 
inherited diseases and infectious disease diagnosis.
Principle of PCR
Selective amplification of the specific DNA sequence of interest 
is achieved through repeated cycles of template DNA denaturation, 
annealing of two specific oligonucleotide primers to nucleic acid 
sequences flanking the target sequence and primer extension with a DNA 
polymerase. Since the primer extension products of each cycle can act
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as templates for subsequent cycles, the number of copies of the target 
sequence can theoretically double with each cycle. PCR can increase 
the copy number of specific nucleic acid sequences (which can be less 
than 100 to greater than 2,000 bases) in length by a factor of 10® 
in only a few hours. Amplified products can be electrophoresed on 
agarose gels and visualised by ethidium bromide staining or hybridised 
with a labelled oligonucleotide probe complementary to an internal
region of the target sequence. The sensitivity of the PCR procedure
4 *5is generally in the order of 10-10 fold higher than that of pre­
existing DNA hybridisation techniques and, under optimal conditions,
5 1can detect one gene copy per 10 cells .
The first step in the PCR procedure (Figure 20) is to select the 
target DNA sequence to be amplified and design suitable 
oligonucleotide primers. These are usually 18-23 base pairs long and 
are complementary to the DNA sequences flanking the target sequence on 
either strand (sense strand and antisense strand). When the sample is 
heated to temperatures above 90°C the two DNA strands separate 
allowing the primers access to the complementary regions. If the 
reaction mixture is then cooled, the primers, which are in excess, 
anneal with their complementary sequences on the target DNA thereby 
defining the region to be amplified and providing a starting point for 
DNA replication. In the presence of a DNA polymerase, the primers 
initiate synthesis of two new DNA strands. This cycle of 
denaturation, primer annealing and DNA extension is repeated and after 
a few cycles the target sequence predominates. Continued cycling 
results in an exponential increase in the number of copies- of target 
molecules. The relationship between the extent of amplification, Y, 
the efficiency of the reaction, X, and the number of cycles is
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Figure 20; The polymerase chain reaction; cycles 1-3.
Cycle 1; During heat denaturation, the two strands of sample DNA 
seperate allowing specific primers access to complementary sequences 
flanking the target region. On cooling to 50-60C, the primers anneal 
and at temperatures usually between 65C and 72C, 5' to 3' extension 
takes place resulting in synthesis of new DNA strand. At this stage, 
extension can occur far beyond the target sequence.
Cycle 2; The cycle is repeated with strands newly formed in 
cycle 1 and the original DNA molecules acting as templates for further 
synthesis.
Cycle 3; Again, DNA molecules formed in previous cycles act as 
template for further synthesis. A proportion of the molecules (marked 
*) are now of the anticipated size corresponding to the target 
sequence bracketed by, and including, the primer sequences. In 
subsequent cycles, these molecules increase in number exponentially 
and become the predominant species.
Cycle v
Cycle < 
I
Cycle < 
III
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Y = (1 + X ) n
If the procedure is 100% efficient over 20 cycles, there is a 
1,048,546-fold amplification. However, under test conditions lower 
amplification efficiencies ( 60-70%) are usually obtained and 30-60 
cycles are necessary.
The specificity of PCR is controlled in two ways. Firstly the 
product of the reaction is a double-stranded DNA molecule of 
specific molecular weight which corresponds to the portion of the 
target bracketed by, and including, the two primers. During the PCR 
process, non-specific DNA synthesis will occur whenever a primer 
anneals to an incompletely homologous region of any DNA present. The 
probability that the second primer will reproducibly but non- 
specifically anneal to the opposite strand at a precise position and 
in close proximity to the first is very low. However, non specific 
amplification may occur and consequently specificity of reaction should 
further be controlled by hybridisation of the amplification product 
with a specific oligonucleotide probe. The probe, usually 20-30 bases 
and detectable by virtue of isotopic or non-isotopic label, has a DNA 
sequence complementary to a region of the target DNA bracketed by the 
primers. In this way, specificity of reaction can be ensured.
Applications
The widespread use of PCR is largely due to tha apparent ease 
with which it can be performed. The utility and efficiency of the 
procedure have been increased by the availability of the DNA 
polymerase of the thermophilic bacterium Thermus aquaticus {Taq
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polymerase). Taq polymerase is thermostable and is able to withstand 
repeated heating to temperatures in excess of 90°C without significant 
loss of activity. The Klenow fragment of Escherichia coli DNA 
polymerase I was employed for much of the early PCR research. This 
enzyme is temperature sensitive and addition of fresh enzyme to the 
reaction mix was necessary after each PCR cycle. Use of a 
thermostable DNA polymerase enables the procedure to be automated and 
many programmable thermal cyclers are now available commercially for 
this purpose.
Factors Affecting the Efficiency of the PCR Reaction
Theoretically/ if one copy of target is present in the reaction 
mix prior to amplification, the number present following amplification 
will be 2n where n equals the number of amplification cycles. In 
practise, several parameters affect PCR efficiency. These include:-
i The nucleic acid template: Because of its inherent power, PCR will 
tolerate both small quantity and low quality DNA template. This 
means that, for example, in forensic analysis a single hair, which can 
yield upto 0.5 ng DNA is a suitable substrate. Whilst many clinical 
specimens have been found to require only minor processing in order to 
liberate the nucleic acid ( often simply addition of a lysis buffer 
and/or heating), some, for example faeces^  and blood^ , require more 
elaborate procedures to eliminate inhibitors of Taq polymerase.
Failure to remove these inhibitors will have a detrimental effect on 
the efficiency of amplification.
ii Oligonucleotide primers: The selection of appropriate 
oligonucleotide primers is critical for a sensitive and specific PCR 
procedure. Not a,f the &actors which affect primer binding efficiency 
are known but guidelines for primer design have been established and
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computer programs for this purpose are now available. No optimum
primer size has been found but they are commonly 15 to 30 bases in
length. A pair of primers will usually be of equal length and similar
G+c inflammatory disease 
119(PID) , ectopic pregnancy and sterility, with culture-positive
1 in
chlamydial infection found in upto 50% of infertile women . Gorini 
121et al demonstrated C. trachomatis infection in 32% of infertile
women and only 5.8% of fertile subjects. Thus, an increased incidence
of sexually-transmitted infections may be expected in this population
compared to the general population.
The demonstration of HPV DNA in semen confirms earlier
observations that the urethra may act as a reservoir of HPV 
84 99 103infection ' ' and supports the suggestion that semen has a
potential role in the transmission of genital HPV infections®®'®^'
Infection (and re-infection) of females may occur via HPV-infected
epithelial cells which have sloughed off urethral lesions into semen
during ejaculation. Alternatively, seminal fluid may become
1 02contaminated due to infection of the prostate gland . However,
studies have shown that HPV lesions are not restricted to the urethra
but are present on external surfaces of the genitalia. Males with
genital HPV infection exhibit lesions on the foreskin, shaft of the
1 22penis, the glans and periurethral areas . These lesions are often
present as very minor epithelial abnormalities and have been referred
98 1 23to as subclinical HPV infections ' . Despite their inconspicuous
morphology, the potential for transmission by direct 
infected/uninfected epithelial contact exists. Thus sexual 
transmission by direct contact or via semen may occur.
Both the studies determine the prevalence of HPV infection in
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Typical PCR Protocol
Repeat Steps
Step 1 Step 2 Step 3 Step 4
25 -  50 Times Up to 
“  105-Fold 
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in DNA94°--
Denaturation
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(Or Starting 
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Figure 21; Typical PCR protocol consisting of denaturation at 94C for 
30 seconds, primer annealing at 37C for 60 seconds and primer 
extension at 72C for, 2 minutes.
optimal Taq fidelity, including low annealing/extension temperatures 
and low magnesium and nucleotide concentrations.
Uses other than detection of known sequences
Following the first descriptions of the PCR procedure, many 
modifications have been described. These include procedures to detect 
and amplify RNA and procedures for applications in which the aim is 
not to detect known sequences but to modify them (eg site-directed 
mutagenesis). PCR procedures have also been developed which allow 
cloning and characterisation of genes for which the sequence is not 
known (eg inverse PCR, sequence-independant single primer 
amplification (SISPA).
i Amplification of RNA sequences via cDNA using reverse 
transcriptase and nested PCR: The PCR procedure can be adapted for
c
the amplification and detection of RNA sequences as well as DNA.
£
This has meant applications in the analysis of mRNA transcripts and
7 8in the detection of viruses with an RNA genome ' . In the case of DNA 
viruses which integrate with the host genome, this procedure allows
q
distinction between productive and latent infection .
The procedure (figure 22a) consists of an initial step in which 
cDNA is generated from the RNA template using reverse transcriptase 
(RTAse) followed by amplification of the cDNA molecule by the standard 
PCR procedure. For the first strand cDNA synthesis, priming may be by 
using random hexamers, oligo dT (for mRNA and virus genomes with poly 
A tails) or the downstream (3') primer. The cDNA copy then provides 
the template for amplification when the upstream primer and Taq 
polymerase are added (both RTAse step and PCR can be carried out in 
PCR buffer ). The efficiency of RNA PCR is dependant largely on the 
efficiency of the cDNA stage which in turn is dependant upon the
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Figure 22a: RNA PCR. RNA is reverse transcribed to give a cDNA/RNA
hybrid molecule. Reverse transcription is primer-mediated, 
employing either a specific ' downstream7 (ie antisense) primer, an 
oligo dT primer for message or other poly-A tailed RNA, or random 6- 
mers. Addition of a DNA polymerase (Taq) and specific primer(s) 
results'in synthesis of the second 7 sense 7 strand. Subsequent PCR 
cycling will result in amplification of the cDNA target sequence.
Figure 22b: Inverse PCR for the amplification of genomic region of
unknown DNA sequence. Regions adjacent to a region of known sequence 
can be amplified and subsequently characterised using this method. 
Genomic DNA is digested with a restriction enzyme and ligated to give 
circular molecules. Amplification with primers across unknown DNA 
sequences results in the production of a linear product consisting of 
sequences copied from regions flanking the primers.
Figure 22a
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purity and integrity of the RNA template. To ensure the final product 
does not arise from the amplification of any DNA sequences present, 
primers can be designed to amplify genes containing introns. As these 
are spliced from the transcribed RNA prior to translation, the product 
from RNA transcripts is smaller than the product derived from the DNA 
sequence.
Where low concentrations of target RNA are present a second 
amplification of first round PCR products may be necessary to obtain 
adequate yields. Nested PCR employs oligonucleotide primers internal 
to the first round primers and is carried out on a small quantity (1- 
2ul) of first round product. After a limited number of cycles , 
usually 20-25, this product can be visualised on ethidium bromide- 
stained agarose gels or detected by hybridisation. Nested primers 
have also, been employed in DNA PCRs where increased sensitivity and 
specificity are required.
ii Inverse PCR: This employs PCR to amplify nucleic acid regions of
1 0unknown sequence which are adjacent to known regions (Figure 22b) .
Instead of primers directing extension towards each other, primers are 
selected so that extension is away from the other primer. The 
template DNA is digested with a restriction enzyme and then 
circularised by ligating the two cut ends on each molecule. The 
circular molecule is amplified with extension occuring in both 
directions across the ligation site, to give a linear product 
consisting of sequences copied from regions flanking the primers.
This product can be DNA sequenced and further regions analysed using 
primers based on these data.
iii Detecting related sequences: PCR for the detection of specific 
sequences employs primers which are homologous to sequences flanking
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the target sequence. However, primers which are not perfect matches 
can also anneal to target sites and may direct extension thereby 
allowing amplification and detection of related sequences. It is 
often necessary to lower the annealing temperature in order that minor 
mismatches can be tolerated and it is important that mismatches are 
not at the 3' end of each primer as this is where the polymerase 
attaches new nucleotides. Tolerance of minor mismatches also means 
that this procedure can be used for site-directed mutagenesis (Figure 
22c)11.
Problems associated with PCR
False positives and contamination. The major problem with PCR
detection is that even if the specificity ( determined by the sequence
of the primers and the annealing temperature) can be established
beyond doubt, the sensitivity is so high that there is a great risk of
obtaining false positives. A single contaminating molecule may be
amplified to produce a band visible on an ethidiuim bromide-stained
agarose gel. This contamination can arise from several sources
including amplified products from previous PCR tests, cloned DNA,
culture-grown virus and positive samples. When handling multiple
samples sequentially, material can easily be transferred unknowingly
from one tube to another from pipettes, gloved fingertips and on dust
particles carried from one laboratory to another. Precautions to
12 13 14prevent contamination have been described ' ' and these are an
essential part of test design. It is important to physically separate 
the three main procedural stages of PCR;
Room 1) Assay mix preparation; Room 2) template preparation and 
addition; Room 3) post-PCR analysis. Each of these rooms should
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Figure 22c
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Figure 22c: Site-directed mutagenesis by 'megaprimer" method. Three
primers are designed. P1 consists of a sequence complementary to the 
sequence at the site of required insertion interrupted by the sequence 
to be inserted. Amplification with P1 and P2, a specific 'upstream' 
primer, results in production of a double-stranded DNA molecule 
containing the inserted sequence. Use of this product as a PCR 
megaprimer in combination with P3, a specific 'downstream' primer, 
results in the production of a full-length molecule containing the 
inserted sequence.
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be dedicated for their particular purpose and should not have been
used previously for the in vitro culture or nucleic acid cloning of
related sequences. Reagents and apparatus used within the rooms
should also be dedicated and no materials entering room 1 should do
so without decontamination. Pipettes used should be positive-
displacement rather than air-displacement and work should be carried
out in laminar flow cabinets where possible. Gloves are essential
while masks, hats, gowns and goggles may all help to avoid
1 4contamination from skin . Handling of reagents should be minimised 
by aliquotting; similarly, specimen preparation procedures should be 
simplified where possible. Reaction mixes can be treated with
AC 4 C
ultraviolet- (or gamma- ) radiation prior to addition of primers 
and template to inactivate contaminant DNA. The enzyme uracil DNA
CO
glycosylase (UDG) has also been used to control carry-over . In this
procedure, dUTP is substituted for dTTP in reaction mixes. Prior to
thermal cycling, reaction mixes, complete with test DNA, are treated
with UDG.- This enzyme cleaves the uracil base from the phosphodiester
backbone of uracil-containing DNA ( ie any DNA product carried over
from previous PCRs) whilst leaving dUTP and 'native 'DNA unaffected.
If reaction mixes are then heated to inactivate the enzyme,
amplification can be performed. The use of nested primers can
potentially improve PCR specificity and reduce contamination problems
associated with PCR product as the second round amplification product
lacks sequences homologous to the first round amplification primers
1 7and consequently cannot act as a template
Provided that a strict protocol is followed, it is 
possible to reduce incidences of carry-over or cross contamination to 
a minimumn. However, it is absolutely essential that contamination
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controls are included every time a PCR is performed. These include 
negative-controls co-processed throughout the entire template 
preparation and reagent controls. DNA used as a positive control 
should be as dilute as possible to minimise contamination from this 
source.'
False negatives: False negative PCR results can occur due to use of
insufficiently homologous primers (for example where genomic variation
within virus types or strains exist), due to the presence of Taq
polymerase inhibitors in DNA template preparations or from
insufficient amplification for the task to be performed. Where
possible, primers should be complementary to conserved genomic
sequences to minimise false negatives due to genomic variation.
Alternatively, such problems can be partly overcome using primers with
18degenerate (inosine) bases or by using more than one set of primers 
19simultaneously .
Non-specific amplification: Non-specific amplification occurs when
primers anneal to sites other than or in addition to the target site.
The product of non-specific amplification can usually be 
differentiated from target bands by the use of post-PCR hybridisation 
with a specific, labelled probe. However, if this is occurring 
extensively, resulting on agarose gel analysis as a visible smear over 
a range of sizes, amplification of sequences unrelated to the target 
sequence will have a detrimental effect on the amplification of specific 
product as both enzyme and nucleotides will be utilised. Optimisation 
of PCR conditions ie adjustment of annealing temperature, and of 
concentrations of primers, enzyme and magnesium, is necessary to 
eliminate this problem.
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Applications of PCR
i The study of^genetic variation-associated diseases: PCR has found
many applications in the study of genetic diseases, some of which are
listed in table 11. The first application of PCR was the prenatal
diagnosis of sickle-cell anaemia . Prior to the use of PCR, detection
of this mutation in foetal material (cells obtained by chorion villus
sampling (CVS) or amniocentesis) was by digestion of the extracted DNA
with the restriction enzyme Mstll (or its isoschizomers CVnI or OxaNI)
followed by Southern blot hybridisation. These restriction enzymes
will cut the DNA at the normal B-globin gene but fail to cut at the
mutated sickle B-globin gene. This procedure usually required two
or more weeks from the date of foetal sampling whereas diagnosis by
PCR takes only two to four days. PCR provides greater speed, accuracy
20and technical flexibility in the diagnosis of this disease . PCR
21also provides a means for rapid sex determination and it is now
possible to detect disorders in single cells separated from the 8-16
cell stage human conceptus, before implantation into the potential 
22mother . PCR has also become an asset in prenatal diagnosis, 
presymptomatic detection and carrier detection of other inherited 
diseases for which the sequence of the critical DNA regions is known, 
including B-thalassemia, a-thalassaemia, most cases of Duchenne 
muscular dystrophy and some cases of haemophilia A and retinoblastoma.
Restriction fragment length polymorphism linkage markers for cystic
23fibrosis are being replaced.by PCR markers for pedigree analysis and
carrier demonstration. PCR also allows investigation of archival
material such as Guthrie cards (newborn blood spots stored on filters)
24for genetic disorders. Retrospective diagnoses of phenylketonuria
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25and cystic fibrosis have been made from this material and it seems 
likely that these cards will provide considerably more information as 
other applications of PCR are found.
HLA typing: The relationship of certain human leucocyte antigen (HLA)
polymorphisms and autoimmune diseases such as insulin dependant
diabetes mellitus (IDDM) and pemphigus vulgaris (an inflammatory
disease of the skin) have also been studied using PCR. Certain HLA
genes which are indicaters of disease susceptibilty have been
recognised and can be used in risk prediction. For IDDM, the marker
for susceptibilty is codon 57 of the HLA DQ beta I gene which normally
codes for an aspartate residue. One study revealed that 96% of IDDM
patients were homologous non asp / non asp at codon 57 compared with
19.5% of healthy patients . Three amino acid mutations in the HLA DR
beta I gene similarly appear to be closely associated with pemphigus 
27vulgaris . Relationships between HLA polymorphisms and disease
28susceptiblity have also been recognised for coeliac disease ,
29 29 30multiple sclerosis , myasthemia gravis , and rheumatoid arthritis .
PCR followed by direct sequencing,of HLA loci has advantages over
31traditional HLA haplotyping methods in that no expression of genes 
is required and that the resolving power between very similar 
haplotypes is down to a single nucleotide.
Neoplastic disorders: PCR has a major role to play in the detection
32and analysis of human cancers, leukaemias and lymphomas . A variety 
of mutations have been recognised in the K-Ras, N-Ras and H-Ras 
oncogenes of DNA isolated from peripheral blood or bone marrow from 
patients with acute myelogenous leukaemia (AML). PCR-mediated 
sequencing provides a rapid and reliable means for their detection.
145
References for Table 11
Highsmith WE,Jr, Perry TR, Prior TW, Silverman LM. 1989. Clin 
Chem; 35; 1260-1261
Hirona A, Beutler E. 1988. Proc Natl Acad Sci; 85; 3951-54 
Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT.
1988.. Nucl Acid Res; 16; 11141-11156
Leitersdorf E, Hobbs HH, Fourie AM, Jacobs M, van der Westhuyzen 
DR, Coetzee GA. 1988. Proc Natl Acad Sci; 85; 7912-7916 
Inaba H, Fujimaka M, Kazazian HH Jr, Antonarakis SE. 1989.
Hum Genet; 81; 335-338
Winship PR, Rees DJ, Alkan M. 1989. Lancet; i; 631-634 
McIntosh I, Curtis A, Millan FA, Brock DJ. 1989. Am J Med; 1989
32; 274-276
Myano M, Nanjo K, Chan SJ, Sanke T, Kondo M, Steiner DF. 1988. 
Diabetes; 37; 862-866
Kishimoto TK, O'Connor K, Springer TA. 1989. J Biol Chem; 264 
3588-3595
Dilelle AG, Huang WM, Woo SL. 1988. Lancet; i; 497-499
Endo H, Hasegawa K, Narisawa K, Tada K, Kagawa Y, Ohta S. 1989.
Am J Hum Genet; 44; 358-364
Dunn JM, Phillips RA, Zhu X, Becker A, Gallie BL. 1989. Mol
Cell Biol; 9; 4596-4604
Ritchie HH, Hughes MR, Thompson ET. 1989. Proc Natl Acad Sci; 
86; 9783-9787
Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. 1986. 
Nature; 324; 163-166
Myerowitz R. 1988. Proc Natl Acad Sci; 85; 3955-3959
Wong C, Dowling CE, Saiki RK, Higuchi RG, Erlich HA, Arnheim N,
Wilson AC. 1987. Nature; 330; 384-386
Table 11
Applications of PCR to the study of genetic diseases
Disease 
Cystic Fibrosis
Drug-induced haemolytic anaemia 
Duchenne muscular dystrophy 
Familial hypercholestrolaemia 
Haemophilia A 
Haemophilia B 
Huntingtons disease 
Hyperinsulinaemic syndrome 
Leukocyte adhesion deficiency 
Phenylketonuria
Pyruvate dehydrogenase deficiency 
Retinoblastoma
Rickets (vitamin D resistant) 
Sickle cell anaemia 
Tay-Sachs disease 
Thalassaemia
Defective gene
CF transmembrane regulator3 
glucose-6-phosphate dehydrogenase 
dystrophin0
j
LDL receptor 
Factor VIIIe 
Factor IXf 
HD locus^
Y\
insulin
Leukocyte integrins1 
Phenalanine hydroxylase-5 
Pyruvate dehydrogenase^
RB11
Vitamin D receptorm 
B globin11
Beta-N-acetyl- hexosaminidase0 
a and B globin^
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PCR has also been used to detect transcripts of the Philadelphia (Ph) 
chromosome associated with chronic myeloid leukaemia (CML). The 
Philadelphia translocation fuses the c-abl proto-oncogene from 
chromosome 9 to a region of chromosome 22 producing tumour-specific 
mRNA . PCR-mediated sequencing has facilitated routine screening of 
bone marrow cells following transplantation for CML and tne detection 
of residual Ph+ cells after treatment34. Specific chromosomal 
rearrangements are associated with several leukaemias and are 
therefore useful diagnostic markers detectable by PCR. Analysis and 
characterisation of genetic abnormalities are greatly assisted by PCR 
technology.
Forensic science: The ultimate goal of forensic DNA analysis is to
obtain a positive identification on the donor of a biological sample 
held as evidence. Restriction fragment length polymorphism analysis 
(RFLP) can be used to generate individual-specific DNA 'fingerprints' 
provided the DNA is relatively undegraded and present in sufficient 
quantity (at least 50ng for a single locus probe). The ability to 
amplify DNA from a wide range of biological samples including blood, 
semen and' hair has provide a simpler and more rapid means to detect 
DNA polymorphisms. PCR-mediated genetic fingerprining has been 
described47 and HLA DQ genes have been typed from a single hair48. A
potentially serious problem with these analyses is that of 
contamination. Foreign DNAs derived from several different sources 
may become associated with the sample before collection, during 
collection or during anlysis. A particular problem is that of 
heterologous human DNA which may be collected as a contaminant. 
Depending upon the circumstances of a crime, DNA mixtures of blood, 
saliva, semen, hair or other tissue may be present. Some of these may
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be separated by differential cell lysis procedures ( for example, the 
insensitivity of semen to lysis in the absence of a reducing agent ) 
and subsequent analysis performed on a single cell4®'50. Procedures 
to prevent contamination during subsequent analysis are as outlined 
earlier.
Infectious Diseases: PCR has now been applied to the detection of a
wide variety of viral, bacterial and protozoal pathogens from a 
variety of biological sources. The procedure is particularly useful 
for the detection of pathogens for which culture in vitro is difficult 
(for example, CMV, polyoma virus, parvovirus B19) or impossible 
(papillomavirus, hepatitis B virus, adenovirus types 40 and 41) and 
where early detection of infection may have significant clinical value 
to the patient or in public health terms (HIV). A million-fold 
amplification of target sequences can be achieved, facilitating the
5
detection of one gene copy in 10 eukaryotic cells. This has meant 
that, although hybridisation of amplified products with radio-isotope 
labelled probes increases the sensitivity of the assay, non-isotopic
■3 C
hybridisation systems are often adequate. Larzul et al for 
example, described PCR using an acteylaminofluorene-labelled DNA probe 
for the detection of hepatitis B virus in serum which could detect 3- 
30 particles. An early application of PCR was for the detection, 
diagnosis and characterisation of HIV1 and the variety of ways in 
which PCR could be applied highlights the versatility and power of the 
technique. Although serological assays for HIV are important in the 
identification of infected persons, detection of early stages of 
infection prior to seroconversion, when the HIV proviral DNA is 
integrated into the host chromosomal DNA, requires a nucleic acid 
hybridisation assay. However, because of the low number of infected
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peripheral blood mononuclear cells (PMBCs) in an HIV-positive
36person , conventional molecular biology techniques such as Southern 
blot were of inadequate sensitivity. Using PCR, 10 integrated HIV
c 07
copies can be detected in the presence of 10 uninfected lymphocytes
facilitating detection in seronegative and paediatric patients , ie
infants born to seropositive mothers. In 1986 a second AIDS virus,
HIV-2, was discovered and shown to be endemic in parts of West
Africa4®. PCR has been used as an adjunct to serological testing to
41determine if a patient is infected with HIV-1 and/or HIV-2 . PCR
has also been used to directly clone and sequence amplified HIV-1 DNA
42 9and HIV-1 cellular RNA . This has facilitated analysis of
transmission patterns and of evolutionary relationships4  ^ between
isolates without the need for virus culture which may lead to strain
selection. It can be seen that PCR is a versatile tool for use in the
study of complex viral infections such as HIV. Other properties of
the technique have also been exploited. PCR can be used to test
specimens obtained by non-invasive means. For example, CMV can be
detected in urine from congenitally infected newborns44 and Epstein-
Barr virus (EBV) can be detected in throat washings . Genomic
analysis of viral isolates has also been performed using PCR. This
has been useful, for example, to differentiate between 'wild' strains
and vaccine strains of mumps virus in cases of post-vaccination
meningitis4®
PCR has been widely applied to the study of human papillomavirus 
infection, particularly genital i n f e c t i o n s ® ' ® ® '  69-95^ 
Detection of HPV has always largely depended upon DNA hybridisation 
techniques as these viruses cannot be cultured in vitro and no
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assays are currently available. Studies employing dot blot and 
Southern blot procedures have led to the suggestion of an association 
of infection of the cervix with certain HPV types (particularly HPV16) 
and the development of cervical neoplasia. However, these types have 
also been detected in histologically normal cervices suggesting other 
factors to be involved. Clear information as to prevalence of HPV 
infections of the cervix in females with and without apparent 
cytological and histological abnormality has been lacking due partly 
to the insensitivity of the techniques employed. PCR offers 
sensitivity of detection far greater than that of pre-existing 
techniques (Table 12) and has great potential as an epidemiological 
tool in the study of HPV infections.
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Table 12
Comparison of techniques for the detection of HPV DNA in clinical 
material
Dot blot:
Southern blot: sensitivity
Advantages
Disadvantages 
sensitivity 
Advantages 
Disadvantages 
sensitivity 
Advantages
Reverse blot:
Sandwich : 
hybridisation
Disadvantages
sensitivity
Advantages
Disadvantages 
Tissue in situ: sensitivity
Advantages
Disadvantages
Filter in situ: sensitivity
(FISH)
Advantages
Disadvantages
PCR: sensitivity
Advantages
Disadvantages
0.1 copies/cell
allows restriction enzyme analysis 
shows integrated or episomal form 
can be used at low/high stringency 
requires approximately 1Oug of DNA 
fairly laborious 
1 copy/cell
rapid
requires only 1ug DNA 
can give false positives 
used at high stringency only 
1 copy/cell
requires only 1ug DNA, type specific 
can be used at high/low stringency 
uses individual labelling reactions 
5-10 copies/cell
rapid
only one HPV type/sample analysed 
variable3 down to 5 copies/ cell
provides cellular localisation
allows correlation of HPV type and
cellular morpholgy
detects rare positive cells
relatedness only (except if sub-
genomic probes used)
variable
rapid
minimal specimen processing 
detects relatedness only 
gives false positives 
used under high stringency only 
0.00001 copies/cell
highly sensitive 
semi-automated
requires sequence information 
vunerable to contamination/false 
positives, expensive
a Sensitivity reported to vary according to probe type and detection 
system. 5 copies/cell obtained using ^H-labeled DNA probe^
Sensitivity difficult to express in this format. Cornelissen*^ 
estimated FISH to be one third as sensitive as in situ hybridisation,
151
CHAPTER 7
Objectives of Section Two
The aim of this section is to apply the polymerase chain reaction 
(PCR) to the detection of HPV DNA in clinical materials including 
cervical scrape and biopsy material, semen and penile scrapes. Other 
researchers have described the use of PCR for the detection of HPV DNA 
in several population groups, but differing results have been obtained 
(see discussion) and no clear picture as to the distribution of 
genital HPV infections, nor to the evidence for an association of HPV 
infection and cervical malignancy, has emerged. Objectives here are 
to:
1) Confirm that HPV DNA can be detected using this method, initially 
testing cloned HPV DNA and later using clinical materials.
2) To optimise the PCR procedure and to investigate certain factors 
which affect PCR efficiency ie primer selection, primer concentration, 
magnesium ion concentration.
3) To investigate the suitability of PCR as a diagnostic and/or 
epidemiological tool.
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Table 13
OLIGONUCLEOTIDE PRIMERS FOR HPV TYPES 11, 16 AND 3'
PRIMER SEQUENCE POSITION
LYHPV11-E6-5'a CGCAGAGATATATGCATATG 221-240
LYHPV11-E6-3'a AGTTCTAAGCAACAGGCACA 291-310
LYHPV16-E6-5'a TCAAAAGCCACTGTGTCCTG 421-440
LYHPV16-E6-3'3 CGTGTTCTTGATGATCTGCA 521-540
HPV31 -E6-5' GTGTCAAACACCGTTGTG 422-439
HPV31 -E6-3' TCAGTACGAGGTCTTCTCC 526-544
PRODUCT
90bp
120bp
123bp
a) As described in L.S Young et al: Br Med J; January 7th 1989;298; 
14-18
PART ONE: MATERIALS AND METHODS
2.1 Oligonucleotide primers
Oligonucleotide primers used for the detection of HPV11 DNA
52were those described by Young et al . This pair were coded LYHPV11
and amplify a 90 base pair region of the E6 ORF between bases 221-310.
Primers for the detection of HPV16, LYHPV16, were also as described by
Young et al and amplify a 120bp region of the E6 ORF between bases
421-540. Primers for the detection of HPV31 DNA were based on
53available sequence data and were selected using the Epicentre 
primer selection program. These amplify a 123bp region of the E6 ORf 
between bases 422 and 544. Table 13 shows the primer DNA sequences. 
Oligonucleotide primers were synthesised at a concentration of 0.2um 
on a model 380 Applied Biosystems DNA synthesizer.
2.2 Reaction Reagents
A 5x reaction buffer was prepared containing 335mM Tris pH8.8 
(25°C), 83mM (NH^^SO^, 34mM MgC^, 50mM B-mercaptoethanol, 34uM EDTA 
and 0.85ug/ml Bovine serum albumin (BSA). Heat-stable components were 
autoclaved individually before combining. Sterile BSA was obtained 
from a commercial source (Gibco BRL) and was added to the reaction 
mix using aseptic technique.
Deoxynucleotides were each obtained at a concentration of 100mM 
(Pharmacia) and were diluted down to 60mM with distilled water and 
equal volumes mixed to give a final concentration of 15mM of each.
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PCR reaction mixes were prepared containing;
5X reaction buffer  10.0 ul
dNTP mix (1 5mM of each)    5.0 ul
25 pmol of each primer, premixed  1.0 ul
sterile water to 49.5ul  32.5 ul
Substrate DNA (1 pg HPV DNA).........   1 .0 ul
Total 49.5 ul
An overlay of 75ul mineral oil was added to prevent evaporation of 
the reaction mix during heating stages of the amplification procedure.
2.3 PCR procedure
PCR reactions were performed in 50ul volumes using a Cambio MKII 
Intelligent Heating Block. After an initial denaturation step of 95°C 
for 5 minutes and annealing at 50°C for 30 seconds, 1.5 unit Taq 
polymerase (in 0.5ul) was added to each reaction tube. This was 
followed by 35 cycles of:
Extension at 67°C for 3 minutes
Denaturation at 91°C for 1 minute
Primer annealing at 50°C for 1 minute,
followed by a final extension at 67°C for 5 minutes.
2.4 Analysis pf the product
20ul samples of each amplification reaction were transferred to 
an eppendorf tube and 5ul Orange G/ Ficoll added. A 4% composite gel 
consisting of 3% Nuseive and 1% Seakem agarose in TBE buffer (0.089M 
tris-borate, 0.089M boric acid, 0.002M EDTA) was prepared. The gel 
tray was placed into the horizontal gel tank and TBE buffer was added 
until in contact with the gel but not overflowing onto the upper
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Table 14
PROBE SEQUENCES FOR HPV TYPES 11, -16 AND -
PRIMER SEQUENCE
LYHPV11-E6-PROBE CCTAAAGGTTGTGTGGCGAGACAACTTTCC
LYHPV16-E6-PROBE GACAAAAAGCAAAGATTCCATAATATAAGG
HPV31-E6-PROBE AACGATTCCACAACATAGGAGGAAGGTGGA
POSITION
251-281
461-490
surface of the gel. The gel is loaded 'dry' to avoid overflow from 
one well to another. The amplification reactions were loaded into the 
wells and electrophoresed at 80mA until the dye front had run 
approximately 2cm into the agarose. More buffer was then added to the 
gel tank in order to totally cover the gel. Electrophoresis and 
visualisation of DNA bands were as described earlier (section 1; 
method 5)
2.5 Preparation of oligonucleotide probe
DNA oligomers of 30 bases in length, complementary to internal 
sequences of the amplified product, were synthesised at a 
concentration of 0.2uM on a Applied Biosystems model 380 DNA 
synthesiser. DNA sequences of internal primers for HPV types 11, -16
and -31 are shown in table 12. 25-50 picomoles (1ul) of each primer
32was end-labelled with P-ddATP by terminal deoxynucleotide 
transferase (TdT) using a DuPont kit (code NEP100). Labelling was 
performed according to manufacturers instructions. Labelled oligomers 
were separated from unincorporated nucleotides using a Phamacia 'Nick' 
column. The probe was obtained in a volume of 400ul and had an 
activity of approximately 3x10^cpm/ul.
2.6 Oligomer hybridisation
To a 15ul aliquot of each reaction mix was added 10ul of the probe
mix consisting of 4ul 60mM NaCl, 1ul 40mM EDTA (pH 8.0), 0.15 pmol
3? 4P-end-labelled probe (~1x10 counts) and sterile H2O to 10ul. After
thorough mixing, the tubes were heated to 95°C for 5 minutes in order
to denature the double-stranded amplification product, and then cooled
to 55°C for 15 minutes during which time the probe and target sequence
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anneal. Heating and cooling steps were carried out using the Cambio 
Mkll programmable thermal cycler. The tubes were briefly centrifuged 
and 5ul Orange g/Ficoll dye mix added to each tube. The mixes were 
electrophoresed on a 4% composite agarose gel, stained with ethidium 
bromide and photographed as described above. The gel was sealed in a 
clear polythene bag and exposed directly to Amersham Hyperfilm MP x- 
ray film overnight at -70°C.
2.7 Procedures for the prevention of cross-contamination and 'carry­
over '
i) Organisation of PCR facilities.
Three separate laboratories were designated for different stages 
of the PCR procedure.
Room 1 : Reagent preparation room in which primers, Taq polymerase and 
nuceotides were stored and bulk reaction mixes were prepared, 
aliquotted into test volumes and stored at -20°C. Manipulations 
were performed in laminar flow hoods.
Room 2 : DNA extraction room: Clinical specimens were received, the 
DNA extracted and added to the reaction mix.
Room 3 : PCR room: Amplifications were carried out in this room.
Positive control material was added here.
DNA cloning had at no time been performed in these rooms. A 
one-way system was in operation, allowing transport of reaction mixes, 
reagents and racks only from room 1 to 2 and then from room 2 to 3. 
Racks were decontaminated by overnight immersion in 1N HC1 followed by 
rinsing in water and autoclaving. Positive displacement pipettes 
(Microman)' were used in all rooms. Gloves were worn during all 
manipulations and were changed regularly.
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ii Reaction mixes: preparation and contamination check
PCR reaction mixes were prepared in bulk (sufficient for 120-150 
reactions ) containing all components except Taq polymerase and 
oligonucleotide primers. These were aliquotted in reaction volumes 
and stored at -20C until required. Prior to use of a batch, 10 tubes 
were selected at random and 1.5u Taq polymerase and 50pM HPV16 primers 
added to each. Two tubes were then seeded with 1pg (5ul) HPV16 DNA 
whilst to eight, 5ul distilled water was added. Amplification and 
analysis by electrophoresis were as described (methods 2.3-2.6)
2.8 Preparation procedure for Caski cell cultures
Caski cells, a cell line derived from cervical carcinoma with 
HPV16 sequences integrated into the genome , were grown in 2oz 
medical flats. When confluent, the cells were stripped from the 
bottle surface using trypsin, resuspended in PBS and pelletted by 
centrifugation. Cells were washed in PBS and counted using a Neubauer 
chamber. The cells concentration was adjusted to 10 cells /ml and
O f
dilutions prepared to give 10 -10 cells/ml.
2.9 Preparation procedure for cervical scrape specimens
Cervical scrape specimens were received on spatulas in universal 
containers of PBS + antibiotics. These were agitated on a whirlimixer 
for 1 minute to detach the cervical material from the spatula. The 
spatulas were removed and the cell suspension was centrifuged at 2000g 
for 10 minutes. The supernatants were discarded and the cell pellet 
resuspended in 1ml PBS. The cell suspension was transferred to a 
screw-capped eppendorf tube and centrifuged for 30 seconds. The 
supernatant was discarded and the pellet resuspended in 1ml PBS. This
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was again centrifuged for 30 seconds, the supernatant discarded and 
the cell pellet resuspended in 100ul TE.
2.10 Phenol/chloroform DNA extraction method
The sample was combined with SDS and proteinase K ( final 
concentrations of 1% and 500ug/ml respectively. After incubation at 
37°C for 1 hour, nucleic acid was extracted twice with an equal volume 
of phenol/chloroform and once with chloroform/isoamyl alcohol and 
precipitated with a tenth volume 5M sodium chloride and 2.5 volumes 
ethanol at -20°C overnight. DNA was pelletted by centrifugation, 
washed with 70% ethanol, dried under vacuum and resuspended in TE 
buffer.
2.11 8M urea DNA extraction procedure for 'difficult'specimens
The sample was combined with an equal volume of lysis buffer 
consisting of 8M urea, 0.4M NaCl, 0.2M Tris pH 8.0, 1% n- 
lauroylsarcosine and 0.02M CDTA. Proteinase K was added to a 
concentration of 100ug/ml. After incubation for 1 hour at 55°C, an 
equal volume of phenol/chloroform was added. This was thoroughly 
mixed and then centrifuged for 2 minutes. The top phase was removed 
and re-extracted with a further volume of phenol/chloroform and then 
with an equal volume of chloroform/iso-amyl alcohol. 50ul 7.5M NH^OAc 
and 250ul absolute ethanol were added and the tubes placed at -70°C 
for 2 hours. The DNA was pelleted by centrifugation for 15 minutes 
and the pellet washed with 70% ethanol. The DNA was dried under 
vacuum and then resuspended in 50ul TE.
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2.12 Boiling procedure
The samples were placed in a boiling water bath for 10 minutes 
and then on ice for 2 minutes. These were microfuged (2700g) for 1 
minute to pellet cellular debris.
2.13 Dot blot hybridisation
PCR reaction sample was diluted to 100ul with sterile 1^0 and 
then denatured by the addition of 25ul 2.5M NaCl, 1.5M NaOH for 30 
minutes at room temperature. The denatured DNA was drawn under vacuum 
onto a Hybond-N nylon membrane using "minifold11 dot-blotting 
apparatus. The DNA dots were neutralised by the addition of 200ul 
1.5M NaCl, 0.5M tris-HCl (pH 7.2) and 0.001M Na2EDTA.This was drawn 
onto the membrane under vacuum. The nylon membrane was removed from 
the apparatus and placed in an envelope of 3MM paper and dried at 37°C 
for 1 hour. The membrane was wrapped in 'clingfilm' and exposed to 
ultra-violet light for 10 seconds. The clingfilm was removed and the 
blots hybridised.
2.14 Southern blot hybridisation
PCR reaction samples and 10ul orange G/ficoll loading buffer were 
mixed. These were electrophoresed on a 4% composite gel and the DNA 
bands visualised with ethidium bromide and photographed as described 
previously (method 2.4). The DNA bands were depurinated by 
immersing the gel in 0.25N HC1 for 10 minutes and Southern transferred 
to a nylon membrane (section 1, methods) using 0.4M NaOH as 
transfer buffer. After transfer the apparatus was dissembled, the 
membrane gently rinsed to remove any adherent agarose and dried at 
37°C for upto 1 hour.
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2.15 Hybridisation of dot and Southern blot membranes
Prehybridisation of the dot blot and Southern blot membranes was 
performed at 42°C for 2 hours in 30% formamide, 5 X SSC, 2 X Denhardt, 
10% dextran sulphate and 150ug/ml salmon sperm DNA. Hybridisation 
took place in the same buffer at 42°C overnight with a ^P-3' end- 
labelled probe oligonucleotide. The membranes were washed twice in 2 
X SSC, 0.1% SDS for 10 minutes at room temperature and twice for 15 
minutes in 0.2 X SSC, 0.1% SDS at 58°C. The membranes were sealed in 
polythene and exposed to x-ray film at -70°C overnight.
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CHAPTER 9
SECTION 2- RESULTS
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T a b le  15
[HPV PRIMERS] VS [TAQ POLYMERASE ] TITRATION
TUBE No.
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20
RX buffer
40ul
n
ii
[Primers1]
25 pMol 
12.5pMol 
6.25pMol 
3.12pMol 
0
25 pMol 
12.5pMol 
6.25pMol 
3.12pMol 
0
25 pMol 
12.5pMol 
6.25pMol 
3.12pMol 
0
25 pMol 
12.5pMol 
6.25pMol 
3.12pMol 
0
[ Taq ]
2.0 units
1.0 unit
0.5 unit
0 unit
[DNA1];
10pij
II ! 
H !
Primer pairs LYHPV11, LYHPV16 and JGHPV31 were each tested with 
the appropriate target HPV DNA, i.e. 10pg cloned HPV11, HPV16 and 
HPV31 DNA purified using the methods described previously (Section 1, 
Methods 14 and 15).
A;OPTIMISATION AND VALIDATION OF PCR CONDITIONS
1: Amplification of cloned sequences
Purified HPV11, 16 and 31 DNAs were prepared from pGHPVI1, pGHPVl6 
and pBHPV31 plasmids as described previously (Section 1, methods 14, 15) 
Amplification of cloned HPV DNA for HPV types 11, 16 and 31 was
go
attempted using PCR conditions described by Kogan (methods 2.2) and primer 
pairs LYHPV11, LYHPV16 and JGHPV31 (method 2.1). 35 cycles of amplification
were performed (method 2.3). Figure 23 shows an ethidium bromide-stained 
agarose gel of specific amplification products generated for these HPV types 
using the primers described. Products of 90, 120 and 123bp were produced 
for HPV types 11, 16 and 31 respectively. Reagent controls which 
contained primers but no target DNA were negative.
2: Evaluation and Optimisation of PCR conditions
i Optimisation of primer and Taq polymerase concentrations
Twenty 40ul aliquots of reaction mix (reaction buffer and dNTPs) 
were dispensed. Serial two-fold dilutions of oligomer primers ranging from 
undiluted to 1 in 8 were prepared in sterile distilled water. The effect of 
decreasing primer and Taq polymerase concentrations on amplification was 
determined by preparing reaction mixes containing doubling dilutions of 
primers and adding 2.5, 1, 0.5 or 0 units Taq polymerase in a 'chessboard ' 
arrangement (Table 15). 1pg target DNA was added to each tube and 35 
cycles of amplification were performed (method 2.3). Figure 24 shows 
an ethidium bromide-stained agarose gel of amplification products 
obtained for HPV16.
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Figure 23: Amplification of cloned HPV DNA types 11, -16 and -31
HPV31 HPV16 HPV11
M - + - + -  + M
120/123bp -
- 90bp
Figure 23: PCR amplification of cloned HPV11, -16 and - 31 DNA.
Lanes 2, 4 and 6 show products obtained for HPV types 11, -16 and -31 
respectively, following 35 amplification cycles of 1pg cloned DNA. 
Lanes 3, 5, and 7 are reaction mixes to which no target DNA was added. 
Amplification products for HPV11, -16 and -31 can be seen to be 90,
120 and 123 base pairs respectively as anticipated. A BRL 1kb ladder 
DNA were also electrophoresed as size markers.
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T a b le  16
DETERMINATION OF OPTIMAL MAGNESIUM CONCENTRATION
Tube [MgCl23 Primers3 HPV DNAb Cellular DNAC water Taq
1 10 1ul LY16 1ul HPV16 7ul _ .5u
2 6.6 1ul LY16 1ul HPV16 7ul - .5u
3 4.4 1ul LY16 1ul HPV16 7ul - .5u
4 2.96 1ul LY16 1ul HPV16 7ul - .5u
5 1 .97 1ul LY16 1ul HPV16 7ul - .5u
6 1.3 1ul LY16 1ul HPV16 7ul - . 5u
7 0.8 1ul LY16 1ul HPV16 7ul - . 5u
8 0.54 1ul LY16 1ul HPV16 7ul - .5u
9 0.00 1ul LY16 1ul HPV16 7ul - . 5u
10 10 1ul LY16 1ul HPV16 - 7ul . 5u
11 6.6 1ul LY16 1ul HPV16 - 7ul . 5u
12 4.4 1ul LY16 1ul HPV16 - 7ul .5u
13 2.96 1ul LY16 1ul HPV16 - 7ul . 5u
14 1 .97 1ul LY16 1ul HPV16 - 7ul .5u
15 1 .3 1ul LY16 1ul HPV16 - 7ul . 5u
16 0.8 1ul LY16 1ul HPV16 - 7ul .5u
17 0.54 1ul LY16 1ul HPV16 - 7ul .5u
18 0.00 1ul LY16 1ul HPV16 - 7ul .5u
a [Primer] 25pM each/ul 
b [HPV DNA] 1pg/ul 
c [Cellular DNA] 0.75ug/ul
Results obtained for HPV11 and HPV31 primers were identical (Table 
17). Overall, there appeared to be equally good amplification in 
reaction mixes containing 2, 1, or 0.5 units Taq polymerase. 
Amplification appeared to decrease linearly with decrease in primer 
concentration ie amplification obtained using primers diluted 1 in 4 
was approximately a quarter of that obtained using neat primers.
ii Optimisation of magnesium concentration
Optimal magnesium concentrations were determined for HPV11, -16 
and HPV31 primer pairs in the presence and absence of cellular DNA. 
This was achieved by adding concentrations of magnesium chloride from
0-1OmM to magnesium-free reaction mixes containing HPV primers, 1.5 
units Taq polymerase and 1pg HPV DNA (Table 16).
Figure 25 show ethidium bromide-stained agarose gels of 
amplification products obtained. Magnesium profiles for HPV 11, -16 
and -31 were similar although HPV31 primers favoured slightly higher 
magnesium chloride concentrations. When no cellular DNA was present, 
HPV11 primers gave optimal amplification at 4 to 6mM whilst HPV16 
primers were equally efficient in magnesium concentrations of 4, 6 or 
8mM. HPV31 primers were optimal at 8mM magnesium but gave good 
amplification at concentrations of 4-8mM. In the presence of 
approximately 5ug cellular DNA, the magnesium concentration profiles 
were similar although no amplification occurred with either primer 
pair in magnesium concentrations of 2mM. Surprisingly, the optimum 
magnesium concentration for HPV11 and -16 primer pairs in the presence
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T a b le  17
Titration of HPV primer and Taq polymerase concentrations
HPV11
LYHPV11 PRIMERS (pMol)
TAQ (units) 50 25 12.5 6.25
2.5 +++ ++ + +
1 +++ ++ + +
0.5 ++ ++ + +
0 - - - -
HPV16
LYHPV16 PRIMERS (pMol)
TAQ (units) 50 25 12.5 6.25 0
2.5 +++ ++ + + . -
1 +++ ++ + + -ino ++ ++ + + -
0 - - - - -
HPV31
JGHPV31 PRIMERS (pMol)
TAQ (units) 50 25 12.5 6.25 0
2.5 +++ ++ + + -
1 +++ ++ + + -
0.5 ++ ++ + + -
0 - - - - -
Figure 24: TITRATION OF [PRIMER] v [ENZYME] FOR HPV16
PRI MER E N Z Y M E
N
112
1 . * 4
r.8
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Figure 24: HPV primers for HPV11, HPV16 and HPV31 were diluted from
neat (lanes labelled N) to 1 in 8 to give primer concentrations of 
50pM to 6.25 pMol. HPV primers were not added to one reaction tube. 
The number of units of Taq polymerase added varied from 0 to 2.5u.
1pg HPV DNA was added to each tube and 35 amplification cycles 
performed. Shown above is an ethidium bromide-stained agarose gel of 
results for HPV16 producing a 120bp product. Although amplification 
was only slightly decreased by reduction of enzyme concentration from
2.5 to 0.5 units/test, decreasing primer concentration resulted in 
significant, almost linear, reductions in product yield. Identical 
results were obtained for HPV11 and -31 primers (Table 17).
l ( o ( c
of an excess of cell DNA was 4mM.
iii) Effect of the number of amplification cycles
Six reaction mixes were prepared for each HPV type 11, 16 and 31, 
containing 5x reaction buffer, 1.5mM dNTPs, 25pM oligonucleotide 
primers, 1.5 units Taq polymerase and 100fg HPV D N A .  A  reaction mix 
was removed from the programmable heating block after 0, 5, 10, 20, 30 
and 35 cycles. Amplification products were analysed by agarose gel 
eletrophoresis and oligomer hybridisation (method 2.6). Figure 26 
shows the results obtained for HPV11. Identical results were obtained 
using HPV11 and HPV31 primers. Amplification was detectable by 
oligomer hybridisation after 20 cycles and by ethidium bromide-stained 
agarose gel after 30 cycles. 35 cycles were required for adequate 
amplification to be achieved.
iv) Determination of the limits of detection
Reaction mixes were prepared complete with HPV primers and 1.5 
units Taq polymerase. H P V  D N A  was added in 10pg, 1pg, 100fg, 10fg,
1fg and 100ag quantities and 35 amplification cycles were performed. 
Amplification products were analysed on agarose gels and by oligomer 
hybridisation (Method 2.6) Figure 27 shows the results obtained 
for HPV 16 primers and D N A .  After 35 amplification cycles product was 
visible on an ethidium bromide agarose gel of all reaction mixes 
seeded with 1fg or more HPV D N A .  By oligomer hybridisation, 100ag HPV 
DNA, equivalent to approximately 10 viral copies ( Avagadros number, 
figure 19) could be detected. Results obtained for HPV11, -16 and -31 
primers are presented in Table 18. Primer pairs for the detection of 
HPV11 and -31 D N A  had similar sensitivities to each other
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Figure 25: DETERMINATION OF OPTIMAL MAGNESIUM CONCENTRATION. Reaction 
mixes containing 0, 2, 4, 6, 8 and 10mM magnesium chloride were 
prepared. LY11 primers and 1pg HPV11 DNA were added to each. To an 
identical set of reaction mixes was added 5ug cellular DNA. Thirty 
five amplification cycles were performed.
This was also performed for HPV16 and -31 primers. Ethidium 
bromide-stained agarose gels of amplification products obtained are 
shown in figures 25a, b and c (respectively for HPV11, -16 and -31). 
Results are tabulated in table 18
Figure 25: Determination o f optimal magnesium concentration
a) HPV11
Cellular DNA No Cellular DNA
| mM MgCl2 11 mM MgCl2
M 0 2 4 6 8  10 0 2 4 6 8  10 M
b) HPV16
Cellular DNA No Cellular DNA
! mM MgCl2 | | mM MgCI2 
M 0 2 4 6 8  10 0 2 4 6 8  10 M
220bp—
1 5 4 _  
134 —
75 —
— 120bp
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Figure 25c: Determination of optimal magnesium concentration
c) HPV31
Cellular DNA Cellular DNA
mM MgCl2 | | mM M gC ^  
M 0 2 4 6 8  10 0 2 4 6 8  10 M
298bp —  
220 —  
154 —
— 123bp
Table 18
Magnesium chloride titrations for HPV11, -16 and -31 primers
10 8 6 4 2 0
HPV 11
with cellular DNA + + + ++ - -
no cellular DNA + + ++ ++ + -
HPV 16
with cellular DNA + + ++ ++ - -
no cellular DNA + + ++ + + -
HPV 31
with cellular DNA + + + + - -
no cellular DNA + ++ + + - -
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Figure 26: EFFECT OF NUMBER OF CYCLES
Figure 26: Thermal cycling of six reaction mixes containing HPV DNA
and primers was terminated after 0, 5, 10, 20, 30 and 35 cycles. 
Amplification products were tested by oligomer hybridisation. Shown 
above is the autoradiograph obtained for HPV16. A positive oligomer 
hybridisation reaction was demonstrable after 20 cycles whilst 
production of bands visible on ethidium bromide stained gels reguired 
30 cycles.
1 7 0
0 5 10 20 30 35 0 5 10 20 30 35
D N A  a d d e d  No D N A .
Table 19
DETERMINATION OF SPECIFICITY
TUBE No. Primers DNA
1 HPV 11 HPV 6
2 IV HPV 11
3 I HPV 16
4 I HPV 1 8
5 I HPV 31
6 I -
7 HPV 16 HPV 6
8 i HPV 11
9 it HPV 16
10 i HPV 18
11 i HPV 31
12 ii -
13 HPV 31 HPV 6
14 ii HPV 11
15 ii HPV 16
16 ii HPV 18
17 ii HPV 31
and to HPV 16 primers although the HPV16 primers were perhaps slightly 
more sensitive.
v) Specificity of amplification
The specificity of amplification by each primer pair was 
initially ensured by checking for homology between published DNA 
sequences for HPV types 1, -2, 6a, -11, -16, -18 and -31. Primer 
sequences were cross-checked for homology with other HPV types using 
the IBl/Pustell sequence data base manager^®^. Computer analysis 
confirmed that DNA sequences selected for oligonucleotide primer 
sequences were specific to the target HPV type. Secondly, specificity 
of amplification was investigated by testing their ability to amplify 
cloned DNAs of HPV types 6, 11, 16, 18 and 31. This was first 
attempted using HPV DNAs purified following excision, by restriction 
enzyme digestion, from plasmid vectors (Section 1, methods 5-6) 
and diluted to concentrations of 10pg/ul. Three sets of six PCR 
reaction solutions were prepared each containing either HPV11, 16 or 
31 oligonucleotide primers. Ten picograms (1ul) of each HPV DNA 
preparation or water control was added to each of one set of six 
reaction mixes (as in Table 19). Thirty five amplification cycles were 
performed after which reaction products were analysed by agarose gel 
electrophoresis. However, purification of these plasmid inserts had 
been carried out in the routine cloning laboratory and, consequently, 
some of these preparations were found to be contaminated with other 
HPV sequences at levels detectable by PCR. This problem was avoided 
by repeating the experiment using a small quantity of bacterial colony 
(containing HPV/pGemini constructs) as substrate for the PCR rather 
than purified insert DNA. Results are shown in figure 28. Primers 
for HPV types 11, 16 and 31 amplify only their target DNA when 
tested against DNA of HPV types 6, 11, 16, 18 and 31.
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Figure 27: Determination of limits of detection. Titrations of HPV
DNA were prepared to give concentrations ranging from 10pg (Lane 1) ; 
100ag (Lane 6) DNA per PCR test. A no-DNA control was also included! 
(Lane 7). 35 cycles of amplification were performed.
Amplification products were electrophoresed through 4% composite 
agarose gels and detected by oligomer hybridisation. An ethidium j 
bromide-stained gel and autoradiograph of oligomer hybridisation of j 
HPV11 products are shown opposite. Results obtained with HPV11, 16 | 
and 31 are shown in table 20. j
Table 20
Determination of the limits of detection of oligonucleotide 
primers for HPV types 11, -16 and -31
Lane 1 2 3 4 5 6 7
HPV DNA 10pg ipg 100fa 10fcr 1f2 100acr 0
HPV11 agarose gel +++ ++ + + wb - -
hybridisation +a + + + + + —
HPV16 agarose gel +++ ++ ++ + + - -
hybridisation + + + + + + —
HPV31 agarose gel +++ ++ + w w - -
hybridisation + + + + + w -
a Unlike bands seen in ethidium bromide stained agarose gels, 
oligomer hybridisation results are expressed as a single positive 
rather than graded from + to +++. This is because band intensity is 
not linearly related to amount of specific product present ( See 
figure 27)
b w = weak positive reaction
Figure 27 : Determination o f lim its o f detection
7 6 5 4 3 2 1 M
— 246bp
— 123 
— 90bp
Specific band
Unbound probe
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Figure 28: Specificity of amplification
P R I M E R S  HPV31 HPV1 6 HPV1 1
H P V  D N A  0 31 181611 60 31 181611 60 31 181611 6  M
A " *>
298bp 
[-220
1— 1 5 4  
h 7 5
Figure 28: 18 reactions were prepared; 6  containing LY11 primers, 6
containing LY16 primers and 6  containing HPV31 primers. Each set of 
tubes was inoculated with an E coli colony of HPV6 , 11, 16, 18 or 31 
(cloned into pGem, pBR322 or pAT153 vectors). 35 cycles of 
amplification were performed. Each primer pair gave a product of the 
appropriate size (90bp for HPV11, 120bp for HPV16 and 123bp for HPV31) 
when tested against a colony contained a clone of its 'parent' D N A .  
LY11 and LY16 primers only gave specific band against parent D N A  
clones; HPV31 primers appeared to give a specific band not only with 
the HPV31 clone but also with the HPV18 clone. However, on re­
running the gel, no band was visible in the lane for the HPV18 clone, 
suggesting that the initial positive result was due to spill-over from 
the adjacent well during electrophoresis.
173
B: COMPARISON OF PRIMER PAIRS FOR THE DETECTION OF HPV 11 AND 16 DNA
Three primer pairs were investigated for use in the detection of 
HPV types 11 and 16. The DNA sequence of the primers and probes and 
their location in the HPV genome are shown in tables 21a and b.
HPV11 
LYHPV11a 
JCHPV11 
CSHPVl1b
: amplify a 90bp region of the E6 ORF between bases 221-310.
: amplify a 160bp region of the E1 ORF between bases 841-1000. 
: amplify a 190bp region of the L1 ORF between bases 7009-7199
HPV16
LYHPV16a : amplify a 120bp region of the E6 ORF between bases 421-540.
SHIBHPV16C : amplify a 11Obp region of the E6 ORF between bases 320-429.
CSHPVl6b : amplify a 160bp region of the L1 ORF between bases 6119-6280
5 2a: as described by Young et al
b: these primer pairs are complementary to sequences either side of 
the BamHI site used for laboratory manipulation of HPV types 11 and 16 
and consequently will not detect HPV DNA disrupted at this restriction 
enzyme site. (See figure 29)
c: as described by Shibati et al 55
1 Evaluation of 'anti-contamination7 primers
CSHPV11 and CSHPV16 were designed as 'anti-contamination7 
primers, a concept first described for HPV DNA detection by Van den 
Brule et al**®. Anti-contamination primers are complementary to 
genomic sequences flanking the restriction enzyme site (Bam HI)
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Table 21a: PRIMERS AND PROBES FOR HPV-11
PRIMER SEQUENCE
LYHPV11-E6-5'a CGCAGAGATATATGCATATG
LYHPV11-E6-3'a AGTTCTAAGCAACAGGCACA 291-310
LYHPV11-E6-PROBE CCTAAAGGTTGTGTGGCGAGACAACTTTCC 251-281
POSITION PRODUCT 
221-240
90bp
GC%
40
45
50
JCHPV11-E1-5' GATTCAGGTACAGAAAATGAGGGGT 841-865
JCHPV11-E1-3' TAATATGCCTGTCATCAATAAAGTCC 975-1000
JCHPV11-E1-PROBE GTAGAGCACACTACAGGTACACAAATATCA 901-930
160bp
44
35
36
CSHPV11-5' 
CSHPV11-3' 
CSHPV11-PROBE
TTATAGATATGTACAGTCAC 7009-7028
GAGCAGACGTCCGTCCTCGA 7181-7199
ATAAGGATATGAGTTTTTGGGAGGTTAACT 7081-7110
190bp
30
65
33
Table 21b: PRIMERS AND PROBES FOR HPV-16
PRIMER
LYHPV16-E6-57 a
SEQUENCE
TCAAAAGCCACTGTGTCCTG
LYHPV16-E6-3'a CGTGTTCTTGATGATCTGCA 521-540
LYHPV16-E6-PROBE GACAAAAAGCAAAGATTCCATAATATAAGG 461-490
POSITION PRODUCT 
421-440
120bp
SHIBHPVl6-5/b 
SHIBHPV16-3/b 
SHIB1G-PROBE13
ATTAGTGAGTATAGACATTA
GGCTTTTGACAGTTAATACA
320-339
410-429
ATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTG
354-390
110bp
GC%
50
45
30
25
35
37
CSHPV16-5' 
CSHPV16-3' 
CSHPV16-PROBE
CAAACCACCTATAGGGGAAC 6119-6138
CCTGTAATGTAGTAAAGTCC 6261-6280
GTACCAATGTTGCAGTAAATCCAGGTGATT 6161-6190
160bp
50
40
40
a) As described by L.S Young et al52
b) As described by D.K Shibati et al55
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STRATEGY FOR THE DESIQ* OF ' ANTICONTAMINATION' PRIMERS
Figure 29: 'Anti-contamination' or cloning-site primers are
complementary to genomic sequences flanking the restriction enzyme site 
used for the laboratory manipulation of the HPV11 or -16 DNA. HPV DNA 
cloned in the laboratory will be either in a linear form or cloned 
into a plasmid vector whereas 'wild' virus will be in a circular form 
(or integrated into the host genome). If amplification of each of 
these forms is attempted with anti-contamination primers, only 'wild' 
virus DNA will give a product of the appropriate size. HPV DNA 
linearised at the cloning site can not act as a template for 
amplification and HPV DNA cloned into a plasmid will give a product of 
far greater size than that anticipated.
Figure 29: STRATEGY FOR THE DESIGN OF 'ANTICONTAMINATION' PRIMERS
DNA form
Primer
annealing
Amplification 
product 
(HPVII)
'Wild' form Laboratory - manipulated forms
HPV
Supercoiied 
viral genome
Plasmid
HPV
Cloned 
viral genome
Linear 
viral genome
Anti-contamination primers
Plasmid
C=>.
HPV
190bp 3Kbp or 
no product
No product
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used for the laboratory manipulation of the HPV11 and 16 DNAs (figure 
29). HPV DNA cloned in the laboratory will either be linearised at 
the Bam HI site or cloned into a vector. Neither of these forms 
therefore can act as a substrate for amplification. JCHPV11 (and 
LYHPV11) primer pair and Shib16 (and LYHPV16) primer pair amplify 
regions of the HPV genome unaffected by laboratory manipulation and 
consequently will amplify and detect all three forms. The ability of 
'anti-contamination ' primers to differentiate between different DNA 
forms was investigated using linear, circularised and recombinant HPV 
DNA in the two following experiments.
i) Assessment of amplification of linearised, recircularised and 
cloned HPV DNA by CSHPV11 and CSHPV16 primers
HPV11 and HPV16 DNAs were excised from HPV/pGem recombinants 
pGHPVl1 and pGHPVl6  by digestion with Bam HI restriction enzyme as 
described previously ( Section 1, methods 1-6 ). The inserts were 
purified and an aliquot of these were recircularised with T4 DNA 
ligase (section 1, method 10). A small volume was electrophoresed in 
a 1 % agarose gel in order to check that recircularisation had occurred 
and the DNA concentration determined by OD2 5 Q. The DNA concentration 
was then adjusted to 10pg/ul. Preparations of linear HPV11 and 16 DNA 
and their HPV/pGem constructs were also adjusted to concentrations of 
10pg/ul. Primer pairs CSHPV11 and JCHPV11 were each added to a set of 
reaction solutions containing 1pg HPV DNA in one of the three forms; 
HPV/pGem plasmid DNA, linearised HPV11 DNA or circularised HPV11 DNA. 
CSHPV16 and Shib16 primers similarly were added to reaction solutions 
containing the three forms of HPV16 DNA. After 35 cycles of 
amplification, products were detected by electrophoresis in ethidium 
bromide-stained agarose gel and by oligomer hybridisation.
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The results are shown in figure 30. It can be seen 
that whilst JC HPV11 primers amplified all three forms of HPV DNA, 
CSHP11 primers amplified only the recircularised form. Similarly, 
CSHPV16 amplified only circular HPV16 DNA whilst Shib16 primers 
detected all three forms.
ii) Amplification of linear HPV DNA when present in high 
concentration
Having demonstrated the ability of CSHPV primers to distinguish 
between laboratory manipulated and 'wild' HPV DNA, the effect of DNA 
concentration was investigated. The previous experiment demonstrated 
that these primers would not amplify 1pg of cloned HPV DNA. Within a 
population of linearised HPV molecules, a certain proportion may form 
dimers or recircularise. If contamination with larger quantities of 
laboratory linearised DNA occurs, it may be that the CSHPV primers 
would amplify a specific product mimicing 'wild' virus. This 
experiment was to determine whether this occurred.
Serial dilutions of linear HPV11 DNA were prepared to give 
concentrations of 5pg, 50pg, 500pg, 5ng and 50ng/ul. Sets of 5 
reaction mixes were prepared containing either CSHPV11 or JC11 
primers. One microlitre of each DNA preparation was added to one 
reaction tube of each set. Dilutions of HPV16 DNA and reaction mixes 
containing CSHPV16 and Shib16 primers were prepared and treated 
similarly. Amplification was for 35 cycles. Amplified products were 
analysed by oligomer hybridisation. Results are shown in figure 31 
and demonstrate that within a population of linearised HPV DNA 
molecules a small percentage will reform in such a way as to provide a 
substrate for CSHPV primers. Thus, the ability of the CSHPV primers 
to distinguish between circular and linear DNA forms is not absolute.
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Figure 30: Amplification of cloned, linear and circular HPV DNA with 
anticontamination primers. Linear (L), circular (C) and plasmid (P) 
forms of HPV11 D N A ,  lanes 1-3, were tested with anticontamination 
primers CSHPV11. The three preparations were also tested with JCHPV11 
primers, lanes 4-6, to ensure their suitability for amplification. 
Similarly, linear, circular and forms of HPV16 D N A  were tested with 
CSHPV16 and Shibl6 primer pairs, lanes 7-12. Control reaction mixes, 
without HPV D N A ,  were also included. Amplification products were 
tested by oligomer hybridisation with specific internal 
oligonucleotide probes. Only circular forms of HPV11 and -16 DNA gave 
specific amplification products when tested with anticontamination 
primer pairs CSHPV11 and CSHPV16 ( 190bp and 160 bp respectively). 
Primer pairs JCHPV11 and Shibl6 amplified all three forms of their 
target D N A  to give amplification products of 160bp and 110bp.
Figure 30: Amplification of cloned, linear and circular HPV DNA 
with anticontamination primers
a) Ethidium bromide-stained agarose gel
Controls Shibl6 CSHPV16 JCHPV11 CSHPV11
-  -  -  P C L  P C L  P C L  P C L  M
1 90bp 
1 60bp 
1 20bp
b) Oligomer hybridisation
Controls Shibl6 CSHPV16 JCHPV11 CSHPV11
- -  -  P C L  P C L  P C L  P C L
specific bands
-unbound
probe
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2 Comparison of the sensitivity of primer pairs LY, JC and CS for HPV11 
DNA detection and LY, shib and CS for the detection of HPV16 DNA
The relative sensitivities of three primer pairs for the 
detection of HPV11 and 16 were compared by determining 
the minimum quantity of cloned HPV D N A  which could be detected by each 
primer pair. The minimum quantity of target D N A  that could be 
detected was determined by titrating cloned D N A  to give 10-fold 
dilutions of 1pg/ul to 100ag/ul and adding 1ul of each dilution to a 
reaction solution. After 35 amplification cycles, products were 
analysed by oligomer hybridisation. Results obtained are shown in 
figures 32 and 33. Primer pairs LYHPV11 and LYHPV16 were again shown 
to be able to detect 100ag target D N A  as found earlier. The detection 
limits of JC and CS primers for HPV 11 D N A  were 100ag and 1fg 
respectively. The limits of detection of Shibl6 and CS16 primers were 
both 1fg HPV16 D N A .  This demonstrates that under given conditions, 
different primer pairs to the same target D N A  do not amplify with 
equal efficiency.
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Figure 31: Effect of concentration of target DNA on
discriminatory capabilities of anticontamination primers.
2 0 1 9  18 171615 1413 12 1110 9 8 7  6 5 4  3 2  1 M  
I I I I I I I I I I I I I I I I I I I I I
190bp —  
160bp —
11Obp—
369bp
246bp
123bp
Specific
band
Figure 31: Amplification of purified HPV 11 and -16 cloned inserts at concentrations of 5pg, 50pg,
500pg, 5ng and 50ng was attempted using CSHPV11 and CSHPV16 primers (lanes 1-5 and 11-15 
respectively). The preparations were also with JCHPV11 and Shibl6 primers (lanes 6-10 and 11-20 
respectively). By oligomer hydridisation, specific CSHPV11 and CSHPV16 amplification products 
(190bp and 160bp respectively) were detected when 50pg-50ng quantities of linearised HPV DNA 
were present whilst JCHPV11 and Shibl6 primers detected HPV DNA in all preparations.
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Figure 32: Comparison of primer pairs LY, JC and CS for the detection
of HPV11: Primer pairs LY11, JC11 and CS11 were each tested in
reaction mixes containing 1pg, 100fg, 10fg, 1fg and 100ag HPV11 DNA 
(Lanes 1-5 for each primer pair). No-4)NA controls were also 
included (Lanes 6). Amplification conditions were as described 
previously. LY11 and JC11 primers could detect down to 1fg HPV11 DNA 
(100ag by oligomer hybridisation) whilst CS11 primers could detect 
down to 10fg HPV11 DNA (1fg by oligomer hybridisation).
Figure 33: Comparison of primer pairs LY, Shib and CS for the detection
of HPV16: Primer pairs LY16, Shibl6 and CS16 were each tested in
reaction mixes containing 1pg, 100fg, 10fg, 1fg and 100ag HPV16 DNA 
(Lanes 1-5). No DNA controls were also included (Lane 6).
Amplification conditions were as described previously. LY16 primers 
could detect down to 100ag HPV16 DNA whilst Shibl6 and CS16 primers 
could detect down to 10fg HPV16 DNA (1fg by oligomer hybridisation).
Figure 32: Comparison of primer pairs LY, JC and CS for
the detection of HPV 11
190bp
160bp
90bp
Figure 33: Comparison of primer pairs LY, Shib and CS for the detection of HPV 16 DNA
S H IB 16 JCHPV11 LYH PV16
160 —
120bp —  
11Obp—
5 4 3 2 1 || 6 5 4 3 2 1 |[6 5 4 3 2 1 |
1 p B _  298-200 -  154
C SHPV11 JCHPV11 LYHPV11
1 82
C: DESIGN OF PCR FOR USE IN  LARGE-SCALE EPIDEMIOLOGICAL STUDIES
Introduction
Having optimised the reaction conditions for the detection of HPV 
DNA, the aim is to apply PCR for use in medium to large- scale 
epidemiological studies of the prevalence of genital HPV infections. 
For this, one needs a test procedure which is simple to perform on 
large numbers of specimens without loss of sensitivity or specificity. 
One must ensure that false positive results due to contamination from 
positive to negative specimens or 'carry-over' ( amplification product 
from previous PCRs) are not generated. Methods to prevent this were 
adopted (methods 2.7).
Two methods of specimen preparation are compared in order to 
determine the most suitable for studies of this type. Although DNA 
extraction by standard methods is employed by many, the procedure is 
time-consuming and laborious if performed on large numbers of 
specimens. One of the cited advantages of PCR over other DNA 
detection procedures (especially those which involve digestion of 
sample DNA with restriction enzymes) is that the procedure can 
tolerate less-pure DNA preparations. Several groups have been able to
minimise pre-PCR treatments to simply boiling the specimen and testing
fi 1a cell-free supernatant . Other groups have found DNA extraction to 
be necessary for efficient amplification
Following amplification, there are several ways in which the 
specific product may be detected. These include dot blot 
hybridisation, Southern blot hybridisation and oligomer 
hybridisation. Here, the sensitivities of the three methods are
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compared in order to determine the most suitable for large scale 
epidemiological studies.
1 Avoidance of contamination / 'carryover'
Attempts to prevent contamination of reaction mixes and
subsequently avoid the generation of false positive results were based
12-14on current guidelines . Dedicated rooms and equipment were used 
exclusively for PCR. Reaction mixes were prepared in bulk and each 
batch tested for the ability to support amplification and to confirm 
that contamination had not occurred during preparation (figure 34). 
Within a batch of test specimens, adequate controls were included to 
monitor spurious contamination, either carry-over or contamination 
from positive to negative specimens. When there was an indication 
that contamination had occurred ie reagent controls or extraction 
controls gave positive signals, specimens were retested to confirm 
results.
Contamination of reagents was monitored by the inclusion of two 
reaction mixes to which only distilled water had been added. 
Contamination of specimens during extraction/processing was monitored 
by the inclusion of three HPV-negative cell controls which were 
processed in parallel with the test samples.
2 Specimen preparation Two methods of specimen processing were
considered; extraction of DNA using phenol/chloroform (method 2.10)
and boiling of cell pellets (method 2.12).
Cell lines: Caski cells (which contain HPV16 DNA integrated into
56the genome ) were prepared from cell cultures as described (method
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2.8). Ten-fold dilutions were prepared and 50ul of the washed cell 
suspensions were transferred to an eppendorf tube for DNA extraction 
(method 2.10). The remaining 50ul were processed by boiling (method 
2.12). PCR amplification were performed using each of the two primer 
pairs LYHPV16 and Shibl6 and the products were analysed by oligomer 
hybridisation. CS16 primers were not tested as the target sequence of 
this primer pair, the L1 region, has been 'lost' from HPV16 sequences 
during or after integration with the host chromosome. Amplified 
products of both preparation procedures were analysed by oligomer 
hybridisation.
Figure 35 shows results obtained. LY16 primers could detect 
HPV DNA in only one Caski cell (approximately 100 copies), whether 
from boiled or extracted preparations. Shibl5 primers could detect 
HPV DNA from one Caski cell in extracted preparations but only gave 
positive signals from boiled preparations containing 10 or more cells. 
This perhaps suggests that the Shibl6 primers are far less tolerant 
of non-nucleic contaminants present in boiled preparations compared to 
LY16 primers. Ethidium-stained agarose gel confirmed earlier 
observations of the increased sensitivity of LY16 primers compared to 
Shibl6 primers.
3 Comparison of post- amplification analysis methods
Dot blot , Southern blot and oligomer hybridisation were compared 
for the analysis of post-amplification reaction solutions.
Three HPV 16-positive reaction mixes were pooled and the optical 
density at 260nm established in order to calculate the DNA 
concentration. The concentration was adjusted to 50ng/ul by dilution
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with water. Serial two-fold titrations were prepared to give 
concentrations of 50, 25, 12.5, 6.25, 3.125, 1.56, and 0.78ng/ul. A 
no-DNA control was included. 1ul of each dilution was analysed by 
each of the three methods.
i) Dot blot hybridisation: 1ul of each DNA dilution was added to 99ul 
sterile water and dot blot hybridisation was performed as described 
(method 2.13)
ii) Southern blot hybridisation: 1ul of each DNA dilution was added to 
9ul TE and 10ul orange G/ficoll loading buffer. Electrophoresis
and DNA-transfer were as described previously (method 2.14) 
Hybridisation of dot and Southern blot membranes were as described 
(method 2.15).
Also included were 15 reaction mixes of varying degrees of 
positivity. Aliquots of amplification products from positive and 
negative specimens were processed by each of the three methods and the 
results compared (Table 22). Oligomer hybridisation, dot blot and 
Southern blot were all shown to detect down to 3ng product although 
weak signals were given. Only dot blot gave a linear relationship 
between quantity of target DNA present and signal obtained, perhaps 
suggesting that inaccuracies had occurred during gel loading. Of 
fifteen specimens tested, results obtained by the three methods varied 
for only one specimen, which was dot blot-positive but negative by the 
other two techniques. It seems likely that this was a weak positive 
reaction below the sensitivity threshold of Southern blot and oligomer 
hybridisation.
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Figure 34: Batch testing reaction mixes: HPV 16
a) Ethidium bromide-stained agarose gel
10 9 8  7 6 5  4 3  2 1 M
b) Oligomer hybridisation
«— 120bp
_ unicorporated 
probe
Figure 34: On preparing a new batch of reaction mixes (usually 120-150), ten were selected at
random, lpg HPV16 DNA was added to two reaction mixes (lanes 5 and 10). Eight were inoculated 
with distilled water (lanes 1-4 and 6-9). 35 amplification cycles were performed and specific reaction 
products detected by oligomer hybridisation.
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Figure 35: Comparison of boiling and phenol/chloroform
extraction for pre-PCR specimen preparations
Boiled cells Phenol/chloroform extraction
Shibl 6 Ly16 Shibl 6 Ly16
 ]f 11 1| 1
1 10 102 103 104 1 10 102 103 104 1 10 102 103 104 1 10 102 103 1 o4
396
246
120bp
Specific
band
Unincorporated
probe
Figure 35: Ten-fold dilutions of Caski cells were prepared in duplicate. The DNA was extracted
from one set using phenol/chloroform and from the other by boiling. Each set was tested with Lyl6 
primers and Shibl6 primers. Lyl6 primers detected HPV DNA from one cell in both extracted and 
boiled preparations. Shibl6 primers detected HPV DNA from one cell in the extracted preparations 
but only from 10 cells from boiled preparations.
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I4 Amplification of HPV DNA from human cell cultures; a 'blind1 trial
' !
In order to demonstrate that PCR can reliably be applied to 
the detection of HPV DNA, a 'blind trial' using a HPV16-containing 
and a HPV16-negative cell line (Caski and Hela cell lines 
respectively) was performed. For this, 6 suspensions of each cell 
type, prepared by a member of the laboratory staff, were given in 
coded tubes to the author who then performed the amplification with 
LYHPV16 primers. PCR results were then passed to the first member of 
staff so that the accuracy of the procedure could be assessed. Thus 
the HPV16 status of each tube was not known by the tester. Caski 
cells were selected as these are strongly HPV16 -positive (100-200 
copies/cell) and would accentuate any procedures likely to result in 
cross-contamination
Cell culture medium was removed from six tubes containing 
HeLa cell monolayers and six containing Caski cell monolayers. The 
monolayers were washed twice with phosphate buffered saline and then 
scraped from the tube surface with a wooden applicator into 1ml PBS. 
Half of each cell suspension was transferred to an eppendorf tube 
which was coded so that the type of cell line present was unknown to 
the author (the remaining 0.5ml cell suspension was stored at 4°C). 
These were microfuged (2,700g) for 1 minute, the supernatant was 
discarded and the cell pellets were passed to the author. The cell 
pellet was resuspended in 200ul PBS and an aliquot of 25ul transferred 
to a screw-capped eppendorf tube and processed by boiling as described 
(method 2.12). 8ul of each supernatant was added to a reaction mix 
and 35 amplification cycles were performed. Amplification products 
were analysed by oligomer hybridisation.
Results are shown in figure 36. When the cell type present in
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each tube were revealed, HPV16 PCR results and anticipated HPV result 
correlated perfectly whether on the basis of ethidium bromide-stained 
agarose gel or oligomer hybridisation. There was no evidence of 
cross-contamination from strongly HPV-positive tubes to HPV negative 
tubes.
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Table 22
Specimen 
Positive :
Test
Comparison of post-amplification procedures
Gel dot blot oligomer Southern
50ng + ++ ++ ++
25ng - ++ w w
12.5ng w + ++ +
6.25ng w + + +
3.12ng - w w w
1 w + + + +
2 + + + +
3 w
4 _ _
5 - + w ++
6 + + w ++
7 + + -
8 — . + + +
9 
10 
11 
12
13
14
15
w = weak positive reaction
Figure 36: Assesment of PCR protocol: 'Blind trial' for HPV16
M + 1211  10 9 8 7 6 5 4  3  2 1 M
396
246
120bp
Specific
band
Figure 36: DNA was extracted from 6 Caski cell suspensions and 6 HeLa cell suspensions by
boiling. These were arranged in a random order and coded by a second party. These were then tested 
with LY16 primers by the author. The a) ethidium bromide-stained agarose gel and b) autoradiograph 
of the oligomer hybridisation are shown above.
Preparations 1-3, 5, 9 and 10 were positive and were thus demonstrated to be Caski cells. Preparations 
4, 6-8,11 and 12 were negative and thus contained HeLa cells. Three reagent controls and a positive 
control are shown in wells 13-16.
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CHAPTER 10
SECTION 2: DISCUSSION
The aim of this section was to investigate the suitability of the
Polymerase Chain reaction (PCR) for the detection of HPV DNA in
clinical material, particularly with regards to use in large scale
epidemiological studies or in a routine diagnostic situation. Firstly
it was necessary to establish the procedure, to optimise reaction
conditions and determine the sensitivity and specificity of the
procedure. Oligonucleotide primers for the detection of HPV types 11
n
and 16 were those described by Young et al , amplifying a 90 and 120 
base pair region of the E6 region of the respective genomes. This 
region has received particular attention as early research suggested 
that it may be important in the potential oncogenic capabilities of 
certain HPV types. Previously published primers were employed as 
these were known to efficiently amplify HPV DNA and also allowed 
direct comparison of data with the other group(s) employing identical 
primers. Oligonucleotide primers for the detection of HPV31 had not 
been described at this time and thus primers were selected from the E6 
region of the HPV genome emperically. Each primer pair was found to 
specifically amplify its target HPV type with the limit of detection 
being 100ag HPV DNA using the amplification conditions described by
(TO
Kogan . Certain parameters of the reaction conditions, primer 
concentration, Taq polymerase concentration, magnesium concentration 
and number of cycles, were investigated but the only modification of 
the original procedure was to reduce the Taq polymerase concentration 
from 2.5 to 1.5 units per 50ul reaction. Initially the Tag polymerase
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was obtained from Cambio Ltd (Cambridge, UK) but for the majority of 
the project Taq polymerase produced by Cetus ( USA) was employed. The 
reaction conditions employed are quite different from those described 
by Cetus which includes potassium chloride (25mM), employs a lower 
magnesium concentration (1-4 mM compared with 6.7mM) and recommends 
the use of less primer (20pM each compared with 50pMol). However,
Cetus Taq polymerase was found to amplify efficiently under the 
conditons of Kogan^.
A major problem of the PCR procedure is the generation of false 
positive results due to contamination or carry-over of the specific 
product. This project was initiated following the very first reports 
of PCR using Taq polymerase. Indeed, PCR was being investigated in 
this department prior to the description of Taq polymerase when Klenow 
polymerase was the enzyme of choice. At this time, the problem of 
'carry-over' was only just emerging and early PCRs were carried out in 
a laboratory previously used for cloning the target HPV DNAs. 
Consequently, early PCRs in this department were vunerable to 
contamination of reagents and clinical specimens with cloned DNA and 
the problems of false positive results were experienced first hand.
Other research groups employing PCR soon experienced problems of this 
kind and procedures to avoid further problems were recommended^-^.
In our department, we were able to minimise these problems by the use 
of dedicated rooms and equipment and the inclusion of appropriate 
negative controls as described previously. Repeat testing was performed 
whenever contamination was suspected but this was very infrequently 
necessary.
During the course of this project, it became clear from the work 
of other research groups that primer selection was of fundamental
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64importance to the development of a sensitive PCR procedure . Also,
research groups reporting on detection levels of HPV DNA in cervical
material varied considerably in their findings. It thus became
necessary to consider use of other primer pairs described for the
detection of HPV DNA. To this end, three primer pairs for each HPV
type 11 and 16 were compared in terms of the minimum quantity of HPV
DNA that they could detect. A particularly innovative approach to
primer design was that of 'anticontamination' primers, primers
60flanking the cloning site, described by Melchers et al . These 
primers potentially could differentiate between 'wild' virus DNA and 
laboratory-manipulated DNA ie between true and false positive 
reactions (except when false positives are generated by contamination 
of a negative specimen with HPV DNA from an adjacent positive 
specimen). Primers selected to flank the cloning site were prepared 
and included in this investigation. These primers were found to 
specifically amplify circular HPV DNA but not linear molecules or HPV 
DNA cloned into a plasmid. However further investigations employing 
purified preparations of linear HPV DNA demonstrated that 
amplification of laboratory-manipulated DNA could occur most probably 
because, within these preparations, a certain number of molecules will 
recircularise or form dimers due to their 'sticky ends'. The 
potential ability of these primers to detect only wild' viral DNA was 
thus not absolute. Of greater concern was the lower sensitivity of 
the anti-contamination primers compared with others tested. 
Anticontamination primers for HPV11 and 16 DNA tested here had a 
detection sensitivity at least 10-fold lower than that of the other 
primer pairs tested for each HPV type. Given that reaction conditions 
were identical, differences in sensitivity between primer pairs is
T a b le  23
Comparison of region amplified, product size, G+C% and detection 
sensitivity for the primer pairs used for the detection of HPV DNA
Primer pair Region amplified Product size G+C%
LYHPV11 
JCHPV11 
CSHPV11
E6
E1
L1
90bp 
160bp 
190bp
40/45
44/35
30/65
Sensitivity 
10Oag 
100ag 
1fg
LYHPV16 
SHIB16 
CSHPV16
E6
E6
L1
120bp 50/45 1OOag
11Obp 25/35 10fg
160bp 50/40 10fg
differing primer anealing efficiencies under these conditions. It
must of course be noted that the reaction conditions employed were
optimised for the LY primers and the optimal conditions for the other
two pairs may be quite different. However, there are other factors
which are likely to affect amplification efficiency including product
size, primer GC% and the region amplified (Table 23). Product size
seems to be important in that it has been reported that smaller
products are amplified more efficiently than larger products^.
However, whilst this may be true when product size differs by several
hundred base pairs, it seems unlikely that this is the sole factor in
this case as the HPV16 products vary by only 40 bp. Primer GC% is
thought to be important in the efficiency and stability of primer
1 06annealing, with 50-60% GC usually being recommended , but no
relationship is apparent here. The genomic region amplified may
affect primer efficiency in several ways. For example, certain
1 07regions of the HPV genome may be deleted (E2, L2 ) or interrupted ( 
1 08E1, E2, E4 ) during integration with the host genome. Clearly,
primers targetted to these regions will be unable to detect the
integrated form. Also, genomic regions vary in the degree of
109conservation between HPV types ie some regions are well conserved
between HPV types whilst other regions are hypervariable. Within an
HPV type or sub-type, strains or variants may exist which similarly
110have conserved and hypervariable regions . Thus, primers targeted 
to hypervariable regions may detect only some strains whilst primers 
to conserved regions may detect all strains. Genomic sequence data on 
which to assess the degree of genomic variation between strains is 
currently lacking. This highlights the need for the use of well 
characterised primers and stresses the importance of primer selection
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in a successful Polymerase Chain Reaction procedure. The LY primers 
were employed for subsequent investigations.
Studies to determine the prevalence and transmission routes of 
genital HPV infections involve the testing of quite large numbers 
(greater than 100) of specimens. The use of PCR in studies of this 
magnititude presents particular problems. The procedure must be 
rapid, reliable and simple in order to decrease the opportunity for 
cross-contamination. Two aspects of the procedure were considered 
with a view to selecting the method most suitable for investigations 
of this type. These were specimen processing and post-amplification 
analysis.
Two methods of specimen processing were considered; DNA
extraction using phenol/chloroform extraction and extraction by
boiling. Opinions vary as to whether it is necessary to extract and
precipitate the specimen DNA prior to test. Some specimens, for
example urine, blood and faeces have been shown to contain inhibitors 
111 112of Taq polymerase ' which co-purify with nucleic acid and
112 113special procedures are necessary to remove them ' . Some groups
have found that nucleic extraction from other clinical specimens is 
not necessary and crude lysates are a suitable substrate for
14,115,116 ^ In this study, it was found that boiled cervical cell 
preparations could be used but semen specimens required nucleic acid 
extraction. Simpler specimen preparation procedures such as boiling 
have clear advantages over the more elaborate nucleic acid extraction 
procedures. Firstly, fewer steps means a more rapid and perhaps more 
economical procedure in terms of reagents and laboratory hours. 
Secondly, by decreasing the number of laboratory manipulations one 
decreases the likelihood of contamination occuring from HPV-positive
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to negative specimens. Thus boiling of cervical cell preparations was 
adopted in preference to DNA extraction although both procedures 
produced target nucleic acid of adequate quality.
Three post-amplification analysis procedures were considered; 
Oligomer hybridisation, Southern blot hybridisation and dot blot 
hybridisation. The sensitivity of the three procedures were compared. 
Dot blot hybridisation and oligomer hybridisation were found to be the 
most sensitive methods, able to detect approximately 3ng product 
(120bp ). Technically, each of the three procedures had advantages 
and disadvantages. Dot blot hybridisation was the most sensitive 
method, was rapid and allowed upto 96 reaction mixes to be analysed 
simultaneously, making it particularly suitable for epidemiological 
studies. Weak dot blot positives however are difficult to interpret 
and all positives require confirmation by the demonstration of an 
appropriately sized band on gel electrophoresis. Oligomer 
hybridisation was also sensitive and positive reactions did not 
require confirmation by other techniques, but the number of reaction 
mixes processed at one time was considerably less than that for dot 
blot hybridisation. Southern blot hybridisation was the most 
elaborate and time consuming procedure of the three and also the least 
sensitive. As products were first electrophoresed in an agarose gel 
and product bands visualised with ethidium bromide staining, 
interpretation of weakly positive signals was easier than for dot blot 
hybridisation signals which require gel electrophoresis to confirm the 
specificity of hybridisation. Secondly, Southern blot hybridisation 
allows control over the stringency of hybridisation not afforded by 
oligomer hybridisation. Given the advantages and disadvantages of the
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three procedures, it was decided that for epidemiological studies, an 
appropriate strategy of post-amplification analysis would consist of 
dot blot hybridisation for screening reaction mixes with confirmation 
of positives by either oligomer or Southern blot hybridisation. An 
alternative is to use a second amplification with 'nested primers' to 
confirm dot blot positive reactions.
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SECTION III
APPLICATION OF PCR TO THE DETECTION OF HPV DNA IN CLINICAL MATERIAL
CHAPTER 11
Objectives of Section three
In Section two, certain parameters of PCR ( primer, Taq
polymerase and magnesium concentrations, number of amplification
cycles etc.) were optimised. The objective of the work described in
this section was to apply the PCR procedure to studies to determine
the prevalence of genital HPV infections in males and females.
Firstly, an investigation was performed to determine the prevalence of
HPV types 11, 16 and 31 in cervical scrape specimens from females
attending a Family Planning Clinic (FPC). DNA was obtained from
cervical scrape specimens by the boiling procedure described in
Section 2 (method 2.12), followed by 35 cycles of amplification.
Analysis of amplified products was by dot blot hybridisation with a 
32P-labelled internal oligonucleotide, shown previously to be slightly 
more sensitive than Southern blot hybridisation and oligomer 
hybridisation (Section 2, page 185). Confirmation of dot blot 
positives was by a second amplification with a nested primer pair.
Studies were then performed to determine the prevalence of HPV 
types 11 and -16 in semen from males attending an Assisted Conception 
Unit (ACU) and from males attending a Genito-urinary Medicine clinic 
(GUM). Earlier work (Section 1, Chapter 4) had shown that HPV DNA 
could be demonstrated in semen using Southern blot hybridisation but 
had suggested that the more sensitive PCR would be needed to establish 
the true extent of HPV shedding into semen. PCR was also used to 
detect HPV types 11 and -16 in penile scrapes and in urethral 
specimens from males attending a GUM clinic, the objective of which 
was to investigate whether HPV infection was particularly associated 
with the glans penis or the urethra.
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CHAPTER 12
DETERMINATION OF THE PREVALENCE OF CERVICAL HPV INFECTION 
IN A "LOW RISK" POPULATION
Introduction
Much evidence has accumulated to support the hypothesis that
certain 'high risk' HPV types are a significant factor in the
development of cervical neoplasia. However, in order to fully
evaluate this hypothesis, it is necessary to obtain data on the
prevalence of these HPV types in women with normal cervices. HPV16,
the most ubiquitous of the 'high risk' HPV types, has been
demonstrated by Southern blot hybridsation in 10-30% of women with
fifi fificolposcopically and histologically normal cervices . By PCR, 
reported prevalences have ranged from less than 5% to 90%^“^. There 
are many factors which could account for this variation including 
geographical variation, sampling method, test sensitivity, test 
accuracy and the female population studied. The true prevalence of 
cervical HPV infections in normal cervices can only be determined by 
testing unselected groups. However, this being impracticable, useful 
data might be generated by study of a population considered to be low 
risk for the development of cervical carcinoma. To this end, females 
attending a Family Planning Clinic for routine cytological examination 
were selected and the prevalence of HPV types 11, 16 and 31 in this 
group determined by PCR. Cytology results were collected and the 
study participants provided information relating to sexual and social 
parameters which are potential risk factors for the development of 
cervical neoplasia.
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METHODS
Study participants: 132 females attending a Family Planning Clinic
in Northampton for routine cytological examination between May and 
October 1989 took part in this study.
Questionnaire Data: Study participants provided information in the
form of a questionnaire regarding their age, marital status, number of 
sexual partners, use of oral contraceptives and history of genital 
warts.
Specimens: Cervical scrape specimens for HPV detection and for
cytological examination were collected from all study participants.
PCR Strategy: Figure 37 shows a flow diagram of the procedures
employed for sample preparation, PCR testing and confirmation of 
positives. Specimen nucleic acid was to be extracted by boiling and 
'first round1 amplification performed. Reaction products were to be 
dot blotted onto nylon and hybridised with internal specific probes. 
Positive reactions would be confirmed by amplification with 'nested' 
primers with observation of an appropriately sized band on eithidium 
bromide stained agarose gel would be taken as confirmation of 
positivity.
Specimen preparation: Specimens were received in the laboratory on
spatulas in 10ml PBS + antibiotics. These were vortexed for 1 minute 
to dissociate the cells from the spatula which was then removed. The 
cells were pelleted by centrifugation at 2000g for 10 minutes, the 
supernatant discarded and the pellet resuspended in 1ml PBS. This 
suspension was transferred to a 1.5ml microfuge tube and centrifuged 
(2,700g) for 30 seconds. The pellet was resuspended in 100ul TE. A 25ul 
aliquot of this was transferred to a screw-capped eppendorf tube and
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Figure 37
Strategy for PCR screening of cervical scrape specimens
for HPV DNA
Specimen Preparation
PCR screening procedure
Cervical scrape specimen
S/
Cells pellet'.ed
V
Cells washed
Cells boiled to release 
DNA
yf
1st round amplification
Dot blot hybridisation 
with internal probe
Confirmation of positives positives
2nd round nested PCR
agarose gel electrophoresis 
(band size determination)
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Table 24: PRIMER SEQUENCES
LYHPV11-57 
LYHPV11-3'
HPV11-E6-PR0BE 
HPV11-E6-NESTED
LYHPV16-5' 
LYHPV16-3'
HPV16-E6-PROBE 
HPV16-E6-NESTED
HPV31-E6-5 
HPV31-E6-3 
HPV31-E6-PR0BE 
HPV31-E6-NESTED
CGCAGAGATATATGCATATG
AGTTCTAAGCAACAGGCACA
CCTAAAGGTTGTGTGGCGAGACAACTTTCC
ATGCCTATAAGAACCTAAAG
TCAAAAGCCACTGTGTCCTG
CGTGTTCTTGATGATCTGCA
GACAAAAAGCAAAGATTCCATAATATAAGG
CACTGTGTCCTGAAGAAA
GTGTCAAAGACCGTTGTG
TCAGTACGAGGTCTTCTCC
AACGATTCCACAACATAGGAGGAAGGTGGA
CCAACATGCTATGCAACG
the cells disrupted by boiling for 10 minutes as described, 
previously (section 2 method 2.12 ),
PCR method: Following boiling, specimens were centrifuged to pellet
cell debris and an 8ul aliquot of cell lysate added directly to a tube 
containing 42ul reaction mix. Reaction conditions were as described 
previously: 35 amplification cycles were performed. Procedures for 
avoidance of false-positive results were adopted (Section 2 method 2.7) 
Oligonucleotide primers: Table 24 and figure 38 show the DNA sequences 
of the primers employed, their relative positions on the HPV genome 
and the size of product. Oligonucleotide primers used for first round 
amplifications were the LYHPV11, LYHPV16 and HPV31 primers described 
earlier.
Test controls: Amplifications were performed in batches of twenty
reactions including controls. Each batch consisted of 15 test 
samples, 3 HPV-negative cell controls which were, processed in parallel 
with the test specimens, a reagent control (no DNA) and a positive 
control ( 1pg appropriate H P V  D N A ) .
Post amplification analysis: Following amplification, reaction mixes
32were dot blotted onto nylon membranes and hybridised with a P- 
labelled oligonuleotide probe under the conditions previously 
described.I(Method 2.13)
Confirmation of positive reaction: Reaction mixes giving positive dot
blot results were further amplified with a nested primer to confirm 
the specificity of reaction. A  nested primer ie a primer internal to 
one of the first primer pair was designed using the Epicentre primer 
selection program. One microlitre of the first round amplification 
product was transferred to a reaction tube containing the nested 
primer plus the primer for the other DNA strand from the original
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Figure 38: Oligonucleotide primers for the detection 
of HPV types 11,16 and 31
1: HPV11
200
i i i i i r
2 5 0 3 0 0 3 5 0
1st 5 ’p 3 ' p Product
Amplification 2 2 1  2 4 0
. P r o b e  
I. . . . . . . . . . . . . . . . . . . . .
2 5 1
2 9 1
- I
2 8 0
3 1 0 90 bp
2nd 5 '  N e s t e d 3 ' Product
Amplification 2 3 4  2 5 2 2 9 1 3 1 0 77 bp
2: HPV16
4 1 0 4 5 0  5 0 0 5 5 0
1st 5 ' p 3 ' p Product
Amplification 4 2 1  4 4 0
P r o b e  
I. . . . . . . . . . . . . . . . . . . . . . . . . . I
4 6 1  4 9 0
5 2 1 5 5 0 120 bp
2nd 5 '  N e s t e d 3 ' Product
Amplification 4 2 9  4 4 6 5 2 1 5 4 0 112 bp
3: HPV31
4 1 0 4 5 0 5 0 0 5 5 0
1st 5 ’p 3 ' p Product
Amplification 4 2 2 4 4 0
P r o b e  
I. . . . . . . . . . . . . . . . . . . . . . . . . . I
4 7 5  5 0 5
5 2 5 545 123 bp
2nd 5 ’p 3 '  N e s t e d Product
Amplification 4 2 2 4 4 0 5 1 0 5 2 7 106 bp
pair. A further 25 amplification cycles were performed under the same 
conditions and the product analysed by electrophoresis on a 4% 
composite agarose gel followed by ethidium bromide staining. Reaction 
mixes giving a band of the specific size required were deemed 
positive.
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RESULTS
1: Questionnaire Responses
Questionnaires were completed by all study participants; the 
responses are shown in table 25.
Figure 39 shows the age distribution of participants. Ages 
ranged from 16 to 48 years with a median of 24 years. Eighty four 
(67%) participants were less than 27 years of age and 31 of these (25% 
of total) were less than 20 years old. Eighty (61%) were single, 39% 
were married, divorced or seperated. Only 29 (22%) were parous. 
Approximately half were or had at some time been smokers. Over 95% 
were using some form of oral contraceptives. Six participants (4.5%) 
had a history of genital warts but none reported having had genital 
herpes. Figure 40 shows the range of numbers of partners. Ninety 
two participants (74%) had had 3 or less partners with forty of these 
having had only one partner. Twenty (16%) had had 5 or more 
partners. Age of first intercourse (figure 41) ranged from 13 to 29 
years old with 14 (10%) having intercourse before 16 years of age and 
124 (94%) before 20 years of age.
2: Cytology data
Table 26 shows cytology results of cervical scrapes from the 131 
participants. Twelve specimens were unsatisfactory and excluded from 
the study. Of the 119 satisfactory specimens, 99 were negative, 12 
were borderline positive and 5 were mildly dyskaryotic. Thus, in 
total, 20 were considered abnormal. Further investigations revealed 
that 7 of these had had at least one abnormal smear previously. An
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TABLE 25: QUESTIONNAIRE DATA
Responses 131 (100%)
Age 16-48yr, median 24.0 yr
Marital status Single 80 (61%)
Married 40 (30%)
Divorced or 12 ( 9%)
Separated
Parous 29 (22%)
Smoking Now 40 (30%)
Past 27 (21%)
Never 65 (49%)
Oral contraception Yes 126 (95.5%)
No 6 (4.5%)
History of genital Herpes 0
infection Warts 6 (4.5%)
Age at 1st intercourse 13-29 yr, median 17 y]
No. of sexual partners 1-25, median 2
TABLE 26: CYTOLOGY DATA
Grade Subjects
Unsatisfactory 12 (9%)
Negative 99 (76%)
Borderline dyskaryosis 15 (11%)
Mild dyskaryosis 5 (4%)
TOTAL 131
Total Satisfactory 119 (91%)
208
TABLE 27: CYTOLOGY vs HPV STATUS
Cytology
TOTAL
11
HPV type 
16 31 HPV+
i
HPV-
Abnormal
(n = 20)
3(15%) 6(30%) 0 9*(45%) 11(55%)
Normal
(n = 99)
25(25%) 38(38%) 8(7.5%) 54 (54%) 46(46%)
TOTAL
n = 119
28(24%) 44(38%) 8(6%) 63***(53%) 57(49%)
* 2 mixed infections (both 11+16)
** 19 mixed infections (13 11+16, 1 11+31, 5 16+31)
*** 21 mixed infections (15 11+16,1 11+31, 5 16+31)
additional 25 subjects with 'normal' smears currently had had at least one 
grade 2a or grade 3 smear in the past. Thus a total of 45 (34%) subjects 
had a past or present history of mildly abnormal cytology.
3: HPV PCR results
The strategy used for PCR screening of cervical scrapes for HPV types 
11, -16 and -31 employed a nested PCR procedure following dot blot 
hybridisation of first-round amplification products. Some specimens gave 
very weak reactions in dot blot hybridisation of first round amplification 
products and these were confirmed positive or shown to be non-specific using 
the second round amplification. The HPV11 dot blot (figure 42) was 
particularly prone to non-specific positives in that 36 specimens gave weak 
signals of which only 11 were confirmed positive by the second 
amplification. Eighteen specimens were weakly positive for HPV16 by 
dot blot hybridisation of first round amplification products (figure
43) and sixteen of these were confirmed positive by a second 
amplification. Problems with weak dot blot signals were not 
encountered using HPV31 oliogonucleotide primers and probe (figure
44).
Of the 119 specimens tested, 63 (53%) were found to contain at least
|
one of the HPV types tested for. HPV16 was the most prevalent type, found 
in 38% of specimens, with HPV11 and 31 found in 24% and 6% respectively. 
Table 27 shows the HPV detection rates in cytologically normal and abnormal 
specimens. Twenty participants (15%) had mildly abnormal cervical 
cytology at the time of the study. Similar detection rates of HPV 
DNA were found in both groups and no significant differences were 
noted. Analysis of questionnaire data and PCR results revealed no 
statistically significant association ( X2 with Yates correction 
factor) except for HPV positivity and a history of genital warts (X2 =
2.8, df = 1, P<0.1).
4: Comparison of cytology results and questionniare data i
Similar analysis of questionnaire data and cytology results !
revealed no statistically significant association. 1
Figure 39: Age distribution of participants and HPV positivity. Ages 
range from 16 years to 48 years, the median age being 24 years. No 
clear association between age of participant and HPV positivity is 
apparrent.
Figure 40: Number of sexual partners and HPV positivity. Although the 
number of sexual partners of participants ranged from 1 to 25, the 
median was 2 partners. The median number of partners for the HPV- 
positive group was 3 partners whilst that the HPV-negative group was 2 
partners. This association is not statistically significant.
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F ig u r e  39
AGE DISTRIBUTION AND HPV POSITIVITY
12-
No. participants
10-
No. HPV Positive
 ...................
20 30 32 34 30 30 40 42 44 40 40
29 31 33 30 37 39 41 43 40 47
AGE (Years)
Figure 40
SEXUAL PARTNERS v HPV POSITIVITY
No. sexual partners
3 0 -
HPV positive
3 0 -
20-
Z  1 5 -
10-
No. of sexual partners
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/F ig u r e  41
AGE OF FIRST SEXUAL INTERCOURSE 
V HPV POSITIVITY
3 5 -
3 0 -
(X
v
b 20 HCO(X
10-
U
□
Age sexual i/course 
HPV positive
La Ik a O Lr r r i i r r r I i i i " r i i f 
13 15 17 19 21 23 25 27 29
14 16 IB 20 22 24 26 28
Age of first sexual intercourse
Figure 41; Participants age at first sexual intercourse ranged 
from 13 to 29 years of age wih a median of 17 years. No significant 
association between age at first sexual intercourse and HPV 
positivity.
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Figure 42: PCR Screening for HPV11:
i) Dot blot of PCR products following first-round amplification. 
Although several specimens are clearly positive (A5, C5, C10, C12, D5, 
D6, E5, F9) many give weak signals which may represent 'background' 
non-specific hybridisation.
ii) Ethidium bromide-stained gel of subsequent nested PCR on specimens 
in dot blot wells C5-12 and D1-12. Stronger positives (CIO, C12, D5, 
D6, and D8: C5 = positive control) confirmed but weaker signals (eg 
D10-12) were negative, suggesting non-specific dot blot result.
Controls 
C5 C6 C7
| I Specimens
C8 C9 C10 C11 C12 D1 D2
1st-round PCR 
Dot blot
++ + - + w
Nested PCR 
agarose gel
++ ++ ++
Specimens 
D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
1st-round PCR 
Dot blot
+ + +  - + W W W
Nested PCR 
agarose gel
++ ++ ++
w = weak signal
Figure 42: PCR Screening for HPV11
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F ig u r e  4 3 : PCR S c re e n in g  f o r  HPV16:
i) Dot blot of PCR products following first-round amplification. 
Fewer weak positive signals than with HPV11
ii) Ethidium bromide-stained gel of subsequent nested PCR on 
specimens in dot blot wells C12-E8 (well D2 empty). Nested PCR 
confirms weak positives at D7, E1, E7 and E8. Two specimens (D11 and 
E6), negative on first round amplification, were positive on nested 
PCR.
Controls 
C12 D1 D3
I | Specimens 
D4 D5 D6 D7 D8 D9 D10
- w ++ - -1st-round PCR 
Dot blot
++
Nested PCR 
agarose gel
+ ++ ++
Specimens
D11 D12 E1 E2 E3 E4 E5 E6 E7 E8
1st-round PCR 
Dot blot
w w w w
N e s te d  PCR
a g a ro s e  g e l
w + + + + +
Figure 43: PCR Screening for HPV16
1 2 3 4 5 6 7 8 9 10 11 12
i ) A
B
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D
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Figure 44: PCR Screening for HPV31:
i) Dot blot of PCR products following first-round amplification. 
Weakly positive signals were far fewer with HPV31 amplifications than 
with HPV11 and 16 amplifications.
ii) Ethidium bromide-stained gel of subsequent nested PCR 
on specimens in dot blot wells A1-A10, B1-B10. Nested PCR 
confirms positives at A9,although still weak, and positive control at 
B10. No additional positive specimens detected.
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DISCUSSION
The aims of this investigation were two-fold; to determine the 
prevalence of cervical HPV infection in a well-characterised 
population considered to be at low risk of cervical neoplasia and to 
identify risk factors for HPV infection and the development of 
cervical abnormality. The study employed the polymerase chain 
reaction in order to obtain high sensitivity and thus facilitate the 
detection of low copy numbers of HPV DNA ('latent7 infection ).
The population tested
Questionnaire data was collected in order to facilitate 
characterisation of the study population and to attempt elucidation of 
risk factors. Participants were generally in their late teens or early 
twenties. Although the number of sexual partners ranged from one to 25, the 
vast majority had had three or less partners. The age at first intercourse 
was between 14 and 29years, the median age being 17 years. Five 
participants (4.5%) reported a history of genital warts. Cytological 
examination showed that the rate of cervical abnormality in this group was 
low with only 5 participants having grade 3 (CIN I) cytology although a 
further 14 had borderline dyskaryosis. This is in keeping with a low risk 
population.
The strategy for use of PCR
The procedure employed an initial amplification and analysis of 
reaction products by dot blot hybridisation followed by a second 
amplification with a nested primer and analysis of products by agarose 
gel electrophoresis. Dot blot hybridisation was selected for analysis
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of first-round amplification products for two reasons. Firstly, 
comparison of the sensitivity of detection by dot blot hybridisation, 
oligomer hybridisation and Southern blot using radiolabelled 
oligonucleotides showed dot blot hybridisation to be the most 
sensitive (Section 2). Secondly, dot blot hybridisation is also the 
most convenient and inexpensive method for fairly large numbers of 
tests. It was intended that the first amplification would screen out 
all negative specimens and positive results would be confirmed by 
another means. Dot blot hybridisation gives no indication of the size 
of product and thus requires confirmation by agarose gel 
electrophoresis ie Southern blot or oligomer hybridisation. However, 
sometimes very weak signals are visible on dot blot hybridisation 
autoradiograph (figures 42-44 ) and, as these may be below the 
detection limits of Southern blot and oligomer hybridisation, it was 
decided that confirmation of positives would be by a second 
amplification followed by analysis of products on an agarose gel. The 
large numbers of positive results generated by the first amplification 
meant that it was more convenient to process all specimens by the 
second amplification rather than selecting only the dot blot positive 
specimens. Thus, whilst the system employed offered high sensitivity for HPV 
DNA detection, it was now fairly elaborate and expensive.
The prevalence of HPV types 11, 16 and 31
The prevalence of cervical infection with HPV types 11, 16 and 31 
in a Family Planning clinic population was determined. HPV types 11 
and 16 were selected for the study as they appear to be the most 
prevalent types in the cervix and represent 'low-' and 'high risk' 
types respectively for cervical malignancy. HPV 31 was selected for
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inclusion as there was a lack of data on the prevalence of this type
in the UK. HPV16 DNA was detected in 38% of specimens, HPV 11 DNA in
24% and HPV31 in 6%. Several reports have now described the 
application of the PCR for the detection of HPV DNA in clinical
material ^9-95 and those pertaining to the prevalence of
cervical HPV infections have differed widely and conflicting 
conclusions have been drawn by the research groups involved. Whilst
van den Brule who detected HPV16 DNA in only 3.6% of cytologically
normal scrapes conclude that their results "strongly suggest an
important etiological role for HPV in the pathogenesis of cervical
72cancer", Griffin et al , who detected HPV16 DNA in 30% of normal
tissues tested, concluded that "the relations between carriage of
'high' and 'low risk' HPV types and cervical cancer is not as clear
cut as previously thought'. Reports of the prevalence of HPV16 in
cytologically normal cervical material range from 0%7  ^to 90%^5 and it
has been suggested that the high prevalence figures described are due
94to cross-contamination of HPV-negative specimens . Whilst it may be
true that the problem of carryover is affecting the data generated
from some laboratories, there are also other variables ije, test
population, sampling method, PCR primers, which may to differing
extents account for the variation in the reported prevalences. For
example, one group has suggested that there is a 40 to 100-fold
reduction in the sensitivity of PCR when paraffin-embedded specimens
72are used rather than cytological specimens which further suggests 
that it is difficult to compare data from different types of clinical 
specimen. It is also interesting to note that certain reports of the 
prevalence of HPV in cytologically normal cervical material^®, 
determined using less sensitive DNA hybridisation techniques than PCR
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T a b le  28
Factors affecting PCR data for the prevalence 
of cervical HPV infection
Population Factors
Geographic location 
Source GU Med clinic
- Family planning clinic
- random
- convent 
'Normal7- cytologically normal
- histologically normal
- previously positive?
PCR Factors
Specimen tested - cervical scrape
- cervical biopsy
- paraffin- embedded tissue
- cervicovaginal lavage 
PCR primers - genomic region amplified
- consensus/ specific
- Number of cycles 
Post- amplification analysis - agarose gel
- radiolabelled probes
have been higher than those obtained by other groups using PCR®^'^®.
Clearly, other factors, relating to the populations tested and the
procedures employed, are involved (Table 28). These variables include;
i) Geographical location. Detection levels reported may simply reflect true
differences in the prevalence of cervical HPV infections in the country or
region in which the study was carried out. The incidence of cervical
carcinoma varies considerably.from country to country, as does the incidence
in different ethnic groups within the same country. This almost certainly
reflects the state of screening and treatment programs in these countries and
the degree of priority given to cervical neoplasia as a public health
concern. It may also reflect differences in social and sexual practices
which predispose a particular population to the carcinogen(s) (viral and/or
non-viral) or perhaps genetic susceptibilty. Because of the effect of
screening and treatment programmes, the incidence of cervical carcinoma is
not a suitable index of exposure to the causative agent(s). A study by 
125Boone et al , based on the frequency of observation of koilocytes in
cervical smears, has demonstrated that the rates of cervical HPV
infection differ from country to country depending on the prevailing
sexual habits. For example, the prevalence of HPV in Sweden was 56
times that found in China. One would therefore anticipate variation
in PCR data from different countries.
Selection of study population selection is very important. Some
studies have looked at cytologically normal cervical material from females
attending a routine screening clinic or a family planning clinic whilst
others have looked at similar clinical material from females attending
genitourinary medicine clinics. The significance of the source of 'normal'
94cervical material has been demonstrated by the studies of Manos and van den 
Brule^® in which clinical material from several different clinic
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has been examined. Manos looked at three populations; females attending for 
a routine gynaecological examination, a family planning clinic population and 
a student health centre population. The HPV prevalence figures were 41%, 31% 
and 44% respectively with HPV 16 DNA positivities of 11, 0, and 22%. Van den 
Brule compared the prevalence of HPV DNA in material from two populations; 
females attending for routine cytology and a population attending for 
gynaecological abnormalities. HPV prevalences of 6% and 12% were reported 
with HPV16 DNA being found in 3.6% and 5% respectively. Thus, if certain HPV 
types are sexually transmitted, it seems likely that the prevalence of HPV 
infection will be higher in populations- of higher sexual activity even in the 
absence of cervical abnormality on cytological examination. However, there 
are still further complicating factors. The study of van den Brule compares 
the prevalence of HPV infection in females attending for routine cytological 
examination and in females with gynacological 'complaints'. The age range of 
those in the former group is 35-55 years whilst the age range of the second 
group is 18 to 60 years, which suggests that the two populations have not 
been matched. It is difficult then to directly compare the incidence of HPV 
in these two groups on the basis of the clinic population to which they 
belong as any trend may be simply age-related. Some other studies of this 
type lack information regarding the degree of cross-matching of populations 
tested.
ii) Clinical material
The most commonly used specimen taken for HPV detection is the cervical 
scrape as these are performed routinely for cytological examination and thus 
have relatively high patient acceptance. They also are less invasive than 
biopsy, though probably more so than the cervicovaginal lavage which is 
essentially a saline rinse of the vagina and cervix. PCR has also been shown 
to be applicable to histological paraffin wax-embedded blocks, thus
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facilitating retrospective examination of material from a vast number of
sources, although PCR on paraffin-embedded sections has been found to be IQ-
40 times less sensitive than on cytological preparations. Whilst all these
specimen are a suitable substrate for PCR analysis, the specimen examined may
well have a bearing on the results obtained and thus on the implied
prevalence of HPV infection. Cervical scrapes provide material from a large
surface area of the superficial cells of the cervix whilst the lavage samples
sites other than just the cervix, with material from the vagina also yielded.
Cervical biopsy samples a very precise area of the cervix and collects
material from epithelial layers below that sampled by cervical scrape. A
lack of correlation between HPV types found in scrape and biopsy material
12.10
from the same individuals has been reported' and this suggests that
findings by the different methods may not be comparable,
iii) PCR factors:
There are several variables associated with the PCR procedure itself 
including oligonucleotide primers used, number of cycles, temperatures/times, 
size of amplified product, post-amplification analysis procedure. Perhaps the 
most significant variable between the different groups is that of primer 
selection. Primers used vary in several ways including size, GC%, the region 
of HPV DNA to which they are homologous and the size of the amplification 
product. It has been shown that under a given set of reaction conditions, 
different primer pairs will have differing sensitivities (Section 2). However, 
amplification conditions for each pair can be optimised and similar 
sensitivities obtained. Most publications containing PCR data cite a 
sensitivity for their assay, based on detection of cloned DNA or HPV DNA 
within the genome of cell lines (HeLa's, Caski's, SiHa) and these are 
largely comparable, being usually of the order of 10-20 copies of HPV genome. 
However, for these primer pairs to work equally well in clinical material
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within the genome of cell lines (HeLa's, Caski's, SiHa) and these are
largely comparable, being usually of the order of 10-20 copies of HPV genome.
However, for these primer pairs to work equally well in clinical material
would assume that the region amplified was equally well conserved in all wild
strains and that episomal and integrated forms of HPV DNA could be detected
equally well. Little is currently known of the degree of genomic variation
among 'wild' strains of HPV.
It can be seen that there are many variables associated with studies
employing PCR for the detection of HPV DNA. This variation is not peculiar
to PCR; there has been a similar lack of corelation between studies employing
other DNA hybridisation techniques. Prevalences of 0 to 45% for HPV16 or 18
127in normal cervical material using dot blot, Southern blot or filter
in situ hybridisation. The greater sensitivity of PCR has perhaps
accentuated the problem. Given the number of variables that exist,
it perhaps is folly to attempt to extrapolate from data obtained under
a given set of conditions from one population to another.
HPV16 DNA was detected in 38% of cervical scrape specimens from
patients with normal cervical cytology. In similar studies in the UK,
Ward reported the detection of HPV16 DNA by PCR in 51% of normal
95cervical scrape specimens from patients attending local authority
clinics and GP surgeries in the Greater Manchester area for routine
cervical screening and Young reported a prevalence of 50% in
cytologically normal cervical scrapes taken at a routine screening
clinic. Thus, there is a reasonable degree of correlation between the
three studies where study population, specimen tested and
oligonucleotide primers used are very similar. The studies of 
72 93Griffin and Johnson were also carried out in the UK, and employed
52identical oligonucleotide primers to those used by Young and in this
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study. They differ however in that they tested biopsies from women 
undergoing hysterectomies who had no history of cytological 
abnormality. Prevalences of 30% and 90% respectively for HPV16 DNA in 
'normal1 cervical material were reported. Johnson et al tested frozen 
biopsies specimens whereas Griffin examined parafin-embedded biopsies 
and the lower prevalence rate reported by the latter may be explained 
by their own observation that a 40 to 100-fold reduction in 
sensitivity occurs when using paraffin-embedded sections compared to 
frozen sections. The prevalence of HPV16 in this population group 
thus appears to be higher than in FPC and routine colposcopy clinic 
populations. The age of study participants may be significant. Cox^ 
suggested that the prevalence of HPV16 increases with age and in this 
study a predominantly young population was tested (15-48, median 24 
years). In Young's study the population were slightly older (18-45, 
median 27 years). No data regarding the age of the participants in 
the three other studies is given but it would be expected that women 
undergoing hysterectomy would be older than women attending an FPC or 
routine screening clinic. Thus a higher prevalence of HPV16 might be 
expected in that population. Other factors may also be significant. 
Despite variation in the prevalences reported, all five studies 
indicate that, in England, cervical HPV 16 infections are common in 
females without cytological abnormality.
Cytology vs HPV positivity vs questionaire data
There was no association between HPV positivity by PCR and abnormal 
cytology. Indeed, several mildly dyskaryotic scrapes were negative for 
HPV DNA. However, tests for only HPV 11,16 and 31 were included in 
the study and one or more other HPV types may be involved. 
Alternatively, other causes of mild dyskaryosis may be involved.
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Comparison of questionaire responses, cytology status and HPV
95positivity revealed no strong associations.' Ward similarly found 
no significant difference between HPV16 prevalences in patients with 
or without cervical abnormality, although follow-up of a small number 
of patients suggested that patients with mildly abnormal smear were 
more likely to progress to CIN if the cervix harbours HPV16. Wards 
study found that 87.5% of patients with abnormal smears were smokers 
while only 30.5% of patients with normal smears smoked. No such 
association was demonstrated in this study.
Although questionnaire data can be useful in characterising study 
populations, this is essentially retrospective information of 
uncorroborated events of a very personal nature that in some cases 
took place many years previously. Consequently the accuracy of this 
information may be questionable. This is highlighted by the study of 
Evans et al^ which employed a questionnaire in order determine the 
sexual behaviour of women attending a genitourinary clinic and showed 
that up to 28% patients gave altered responses to questions when asked 
identical questions on a second occasion. Thus, elucidation of risk 
factors is not possible, particularly with the small numbers of study 
participants.
This study has determined the prevalence of cervical infections 
with HPV types 11,16 and 31 in females attending a family planning 
clinic. Approximately half the study participants were found to be 
HPV positive and no relationship between HPV infection and cytological 
abnormality was demonstrable. This may lead one to question the 
association of certain HPV types and cervical malignancy. Howver, it 
may be that the number of specimens and the population tested were to 
small and that a larger population sample is required. Also, the
223
development of cervical malignancy is thought to be a multifactorial 
process taking place over a number of years. Consequency patient 
follow-up over a period of many years would be necessary to evaluate 
whether HPV-positive participants had a higher occurence of cervical 
malignancy than those who were HPV-negative.
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SECTION III
CHAPTER 13
DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) DNA BY PCR IN SEMEN 
FROM MALES WITH AND WITHOUT PENILE WARTS
Introduction
Genital human papillomavirus (HPV) infections occur in both sexes
and there is strong evidence to suggest that they can be sexually 
97 98transmitted ' . While many studies have focused on infections of
females, far fewer have examined the prevalence of genital HPV
infection in males, probably due to the comparatively lower frequency
of genital malignancy in males and to difficulties in obtaining
99adequate specimens. Grussendorf et al demonstrated HPV DNA in 5.8%
of penile swabs from the glans and sulcus corona glandis of men
without clinical evidence of genital HPV infection. HPV DNA has also
100 84been demonstrated in semen , urine and in prostatic cancer 
101 102tissue ' suggesting that the urethra and/or prostate are
potential reservoirs of HPV carriage.
The significance of semen as a vehicle in the transmission of
genital HPV infections in unknown. The detection of HPV DNA by
Southern blot hybridisation in human semen from males with intrameatal
1 03penile warts was described earlier (Section 1). HPV6/11 DNA was
detected in 5 of 15 semen specimens but HPV16 DNA was not detected.
HPV DNA levels in semen were very low and at the limit of detection 
(approximately 10® copies/ml semen) by the Southern blot hybridisation
225
procedure employed . PCR has provided a means by which very low copy 
numbers of HPV DNA present in clinical material may be detected.
Studies to determine the prevalence of genital HPV infection in females 
have revealed widespread distribution of the virus in populations in 
which cervical malignancy rates are low. Similar sudies are required 
to determine the extent of virus spread and carriage in males. Here, 
the detection of HPV DNA in semen from males with and without genital 
warts is attempted using the more sensitive polymerase chain reaction 
(PCR).
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METHODS
Study Populations: 29 semen specimens were received from males
attending Department of Genitourinary medicine (GUM), Leeds Infirmary. 
Patients were grouped as follows: Group A were males attending for
the treatment of intrameatal warts (20 specimens received); Group B 
were attending for treatment of genital warts (seven specimens 
received); Group C had no evidence of penile warts (two specimens 
received). These specimens had previously been tested for HPV DNA by 
Southern blot hybridisation (Section 1, Chapter 4).
104 semen specimens were obtained from males attending King's 
College Assisted Conception Unit (ACU) for investigations of 
infertility. Seventy of these specimens had previously been tested by 
Southern blot hybridisation (Section 1, Chapter 4).
DNA extraction for PCR: 400ul of each semen specimen were extracted as 
described previously (Section 2, method 2.11).
Precautions to prevent 'carry-over': Routine precautions for the
prevention of cross-contamination were employed as previously 
described. Controls were included with each batch of DNA extractions 
(3 HPV-negative cell cultures) and amplifications (2 distilled water 
controls and a 100fg cloned DNA positive control).
Polymerase Chain Reaction: Oligonucleotide primers used for the
detection of HPV11 and HPV16 DNA were LYHPV11 and LYHPV16 described 
previously. 8ul extracted semen DNA (approximately 500ng nucleic 
acid) were added to PCR reaction solutions described previously.
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PCR reactions were performed in 50ul volumes using a Cambio MKII 
Intelligent Heating Block as described previously (Section 2, method 
2.3). After 35 amplification cycles, reaction products were analysed 
by oligomer hybridisation.
Results
Semen specimens from patients attending a GUM clinic and an ACU j 
were tested for HPV11 and HPV16 by PCR. All of 20 specimens from |
L i
patients with intrameatal warts (Group A) were positive for HPV 16 and 
19 specimens were also positive for HPV11. Four of 7 specimens from 
males with penile warts (Group B) contained HPV11 DNA and three of 
these also contained HPV16 DNA. One of two specimens from males 
without penile warts (Group C) was positive for HPV16 DNA. Of 104 
semen from patients attending the ACU, 23 (22%) were positive for ■ '[
HPV11 DNA and 35 (33%) were positive for HPV16 DNA. Fifteen specimens j 
contained both HPV types 11 and 16. Southern blot hybridisations had 
previously been performed on 70 of the semen specimens from males !
attending the ACU and on the 29 specimens from males attending a GUM- 
clinic (Section 1,Chapter 4). Table 29 shows the combined Southern
i
blot and PCR data. By Southern blot hybridisation, eight of 20 (40%) j
I
specimens from males with intrameatal warts (Group A) and 1 of 7 (14%) 
specimens from males with penile warts (Group B) were positive for
HPV6/11 DNA. Two specimens from males without penile or intrameatal
! , | 
warts (Group C) were negative as were 70 specimens from the ACU. s
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T a b le  29 : PCR and S o u th e rn  b lo t  h y b r id is a t io n  r e s u lts  f o r  HPV DNA
in semen from men with and without penile warts.
GU Med Clinic 
population
Southern Blot PCR
HPV6/11 HPV16 HPV+ HPV11 HPV16
Group A 
Intrameatal warts 
(n=20) (40%) (40%)
19
(95%)
20
(1 0 0%)
Group B 
Penile warts 
(n=7) (14%) (14%)
4
(56%)
3
(43%)
Group C 
No warts 
(n=2) (50%)
Infertility clinic 
population
(n=104#) 23
(22%)
35
(33%)
a: includes 19 dual HPV11+16 infections
b: includes 3 dual HPV11+16 infections
c: includes 15 dual HPV11+16 infections
#: 104 specimens tested by PCR but only 70 tested by Southern
HPV+
20a
(1 0 0%)
(56%)
1
(50%)
43c
(42%)
blot
Discussion
PCR has been applied to the detection of HPV DNA in semen in 
order to estimate the prevalence of urethral HPV infections in 
populations with low and high incidence of penile warts, to determine 
semi-quantitatively the extent of virus excretion into semen and to 
assess the significance of semen in the transmission of genital HPV 
infections.
In order to determine the extent of HPV shedding into semen, we 
have tested specimens from males attending a GUM Clinic for 
treatment of intrameatal penile warts. By Southern blot, 40% and 0% 
were positive for types 6/11 and 16 respectively. By PCR, all were 
positive for HPV16 DNA and 19 of 20 (95%) positive for HPV6/11. It is 
interesting to note that HPV 16 DNA could be detected in all specimens 
by PCR but in none by Southern blot. We know the limits of detection 
of Southern blot and PCR to be approximately 10 and 10-50 copies HPV 
DNA respectively (Section 1, Chapter 4 and Section 2, Chapter 9). 
Although HPV 16 is shed into semen, clearly the number of viral genome 
copies is lower than that of HPV 6/11. Types 6 and 11 are most 
commonly found associated with condylomatous lesions whereas type 16 
frequently exists in flat pigmented lesions or in clinically 
inapparent lesions1^4. It seems likely that cell shedding will occur 
more readily from condylomatous lesions than from HPV16-related 
lesions and this may explain this observation. Alternatively, the 
viral copy number per infected cell may vary between HPV types. Semen 
from males attending the GUM clinic for treatment of non-intrameatal 
penile warts were also tested and found 56% positive for HPV11 and/or 
HPV16 DNA suggesting that urethral infections are present in 
approximately half of this patient group.
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The prevalence of genital HPV infections in males in the general
population is difficult to determine due to a lack of satisfactory
sampling techniques. Penile scrapes yield only limited amounts of
material but can be useful in sampling outer surfaces of the penis and
areas of the urethra proximal to the urinary meatus. Urine has been
84used to test for urethral carriage of HPV but semen is perhaps more 
useful in investigations of the processes of sexual transmission. 
However, semen specimens from the general population are difficult to 
obtain and it was because of this that semen from males attending 
King's ACU were selected as representative of a population with a low 
incidence (less than 1%; Dr Ruth Curson, King's ACU, personal 
communication) of penile warts. HPV DNA was detected by PCR in 41% of 
specimens tested, 8% containing HPV 11 DNA only, 19% HPV16 DNA only 
and 14% containing both HPV11 and 16 DNA. When tested by Southern 
blot, however, no HPV DNA was detected. Following PCR, ethidium 
bromide staining of electrophoresed amplified products revealed only 
faintly visible DNA bands and oligomer hybridisation was required for 
clear visualisation of positive specimens, demonstrating that only 
very small quantities of HPV DNA (1 — 1 Ofg of DNA equivalent to 
approximately 100 genome copies)were present. As no in vitro culture 
system for HPV is currently available, it is not possible to determine 
whether the DNA detected represents infectious virus.
These data suggest that urethral HPV infections, as indicated by 
the presence of HPV DNA in semen, are prevalent among populations in 
which the incidence of clinically apparent genital warts is low. 
Further assessment of the significance of semen in the transmission of 
genital HPV infections, particularly 'high-risk' types, awaits the 
development of a suitable in vitro culture system.
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CHAPTER 14
DETECTION OF HPV DNA IN PENILE SCRAPE MATERIAL FROM MALES 
ATTENDING A GENITOURINARY CLINIC
Introduction
Further to earlier investigations which demonstrated the presence
of HPV DNA in semen, detection in penile scrape material is now
reported. Whilst it seems clear that the male may act as a reservoir
of infection, mechanisms of transmission have not been elucidated.
Direct contact between infected epithelia on the external surfaces of
the penis may occur and HPV DNA has been demonstrated in penile
99scrapes of healthy males . The demonstration of HPV DNA in semen 
suggests that semen may act as a vehicle in the transmission of 
genital HPV infections. HPV types 6/11 and 16 have been found 
associated with morphologically different penile lesions and an 
earlier study suggested that copy number within infected cells may 
differ between the two HPV types. Routes or mechanisms of 
transmission of different HPV types therefore may also vary.
Examination of penile scrape material from the urethra and from 
the glans penis for the presence of HPV type 11 and 16 DNA has been 
performed in order to determine whether either HPV type is 
particularly associated with infection of internal or external penile 
surfaces. The results will also indicate the prevalence of penile HPV 
infections in males attending a Genitourinary medicine clinic.
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Methods
Specimen Sources; Fourty eight males atttending a GUM clinic were 
asked to complete questionnaires relating to age and sexual activity 
(number of sexual partners, history of sexually-transmitted disease^ 
etc). Clinical specimens were collected from the urethra and glans 
penis of each participant. Urethral specimens were taken by insertion 
of a plastic loop into the distal urethra. Specimens were taken from 
the glans penis and meatus using a wooden spatula as used for cervical 
scrapes. Specimens were placed in 10mls PBS + antibiotics in sterile 
universal containers.
Method: In the laboratory, specimens were vortexed for 30 seconds to
dissociate cellular material from the loop or spatula. Three cell 
controls, suspensions of baboon kidney cells, were processed in 
parallel with test specimens. Specimens were centrifuged at 1000g 
(2150 rpm MSE Chillspin) for 5 minutes, the supernatant discarded and 
cell pellet resuspended in 1ml PBS. Cell suspensions were 
transferred to microfuge tubes, centrifuged for 30 seconds and 
resuspended in 50ul PBS. Cell counts were obtained on a 1ul aliquot 
added to 9ul trypan blue (0.5% in saline) and counted in a Neubauer 
chamber. The remaining 49ul were boiled for 10 minutes and placed on 
ice for 2 minutes. An 8ul aliquot was added to a PCR reaction mix 
containing the appropriate oligonucleotide primers and amplification 
was carried out as described. 20ul of each amplification mix was 
tested by oligomer hybridisation as described previously.
Primers: Specimens were tested with oligonucleotide primers LYHPV11
and LYHPV16 for the detection of HPV types 11 and 16. Specimens were
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also tested with oligonucleotide primers for the B-globin gene 
(described by Saiki et al ) in order to confirm the presence of 
cellular DNA and to demonstrate its suitability for amplification.
PCR and post-amplification procedures: Thirty five amplification
cycles were performed under conditions described previously (Section
2, method 2.3). Following amplification, reaction mixes were analysed
32by oligomer hybridisation with P-labelled internal probes (Section 
2, method 2.6).
Results
Participants questionaire responses and PCR results are shown in 
Table 30.
Questionaire Responses
Questionaires were received from all participants of the 
study. Responses are presented in Table 31. The age range was from 
19-47 years with a median of 26 years. The number of lifetime sexual 
partners ranged from 1 to greater than 10. One participant (2.1%) had 
had a single sexual partner during their lifetime whilst 37.5% had had 
greater than 10. One third of patients had had only one partner 
during the last year but 21% had had more than 3 sexual partners 
during this time. Three (6.2%) of the 48 participants currently had 
genital warts, one had had a past infection. Almost half of the 
participants (46%) had at some time been diagnosed as having a 
sexually transmitted disease. Six patients (12.5%) reported sexual 
contact with persons with genital warts; two further patients had 
partners who had had abnormal cervical smear results at some time,
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Sample Success Rate
PCR results obtained from loop and spatula specimens are summarised in 
Table 32. Two methods of sampling were performed in order to 
investigate the localisation of the different HPV types on external or 
internal penile surfaces. Specimens from 48 participents were tested. 
Comparison of PCR results obtained with B-globin primers for both 
specimens revealed differing sampling efficiencies. Forty four of 48 
loop specimens (91.6%) were B-globin positive whilst only 16 of 48 
(33.3%) of penile scrape specimens were positive. Four patients were 
excluded on the basis of loop and scrape specimens both giving 
negative PCR results with B-globin primers.
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Table 30
U = Urethral 
G = Glans penis 
= years
12/12 = number of sexual partners in last year
Life = number of sexual partners in lifetime
STD = STD in the past
warts = genital warts in the past
contact = sexual contact at some time with 
individual with genital warts 
ab smear = sexual contact at some time with
individual who has had an abnormal 
cervical smear
Results + = PCR positive by oligomer hybridisation
- = PCR negative by oligomer hybridisation 
w = weak PCR positive by oligomer 
hybridisation
Sample
Age
Partners
History
Table 30: Questionairre Responses and PCR Results
Patient
No.
Sample Age Partners 
12/12 life
History ]
11
Results 
16 B-'
1 U 19 >3 ng none - + +
G - + +
2 U 33 ng ng STD - - -
G - - +
3 U 25 2-3 ng contact + + -
G + + -
4 U 24 1 ng STD w + +
G - w -
5 U 32 2-3 ng STD + - -
G - - -
6 U 29 1 ng none - + -
G - - -
7 U 26 >3 ng STD - - +
G - + +
8 U 29 2-3 ng none - + -
G - - -
9 G 23 >3 10 STD - - -
U - - +
10 G 20 2-3 2-5 none - - +
U - + +
11 G 23 >3 >10 STD - - +
U - - +
12 G 45 1 2-5 none - - w
U - - +
13 G 47 2-3 >10 STD - - -
U - - +
14 G 32 >3 >10 ab smear - - +
U - - +
15 G 35 2-3 6-10 none - - -
U - - +
16 G 25 >3 6-10 none - - -
U - - +
17 G 21 1 2-5 STD,contact - - -
U + + +
18 G 24 >3 >10 none - - +
U - - +
19 G 19 2-3 >10 none - - -
U - - +
20 G 32 2-3 >10 STD - - -
U + + +
21 G 23 >3 >10 STD - - +
U + - +
22 G 20 2-3 2-5 warts,contact - - -
U w + w
23 G 22 >3 >10 STD,contact - - -
U - - -
24 G 44 2-3 >10 STD - - -
U - - +
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Table 30 (cont'd)
Patient Sample Age Partners History Results
No. 12/12 life 11 16 B-glob
25 G 20 2-3 2-5 STD _ _ +
U - - +
26 G 22 1 6-10 contact - - -
U - w w
27 G 25 1 6-10 none - - -
U - - w
28 G 45 2-3 6-10 none - - +
U - + w
29 G 20 2-3 2-5 contact + + -
U + + +
30 G 32 2-3 >10 warts - - -
U + + -
31 G 36 1 6-10 STD - - -
U + - +
32 G 33 2-3 >10 none - - -
U + + +
33 G 45 1 >10 none - - _*
U - - -
34 G 19 2-3 6-10 none - - -
U + + +
35 G 22 1 1 none - - _*
U - - -
36 G 36 2-3 >10 STD - - -
U + + +
37 G 28 2-3 >10 ab smear - - _*
U - - -
38 G 36 2-3 >10 STD - - w
U - + w
39 G 38 1 >10 STD - - -
U - - +
40 G 37 1 2-5 STD - - -
U - + +
41 G 22 >3 >10 none - - w
U - - +
42 G 25 1 2-5 none - - -
U - - +
43 G 24 1 2-5 none - - +
U - - +
44 G 27 2-3 2-5 warts,STD w - -
U + - +
45 G 22 1 2-5 none - - _*
U - - -
46 G 33 1 2-5 none - - -
U - - +
47 G 30 1 6-10 warts,STD - - -
U - - +
48 G 29 2-3 2-5 none - - -
U - - +
* : These patients were excluded from study as inadequate specimens
were provided
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Table 31: Questionnaire Responses
Response
Age:
Number of sexual partners:
48 (100%)
19-47y, 
median 26y, mean 28.7y
During i) Last 12 months
ii) Lifetime
Not given 
1
2-3 
>3
Not given 
1
2-5
6-10
>10
Genital warts - current infection 
- past infection
History of STD 
Contact history3 - HPV
- Abn Sm
1 (2 .1%) 
16 (33.3%)
21 (43.7%) 
10 (20.8%)
8 (16.7%) 
1 (2 .1%) 
13 (29.2%)
9 (16.7%)
18 (37.5%) 
3 (6.2%)
1 (2 .1%)
22 (45.8%) 
6 (12.5%)
2 (4.2%)
a Contact history - HPV; Study participants having had sexual contact 
with individuals with genital warts.
- Abn Sm; Study participants having had sexual 
contact with individuals who have undergone clinical investigations for 
abnormal cervical cytology.
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Table 32
PCR Results: HPV Prevalence and Sampling Efficiencies
) Prevalence: HPV positive specimens 52.3% (23/44)
type 11 8.3% (4/44)
type 16 25.0% (11/44)
types 11/16 16.7% (8/44)
) Loop v spatula
i) Adequate loop specimens from 91.6% (44/48)
Adequate spatula specimens from 33.3% (16/48)
ii) Specimen v HPV type 
Loop specimens
Spatula specimens
n=44
n=1 6
22 (50%) HPV negative 
4 (9%) HPV11 positive
10 (22%) HPV16 positive
8 (18%) HPV11+16 positive
11 (69%) HPV negative
2 (12%) HPV16 positive
3 (17%) 11+16 positive
ii) Where both specimens adequate,
Both specimens negative 
Both specimens yield same types 
Only loop positive 
Only spatula positive
16 patients 
8 (50%)
4 (25)
3 (18.7%) 
1 (6 .2%)
Correlation of loop and spatula results 12 (75%)
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HPV Prevalence
Of 44 patients, 23(52.3%) were positive for HPV11 and/or 
HPV16 in loop and/or spatula specimens. HPV results obtained are 
presented in Table 32. HPV16 was the most common type, found alone in 
11 patients (25%) and together with HPV11 in a further 8 specimens,
(a total of 41% of patients. HPV11 was detected in 4 patients as a
single infection and in 12 (25%) of patients overall.
HPV type vs specimen type
Of forty four (B-globin-positive) loop specimens, 22 (50%) 
specimens were positive for HPV DNA. Four (9%) were positive for 
HPV11 DNA, 10 (22%) for HPV16 DNA and a further 8 (18%) were positive 
for both.
Only 16 spatula specimens gave adequate specimens for inclusion 
of which 5 (31%) were positive for HPV DNA. All five contained HPV16 
DNA while 3 (18.75%) also contained HPV11 DNA.
Loop v spatula from same patients
Both loop and spatula specimens were adequate from only 16 of the 
48 patients. Of these, 8 were negative for both loop and spatula
specimens, 4 were positive with the same type(s) detected in both the
loop and the spatula (1 type 16, 3 11/16). Three were positive in the 
loop only (2 HPV16, 1 type 11) and from 1 patient only the spatula was 
positive (type 16). Overall, the same results obtained for both 
specimens from 12 of 16 (75%) patients tested.
HPV status vs Questionnaire data
Questionnaires were received from all participants of the
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study. The age range was from 19-47 years with a median of 26 years. 
The mean age of the HPV-positive group was 27.9 years compared to the 
mean age of the HPV-negative group of 29.4 years (Table 33, 1)).
Thus there was no significant difference in terms of age between HPV 
positive and HPV-negative individuals.
No correlation was found between HPV status and the number of 
sexual partners of the participant either lifetime or during the past 
twelve months (Table 33, 2)). One participant (2.1%) had had a single 
sexual partner during their lifetime whilst 37.5% had had greater than 
10. One third of patients had had only one partner during the last 
year but 21% had had more than 3 sexual partners during this time. 
Overall, the average number of sexual partners of the HPV-positive 
group was slightly lower than that of the HPV-negative group.
Fourty six percent of participants had previously been diagnosed 
as having a sexually transmitted disease. Of these, 11 (55%) were 
HPV-positive and 9 were HPV-negative. Exactly half of those attending 
the clinic for the first STD occurrence were HPV-positive.
Participants with genital warts (n=3) were all found to be HPV 
positive, one with HPV 11, one with HPV16 and one with both types.
One participant had a history of genital warts in the past but 
specimen(s) from this patient were HPV negative.
Six participants reported sexual partners with genital warts.
The current sexual partners (at the time of sampling) of two of these 
had genital warts. Only one participant of the six had genital warts  ^
currently or in the past. Five of the six participants were HPV DNA 
positive, three with both types HPV11 and 16, two with HPV type 16 
alone. Thus a high prevalence of HPV infection could be demonstrated 
in people known to have had sexual partners with genital warts.
240
Table 33
HPV Status v Questionaire Data
1) Age Banding
AGE_______<20 21-5 26-30 31-35 36-40 >40
HPV +ve 
HPV -ve 
Total
5 (71) 
2 (29) 
7
5 (36) 
9 (64) 
14
4 (67) 
2 (33) 
6
4 (50) 
4 (50) 
8
4 (80) 
1 (2 0 )
5
1 (25)
3 (75)
4
2) Number of sexual partners 
12 months Lifetime
NG 1 2-3 >3 Total NG 1 2-5 6-10 >10 Total
HPV+ 0 6 14 3 23 7 0 6 4 6 23
(46) (70) (30) (87) (50) (50) (37)
HPV- 1 7 6 7 21 1 0 6 4 10 21
(54) (30) (70) (12) (50) (50) (62)
Total 1 13 20 10 44 8 0 12 8 16 44
() = % of that category of patient
3) History of STD
HPV+ve
HPV-ve
Total
Yes
11 (55.0) 
9 (45.0)
20
No
12 (50.0) 
12 (50.0) 
24
Total
23
21
44
4) Current genital warts/ History of genital warts 
Yes No Total
HPV+ve 3 (75) 20 (50) 23
HPV-ve 1 (25) 20 (50) 21
Total 4 40 44
HPV+ve
HPV-ve
Genital warts 
Current 
3 
0
History of 
0 
1
5) Contact/Partner history 
Yes
HPV+
HPV-
Total
5 (62.5) 
3 (37.5) 
8 (22.2)
No
18 (50)
18 (50)
36 (81.8)
Total
23
21
44
HPV+
HPV-
Partner History 
Warts Abnormal smear
5 0
1 2
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Discussion
The aims of this investigation were two-fold; firstly, to 
determine the prevalence of penile infection with HPV types 11 and 16 
in males attending a genitourinary clinic and, secondly, to determine 
whether infection with particular HPV types was associated with 
internal or external penile surfaces. A minor part of the study was 
to examine information provided by participants and to identify any 
risk factors for HPV infection in males. The overall prevalence of
HPV infection in this population was 52%. HPV16 was the most
prevalent type being found in 25% of the population and in an 
additional 17% as a mixed infection with HPV type 11. HPV11 was found 
in a further 8% of the population as a single infection. This 
demonstrates that penile HPV infection is common in this population
The second aim was to compare HPV types located in the urethra 
and on the surface of the glans in order to determine whether 
infection with a particular HPV type was localised to cell populations 
of either area of the penis. However this was not possible as
sampling methods were shown not to be of comparable sensitivity. A
high proportion of specimens (67%) obtained by scraping a wooden 
spatula across the surface of the penis were inadequate. A plastic 
loop inserted into the urethra gave adequate cellular material in over 
90% of cases. Whilst it seems likely that this variation was purely 
quantitative ie. loop specimens yielded more cells, an alternative 
explanation may be that one sampling method is more prone to 
contamination with non-specific inhibitors of Taq polymerase. Testing 
all specimens with primers to 'house-keeping' genes such as the B- 
globin primers used here confirms that sufficient cellullar material 
of adequate purity has been obtained by a particular sampling method.
Adequate loop and spatula specimens were obtained from only 16 
patients. Of these 12 (75%) gave identical results from both loop and 
spatula. Three patients were positive in the loop only and one was 
positive in the spatula only. Overall, 50% of loop specimens were 
positive for HPV DNA whereas only 31% of spatula specimens were 
positive. These observations may suggest that urethral infection 
with HPV is more common than infection of the glans but, given the 
differing efficiencies of the two sampling methods, this conclusion 
cannot be drawn. There was no correlation between HPV types and 
sampling method employed and both HPV types were found in specimens 
from the urethra and/or glans, suggesting that HPV types 11 and 16 may 
infect either area of the penis. However, the number of specimens 
tested was very small and is insufficient for statistical analysis.
Questionnaire data was collected from study participants. Whilst 
this information allowed assessment of participants in terms of 
factors likely to predispose an individual to infection, no 
significant correlation between HPV status and age, number of sexual 
partners or a history of sexually transmitted disease could be 
identified. HPV positivity did correlate well with sexual contact 
with a partner with warts and all participants with current genital 
warts were HPV-DNA positive.
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SECTION FOUR
CHAPTER 15
FINAL DISCUSSION
The initial aim of this study was to determine whether HPV types
associated with cervical malignancy could be detected in semen, in
order to assess the significance of semen in the transmission of
genital HPV infections. Semen specimens were tested from two patient
populations; patients attending a GUM clinic for the treatment of
penile warts and other sexually-transmitted infections and patients
attending an ACU for investigations of infertility. The latter group
were selected as a population in which the prevalence of penile warts
was low, and because large numbers of specimens were available from
this source. Having established a DNA extraction procedure for semen,
detection of human papillomavirus DNA was first attempted using dot
blot and Southern blot hybridisation assays. Problems of non-specific
hybridisation were encountered using dot blot hybridisation but, using
Southern blot hybridisation, HPV type 6/11 DNA was demonstrated in 40%
of specimens from males with intrameatal penile warts. This was the
103first report of 'genital type' HPV DNA being demonstrated in semen . 
HPV 6/11 DNA could not be detected in semen from attenders of the 
Assisted Conception Unit. HPV types 16 and 18 were not detected in 
either population suggesting that these types are either not shed into 
semen or are shed at levels below those detectable by Southern blot 
hybridisation. Studies were performed to localise HPV DNA within 
positive specimens but these were greatly hindered by the small number 
and quantity of HPV-positive material. If semen is centrifuged at low 
speed, the HPV DNA is associated with the cell pellet rather than the
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supernatant, suggesting that the virus is not present as free virions. 
When HPV DNA-containing semen is fractionated on a Percoll gradient, 
it was shown to be present in the upper fractions in which epithelial 
cells are found. This suggests that that the HPV DNA is associated 
with epithelial cells rather than with the spermatozoa which do not 
band but are distributed throughout the gradient. Further studies 
employing immunocytochemistry and in situ hybridisation were performed 
on a small number of specimens. Although there was some suggestion of 
positivity by both techniques a precise localisation was not possible.
As only 40% of specimens from males with current intrameatal 
warts (ie a current urethral infection with HPV) were shown to contain 
HPV DNA, this raised the possibility that HPV DNA was shed into semen 
in quantities below the sensitivity of Southern blot hybridisation 
(shown to be approximately 10  ^copies/ml), and that the more sensitive 
technique, the Polymerase Chain Reaction (PCR), may be a more 
appropriate procedure for determination of the true prevalence of HPV 
DNA in semen.
At this time, PCR was in its earliest infancy, with only a few 
reports having been described using the technique. Initial aims were 
to confirm the suitability of PCR for the detection of HPV DNA and to 
optimise conditions for the primers employed. Primers for the
detection of HPV11 and 16 were taken from a study by Young et al as
52these were reported to give good sensitivity and specificity .
Using identical primers would also allow direct comparison of data 
obtained with those of Young. Primers for the detection of HPV31 had 
not been reported and so these were selected empirically from reported 
sequence data, as were internal probe sequences for HPV11, 16 and 31. 
Having established the basic parameters including primer, enzyme and
magnesium concentrations and the number of amplification cycles 
required, other factors relating to the suitability of PCR for use in 
medium/large scale epidemiological were considered. Specimen preparation 
procedures for studies of this sort should ideally be rapid and simple, as 
elaborate procedures are more likely to be susceptible to contamination.
For cervical scrape specimens, washing collected cells followed by boiling 
was found to be adequate pretreatment. Post-amplification procedures were 
also compared. Dot blot hybridisation was found to be the most sensitive 
procedure but required confirmation of specificity. Southern blot 
hybridisation gave good results in terms of specificity but was rather less 
sensitive. Oligomer hybridisation was found to be convenient but rather
variable in the quality of result produced, particularly when using labelled
32P-dCTP a week or more past its activity date. Other primer pairs were 
evaluated including 'anti-contamination' primers. These primers were shown 
to be able to differentiate between laboratory manipulated and 'wild' virus 
DNA although they would amplify laboratory manipulated viral DNA if 
recircularisation had occurred. Sensitivity of detection was far lower
3
using these primers (approximately 10 copies for both HPV11 and 16) than 
using LYHPV11 or 16 primers (10-100 copies ).
Having applied and optimised PCR procedures, detection of HPV DNA in 
clinical specimens was performed. Although the aim was to apply PCR to the 
detection of HPV in semen, cervical scrape material was initially tested for 
two reasons. Firstly, cervical material has been studied using other 
hybridisation procedures (dot blot, Southern blot, filter in situ 
hybridisation) by many research groups and could therefore act as a point of 
reference for PCR studies. No similar research had been performed on semen. 
Some groups had at this time reported initial PCR findings on cervical 
material and again this would allow direct comparison with this study.
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Secondly, the true prevalence of cervical HPV infection was still unclear 
and, if the data obtained were combined with data on the prevalence of male 
genital HPV infections (as indicated by the presence of HPV DNA in semen), 
a clear picture of the epidemiology of genital HPV infections could emerge.
The prevalence of infection with HPV types 11, 16 and 31 was studied by 
PCR testing cervical scrape material from 132 females attending the 
Northampton FPC. The test was designed in such a way to provide a 
sensitive, specific procedure which could be used in epidemiological 
studies, employing a nested PCR procedure. Of the 125 specimens tested, 63 
(50%) were found to contain at least one HPV type. HPV 16 was the most 
prevalent type (38% specimens positive), with HPV types 11 and -31 found in 
24% and 6% respectively. No differences in detection rates were observed 
between cytologically normal and abnormal populations.
PCR was then used for the detection of HPV 11 and -16 DNA in semen
from males attending the GUM clinic and the ACU. By PCR, HPV types 11
and/or -16 were shown to be present not only in all semen specimens from
males with intrameatal penile warts and in 56% of specimens from patients
with non-intrameatal penile warts, but also in 41% of specimens submitted to
the ACU. Although this population was considered low risk for penile warts
(incidence <1%), it cannot be assumed to reflect the incidence of urethral
HPV shedding in the general population as it is a selected group. The
incidence of sexually-transmitted infections may be higher in this group
than in an unselected group and consequently the prevalence of genital HPV
infections in this population may be higher than in the general public.
Certain other sexually transmitted infectious agents (Neisseria gonorrhoeae,
Treponema pallidum, Chlamydia trachomatis, mycoplasma hominis, ureaplasma
urealyticum) have been suggested as having an aetiological role in 
117infertility . Infectious agents which cause inflammation of the
248
genital tract may reduce female fertility by interfering with the
transmission of spermatozoa and ova , or by interfering with
fertilisation or the implantation of the fertilised ovum. Agents
which affect the testicles may reduce spermatogenesis, cause formation
of abnormal spermatozoa, reduce sperm motility and/or block the sperm
ducts and hence reduce male fertility. During the last fifteen years,
there has been increasing interest in C. trachomatis as a causal agent
of reproductive failure. C. trachomatis is an important cause of non-
118gonococcal urethritis and possibly of epididymitis and is
considered the main aetiological agent in pelvic inflammatory disease 
1 1 9(PID) , ectopic pregnancy and sterility, with culture-positive
120chlamydial infection found in upto 50% of infertile women . Gorini 
121et al demonstrated C. trachomatis infection in 32% of infertile
women and only 5.8% of fertile subjects. Thus, an increased incidence
of sexually-transmitted infections may be expected in this population
compared to the general population.
The demonstration of HPV DNA in semen confirms earlier
observations that the urethra may act as a reservoir of HPV 
fi4 99 10*3infection' ' and supports the suggestion that semen has a
83 84 103potential role in the transmission of genital HPV infections ' ' .
Infection (and re-infection) of females may occur via HPV-infected
epithelial cells which have sloughed off urethral lesions into semen
during ejaculation. Alternatively, seminal fluid may become
1 02contaminated due to infection of the prostate gland . However,
studies have shown that HPV lesions are not restricted to the urethra
but are present on external surfaces of the genitalia. Males with
genital HPV infection exhibit lesions on the foreskin, shaft of the
122penis, the glans and periurethral areas . These lesions are often
249
present as very minor epithelial abnormalities and have been referred
98 123to as subclinical HPV infections ' . Despite their inconspicuous
morphology, the potential for transmission by direct
infected/uninfected epithelial contact exists. Thus sexual
transmission by direct contact or via semen may occur.
Both the studies^determine the prevalence of HPV infection in
cervical specimens from patients attending a family planning clinic
and to determine the prevalence of urethral infection (as indicated by
HPV DNA in semen) from males attending an ACU suggest that genital HPV
infections are common (over 40% of both populations tested). This
perhaps suggests that transmission by the sexual route is not the only
mechanism. This is supported by evidence suggesting vertical 
128transmission , by the demonstration of prevalent genital-type HPV
129infections in pre-school children and by demonstration of apparent
130genital HPV infection in virginal females . This study has
demonstrated the potential of semen to transmit HPV infection but
determination of the significance of non-sexual transmission in the
natural history of HPV infection has not been carried out.
Significant progress in attempts to develop an in vitro culture
131 132system for HPVs has been made during the past two years ' and, 
although routine culture of HPVs from clinical specimens remains a 
prospect for the future, elucidation of the natural history of HPV 
infection awaits further developments in this area.
A second question raised is whether the widespread prevalence of 
apparent cervical HPV infection undermines the association of HPV 
infections with cervical carcinoma. There is considerable evidence 
both from epidemiological and in vitro transformation studies 
supporting the association of genital HPV infection and cervical
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carcinoma (see Chapter 1 for review). Also, infections with certain
DNA viruses associated with human malignancy (eg Epstein Barr virus)
are common yet malignancy occurs in only a very small percentage of
infected individuals, suggesting that other factors (enviromental,
social, immunological, genetic) are involved and that infection with
the virus alone is not sufficient to precipitate development of
malignancy. Thus parallels with other tumorigenic DNA viruses exist.
Prevalent genital HPV infection and low frequency of malignant
progression are not incompatable with an aetiological role for HPV in
cervical malignancy.
The third question relates to the role of PCR in the detection of
genital HPV infections. For cervical screening purposes, a detection
system is required which predicts at an early stage the likely
progression of latent or benign infections to a premalignant or
malignant state. The sensitivity of PCR may make it useful in
detection of subclinical infection but detection of low level HPV DNA
per se has no predictive value. Since raised viral copy number may be
important in malignant progression, quantitative PCR may have far
133greater clinical utility m  this regard . Alternatively, detection
of specific transcripts of HPV genomic regions associated with
94malignant conversion may similarly be of greater predictive value. 
However, serological assays have increasingly been shown to be useful 
in showing specific antibody rises to HPV epitopes associated with 
malignancy in cervical cancer patients. If it is demonstrated that 
antibody rises can be shown sufficiently early to allow clinical 
intervention and thus prevent malignant progression, given the 
widespread capability of routine diagnostic laboratories to perform 
large-scale serological screening programs, a serological means of
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screening is perhaps a more realistic option for the near future.
An area where the potential for transmission by semen may be
particularly important is that of artificial insemination by donor
(AID). To date, Neisseria gonorrhoeae, Trichomonas vaginalis,
Ureaplasma urealyticum, Streptococcal species, Mycoplasma hominis,
human imunodeficiency virus (HIV), Chlamydia trachomatis and hepatitis
B virus have all been transmitted unwittingly from donor semen to
124inseminated women . Because of these occurrences, screening
procedures are performed before acceptance of a donor. Men
who have had sexual contact with another man or a female prostitute
are excluded as are men who have a history of sexually transmitted
disease, multiple sexual partners, intravenous drug use or blood
transfusion (within one year) in themselves or their partners.
Laboratory investigations for infectious agents are also performed.
These include serological tests for HIV and hepatitis B virus and
culture from the semen for cytomegalovirus, Chalmydia, Neisseria
gonorrhoeae, Ureaplasma urealyticum and Mycoplasma hominis,
Streptococcal species and Trichomonas vaginalis. There have been no
reports to date of HPV or herpes simplex virus infection (HSV) by AID.
In the case of HSV, this may be because semen donors with current or a
history of genital herpes would be rejected. Similarly, donors with
frank penile warts would be rejected but donors with subclinical
penile HPV, the lesions most commonly associated with 'high risk1 HPV
types 16 and 18, would not be rejected on this basis. An option is
examine potential donors more rigorously for subclinical infection,
12^including examination for acetowhite lesions and employing
go 104
peniscopy (also called colposcopy ). There is also, perhaps, a
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need for a screening test for HPV in semen. Here, molecular methods 
for HPV DNA detection in semen have been assessed. Dot blot and 
Southern blot-based techniques are unsuitable because of problems with 
specificity and sensitivity. PCR has been shown to be able to detect 
HPV DNA in semen but does not necessarily detect only infectious 
virus and may lead to exclusion of semen specimens which offer no risk 
of HPV infection to the recipient. In the meantime, therefore, 
current guidelines for the examination of semen donors, complemented 
with peniscopic examination, may offer the most appropriate screening 
system.
253
REFERENCES FOR SECTIONS 2 ,
254
3 AND 4
REFERENCES FOR SECTIONS 2, 3 AND 4
1 : Saiki RK, Scharf S, Faloona F, Mullis K, Horn G, Erlich HA,
Arnheim N. 1985. Enzymatic amplification of B-globin genomic 
sequences and restriction site analysis for diagnosis of sickle cell 
anemia. Science; 230; 1350-1354
2: Chien A, Edgar DB, Trela JM. 1976. Deoxyribonucleic acid polymerase 
from the extreme thermophile Thermus acruaticus. J Bacteriol; 127; 3; 
1550-57
3: Wilde J, Eiden J, Yolken R. 1990. Removal of inhibitory
substances from faecal specimens for detection of group A rotaviruses 
by reverse transcriptase and polymerase chain reaction. J Clin 
Microbiol; 28; 1200-07
4: de Franchis R, Cross NCP, Foulkes NS, Cox TM. 1988. A potent
inhibitor of Taq polymerase copurifies with human genomic DNA. Nuc 
Acid Res; 16; 21; 10355
5: Kawasaki E.1989. Amplification of RNA sequences via complementary
DNA (cDNA) . Amplifications; 1;3; 4-6
6: Johnson MA, Blomfield PI, Bevan IS, Woodman CBJ, Young LS. 1990.
Analysis of human papillomavirus type E6-E7 transcription in cervical 
carcinomas and normal cervical epithelium using the polymerase chain 
reaction. J Gen Virol; 71; 1473-79
7: Rotbart HA. 1990. Enzymatic amplification of the enteroviruses.
J Clin Micro; 28; 3; 438-42
8: Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B,
Fang Z-Y. 1990. Polymerase chain reaction amplification and typing of 
rotavirus nucleic acid from stool specimens. J Clin Microbiol; 28; 2; 
276-82.
9: Hart C, Schochetman G, Spira T, Lifson A, Moore J, Galphin J,
Sninsky J, Ou C-Y. 1988. Direct detection of HIV RNA expression in 
seropositive persons. Lancet;ii; 596-99
10: Ochman H, Medhora MM, Garza D, Hartl DL. 1990. Amplification of
flanking sequences by inverse PCR. Chap 27;219-227 In; Innis MA, 
Gelfand DH, Sninsky JJ, White TJ (eds): PCR protocols; A guide to
methods and applications. Academic Press, London
11; Higuchi R, Krummel B, Saiki RK. 1988. A general method for in 
vitro preparation and site specific mutagenesis of DNA fragments: 
study of protein and DNA interactions. Nucl Acid Res; 16; 7351-7367
255
12: Clewley JP. 1989. The polymerase chain reaction; a review of
the practical limitations for human immunodeficiency virus diagnosis.
J virol Methods; 25; 179-87.
13: Kwok S, Higuchi R. 1989. Avoiding false positives with PCR.
Nature; 339; 237-8
14: Kitchin P, Szotyori Z Fromholc C, Almond N. 1990. Avoidance
of PCR false positives. Nature; 344; 201
15: Sarkar G, Sommer SS. 1990. Shedding light on PCR contamination.
Nature; 343; 27
16: Deragon J-M, Sinnett D, Mitchell G, Potier M, Labuda D. 1990.
Use of g irradiation to eliminate DNA contamination for PCR. N A R;
18; 20; 6149
17: Porter-Jordan K, Rosenberg El, Keiser JF, Gross JD, Ross AM,
Nasim S, Garrett CT. 1990. Nested polymerase chain reaction assay 
for the detection of cytomegalovirus overcomes false positives caused 
by contamination with fragmented DNA. J Med Virol; 30; 85-91 
18: Knoth K, Roberts S, Poteet C, Tamkun M. 1988. Highly degenerate,
inosine-containing primers specifically amplify rare cDNA using the 
polymerase chain reaction. Nuc Acid Res; 16; 10932 
19: Hewlett IK, Ruta M, Cristiano K, Hawthorne CA, Epstein JSW.
1989. Co-amplification of multiple regions of the HIV-1 genome by the 
polymerase chain reaction : potential use in multiple diagnosis. 
Oncogene; 4; 1149-51
20: Kazazian, Jnr HH. 1989. Use of PCR for the diagnosis of monogenic 
disease. In : PCR technology: Applications and principles of DNA
amplification. Erlich H (ed). New York, Stockton Press, pp153-169 
21: Pinckert TL, Lebo RV, Golbus MS. 1989. Rapid determination of
foetal sex by deoxyribonucleic acid amplification of Y chromosome- 
specific sequences. Am J Obstet Gynecol; 161; 693-8 
22: Coutelle C, Williams C, Handyside A, Hardy K, Winston R,
Williamson R. 1989. Genetic analysis of DNA from single human 
oocytes: a model for preimplantation diagnosis of cystic fibrosis. Br 
Med J; 299; 22-4
23: Feldman G, Williamsen R, Beaudet A, O'Brien W. 1988. Prenatal
diagnosis of cystic fibrosis by DNA amplification for detection of KM- 
19 polymorphism. Lancet ii:102-103
256
24: Lyonnet S, Caillard C, Rey F, Berthelon M, Frezal J, Rey J,
Munnich A. 1988. Guthrie cards for detection of point mutations in 
phenylketonuria. Lancet; ii; 507
25: Williams C, Weber L, Williamson R, Hjelm M. 1988. Guthrie spots
for DNA-based carrier testing in cystic fibrosis. Lancet;ii; 693 
26: Morel PA, Dorman JS, Todd JA, Mcdevitt HO, Trucco M. 1988.
Aspartic acid at position 57 of the HLA DQ beta chain protects against 
type 1 diabetes; a family study. Proc Natl Acad Sci; 85; 8111-5 
27: Scharf SJ, Long CM, Erlich HA. 1988. Sequence analysis of the
HLA-DR beta and HLA-DQ beta loci from three pemphigus vulgaris 
patients. Hum immunol; 22; 61-69
28: Bugawan TL, Horn GT, Long CM, Mickelson E, Hansen JA, Ferrara GB,
Angelini G, Ehrlich HA. 1988. Analysis of HLA-DP allele sequence 
polymorphism using the in vitro enzymatic amplification of DP-alpha 
and DP-beta loci. J immunol; 141; 4024-30
29: Oksenberg JR, Sherritt M, Begovich AB, Ehrlich HA, Bernard CC, 
Cavalli-sforza LL, Steinman L. 1989. T-cell receptor V alpha and C 
alpha alleles associated with multiple sclerosis and myasthenia 
gravis. Proc Natl Acad Sci;86; 988-92
30: Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell
JI. 1989. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate 
that DRB1 is the major susceptibility locus within the HLA class II 
region. Proc Natl Acad Sci USA; 86; 10049-10053
31: Gyllensten VB, Erlich HA. 1988. Generation of single stranded
DNA by the polymerase chain reaction and its application to direct 
sequencing of the HLA-DQA locus. Proc Natl Acad Sci USA; 85; 7652- 
7656 •
32: Kitchin PA. 1990. Clinical applications of the polymerase chain
reaction. Int J STD Aids;1; 161-73
33: Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON,
McCormick FP. 1988. Diagnosis of chronic myeloid and acute 
lymphocytic leukaemias by detection of leukaemia-specific mRNA 
sequences amplified in vitro. Proc Natl Acad Sci USA; 85; 5698-5702 
34: Lee MS, Chang KS, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo
JM, Stass SA. 1988. Detection and minimal residual bcr/abl 
transcripts by a modified polymerase chain reaction. Blood; 72; 893- 
97
257
35: Larzul D, Chevrier D, Guesdon J-L. 1989. A non-radioactive
diagnostic test for the detection of HBV DNA sequences in serum at the
single molecule level. Molec Cell Probes; 3; 45-57
36: Harper ME, Marselle LM, Gallo RC, Wong-Staal F. 1986. Detection
of lymphocytes expressing HTLV III in lymphnodes and in peripheral 
blood from infected individuals by in situ hybridisation. Proc Natl 
Acad Sci USA; 83; 772-776
37: Pang S, Koyangi Y, Miles S, Wiley C, Vinters HV, Chen ISY. 1990.
High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia 
patients. Nature;343; 85-89
38: Horsburg CR Jnr, Ou CY, Jason J, Holmberg SD, Longini Jnr IM,
Schable C, Mayer K H, Lifson AR, Schochetman G, Ward JW, Rutherford 
GW, Evatt BL, Seage III GR, Jaffe HW. 1989. Duration of human 
immunodeficiency virus infection before detection of antibody.
Lancet; ii; 637-40
39: Laure F, Courgnaud V, Rouzioux C, Blanche S, Veber F, Jacomet C,
Burgard M, Griscelli C, Brechot C. 1988. Detection of HIV1 DNA in
infants and children by means of the polymerase chain reaction.
Lancet; ii; 538-41
40: Clavel F. 1987. HIV-2, the West African AIDS virus. AIDS; 1;
135-40
41: Rayfield M, DeCock K, Heyward W. 1988. Mixed human
immunodeficiency virus (HIV) infection of an individual: 
demonstration of both HIV type 1 and HIV type 2 proviral sequences by 
polymerase chain reaction. J inf Dis; 158; 1170-76 
42: Ou C-Y, Kwok S, Mitchell SW, Mack DH, Sninsky J, Krebs JW,
Feorini P, Warfield D ,  Schochetman G. 1988. D N A  amplification for 
direct detection of HIV-1 in D N A  of peripheral blood mononuclear 
cells. Science ; 239; 295-97
43: Ou C-Y, Robbins K, Jason J, Horsburgh CR jr, Evatt B, Schpchetman
G. 1989. Direct analysis of genetic diversity and evolution of HIV 
in infected persons using polymerase chain reaction (PCR). Abstr Int 
Conf AIDS, 5th, Montreal; 1; 580
44: Demmler GJ, Buffone GJ, Schimbor CM, May RA. 1988. Detection of
CMV in urine from newborns using polymerase chain reaction DNA 
amplification. J inf Dis; 158; 1177-84
258
45: Sixbey JW, Shirley P, Chesney PJ, Buntin DM, Resnick L. 1989. 
Detection of a second widespread strain of Epstein-Barr virus.
Lancet; ii; 761-65
46: Forsey T, Mawn JAQ, Yates PJ, Bentley ML, Minor PD. 1990.
Differentiation of vaccine and wild mumps viruses using the polymerase 
chain reaction and dideoxynucleotide sequencing. J Gen Virol; 71; 
987-90
47: Jeffreys AJ, Wilson V, Neumann R, Keyte J. 1988. Amplification
of human minisatellites by the polymerase chain reaction: towards DNA 
fingerprinting of single cells. Nucl Acid Res; 16; 10953-71 
48: Higuchi R, von Beroldingen CH, Sensabaugh GF, Erlich HA. 1988.
DNA typing from single hairs. Nature; 332; 543-6
49: Guisti A, Baird M, Pasqulae S, Balazs I, Glassberg J. 1986. J
For Sci: 31; 409-17
50: Li H, Gyllensten UB, Cui X, Saiki RK, Erlich HA, Arnheim N.
1988. Amplification and analysis of DNA sequences in single human 
sperm and diploid cells. Nature; 335; 414-17
51: Ostrow RS, Manias DA, Clark BA, Okagaki T, Twiggs LB, Faras AJ.
1987. Detection of human papillomavirus DNA in invasive carcinomas of 
the cervix by in situ hybridisation. Cancer Res; 47; 649-53 52:
52 Young LS, Bevan IS, Johnson MA, Blomfield PI, Bromidge T,
Maitland NJ, Woodman CBJ. The polymerase chain reaction: a new 
epidemiological tool for investigating cervical human papillomavirus 
infection. BMJ; 298; 14-18.
53 Goldsborogh M, DiSilvestre D, Temple GF, Lorincz AT. 1985. 
Nucleotide sequence of human papillomavirus type 31: a cervical 
neoplasia-associated virus. Virol; 171; 306-11
54 Kellogg DE, Kwok S: Detection of human immunodeficiency virus: 
Chapter 40 337- In: Innis MA, Gelfand DH, White TJ and Sninsky JJ: 
PCR protocols; a guide to methods and applications. Academic press 
1990
55 Shibata DK, Arnheim N,Martin WJ. 1988. Detection of Human 
papillomavirus in paraffin-embedded tissue using the polymerase chain 
reaction : J exp Med; 167; 225-230.
56 Pater MM, Pater A.1985. Human papillomavirus types 16 and 18 
sequences in carcinoma cell lines of the cervix. Virology; 145; 313— 
318
259
57 Boshart M, Gissman L, Ikehberg H, Kleinheinz A, Scheurlen W, zur 
Hausen H. 1984. A new type of papillomavirus DNA, its presence in 
genital cancer biopsies and in cell lines derived from cervical 
cancers. EMBO J; 3; 1151-17
58 T i n d a l l  K R ,  K u n k e l  T A .  1988. F i d e l i t y  o f  D N A  s y n t h e s i s  b y  t h e  
T h e r m u s  a q u a t i c u s  D N A  p o l y n e r a s e .  B i o c h e m ;  27; 6008-13
59 Longo MC, Berninger MS, Hartley JL. 1990. Use of uracil DNA 
glycosylase to control carry-over contamination in polymerase chain 
reactions. Gene; 93; 129-134
60 van den Brule AJC, Claas ECJ, du Maine M, Melchers WJG, 
Helmerhorst T, Guint WGV, Lindeman J, Meijer CJLM, Walboomers JMM.
1989. Use of anticontamination primers in the polymerase chain 
reaction for the detection of human papillomavirus genotypes in 
cervical scrapes and biopsies. J Med Virol; 29; 20-27
61 V a n d e n v e l d e  C, V e r s t r a e t e  M ,  V a n  B e e r s  D. 1990. F a s t  m u l t i p l e x  
p o l y m e r a s e  c h a i n  r e a c t i o n  o n  b o i l e d  c l i n i c a l  s a m p l e s  f o r  r a p i d  v i r a l  
d i a g n o s i s .  J V i r o l  M e t h o d s :  30; 215-228
62 Clewley JP. 1991. The Polymerase Chain Reaction: Basic 
procedures and use for virus detection. In: Methods in Gene 
Technology: Volume 1; JAI Press Ltd, pp219-238
63 Kogan SC, Doherty M, Gitschier J. 1987. An improved method for 
prenatal diagnosis of genetic diseases by analysis of amplified DNA 
sequences; Applications to Haemophilia A. New Eng J Med; 317; 
985-990
64 Rodu B. 1990. Molecular biology in medicine. The polymerase 
Chain Reaction: the revolution within. Am J Med Sciences: 299; (3);
210-216
65 Syrjanen KJ. 1989. Epidemiology of Human papillomavirus 
infections and their association with genital squamous cell cancer. 
Acta Pathol Microbiol immunol Scand; 97; 957-970
66 Cox MF, Meanwell CA, Maitland NJ, Blackledge G, Scully C. Jordan 
JA. 1986. Human papillomavirus type 16-homologous DNA in normal 
human ectocervix. Lancet;ii; 157-8
67 Toon PG, Arrand JR, Wilson LP, Sharp DS. 1986. Human 
papillomavirus infection of the uterine cervix of women without 
cytological signs of neoplasia. Br Med J; 293; 1261-4
260
68 Wickendon C, Steele A, Malcolm ADB, Colman DV. 1987. Prevalence of 
HPV DNA and viral copy numbers in cervical scrapes from women with 
normal and abnormal cervices. J Pathol;153; 127-135 cervical scrapes.
69 Melchers W, van den Brule A, Walboomers J, de Bruin M, Herbink P, 
Meijer C, Lindeman J, Quint W. 1989. Increased detection rate of human 
papillomavirus in cervical scrapes by the polymerase chain reaction as 
compared to modified FISH and Southern-blot ananlysis. J Med Virol;
27; 329-335.
70 Cornelissen MTE, van den Tweel JG, Struyk APHB, Jebbink MF, Briet 
M, van der Noordaa and Schegget JT. 1989. Localisation of human 
papillomavirus type 16 DNA using the polymerase chain reaction in the 
cervix uteri of women with cervical intraepithelial neoplasia. J Gen 
Virol; 70; 2555-2562.
71 Syrjanen S, Saastamoinen J, Chang F, Hongxiu J, Syrjanen K. 1990. 
Colposcopy, punch biopsy, in situ DNA hybridisation and the polymerase 
chain reaction in searching for genital human papillomavirus (HPV) 
infections in women with normal PAP smears. J Med Virol; 31; 259-266
72 Griffin NR, Bevan IS, Lewis FA, Wells M, Young LS. 1990 . 
Demonstration of multiple HPV types in normal cervix and in squamous 
cell carcinoma using the polymerase chain reaction on paraffin wax 
embedded material. J Clin Pathol; 43; 52-56
73 Tidy JA, Parry GCN, Ward P, Coleman DV, Peto J, Malcolm ADB, 
Farrell PJ. 1989. High rate of human papillomavirus type 16 infection 
in cytologically normal cervices. Lancet; Feb 25 1989 434
74 Dallas PB, Flanagan JL, Nightingale BN, Morris BJ. 1989.
Polymerase Chain reaction for fast, non-radioactive detection of high- 
and low-risk papillomavirus types in routine cervical specimens and in 
biopsies. J Med Virol;27; 105-11
75 Bevan IS, Blomfield PI, Johnson MA, Woodman CBJ, Young LS. 1989. 
Oncogenic viruses and cervical cancer. Lancet;i; 907-08.
76 Chow VTK, Tham KM, Bernard HU. 1990 . Thermus aquaticus DNA 
polymerase-catalysed chain reaction for the detection of human 
papillomaviruses. J Virol Methods; 27; 101-113
261
77 Chow V, Tham Km, Yeo-Gloss M, Lim-Tan SK, Sng I, Thirumoorthy T, 
Bernard H-U. 1990 : Molecular diagnosis of genital HPV DNA types by
polymerase chain reaction and sensitivity-standardised filter in situ 
hybridisation in randomly sampled cohorts of Singapore women.
Molecular and Cellular Probes 4; 121-131
78 Gregoire L, Arella M, Campione-Piccardo J, Lancaster WD. 1989 . 
Amplification of Human papillomavirus DNA sequences by using conserved 
sequences. J Clin Microbiol; 27; 2660-2665
79 He Y-K, Zhang J-Z, Xu Q, Gao J-M.1989 . Detection of human 
papillomavirus DNA in cervical cancer tissue by the polymerase chain 
reaction. J Virol Methods ; 26; 17-26.
80 Levi JE, Delcelo R, Alberti VN, Torlini H, Villa LL. 1989 ;Human 
papillomavirus DNA in respiratory papillomatosis detected bvin situ 
hybridisation and the polymerase chain reaction: Am J Pathol 135; 6; 
1179-1184
81 M a i t l a n d  N J ,  B r o m i d g e  T ,  C o x  M F ,  C r a n e  I J ,  P r i m e  S S ,  S c u l l y  C .
1989: Detection of human papillomavirus genes in human oral tissue 
biopsies and cultures by polymerase chain reaction; Br J Cancer;59; 
698-703.
82 Mcdonnell JM, Mayr AJ, Martin WJ. 1989. DNA of human 
papillomavirus type 16 in dysplasic and malignant lesions of the 
conjunctiva and cornea. New Eng J Med; 320; 22; 1442-1446
83 M c N i c o l  PJ, D o d d  JG. 1990. D e t e c t i o n  o f  h u m a n  p a p i l l o m a v i r u s  D N A  
i n  p r o s t a t e  g l a n d  t i s s u e  b y  u s i n g  t h e  p o l y m e r a s e  c h a i n  r e a c t i o n  
a m p l i f i c a t i o n  a s s a y .  J C l i n  M i c r o ;  28; 3 ; 409-412.
84 Melchers WJG, Schift R, Stolz E, Lindeman J, Quint WGV. 1989.
Human papillomavirus detection in urine samples from male patients by 
the polymerase chain reaction. J Clin Micro; 27; 1711—14
85 M o r r i s  B J ,  F l a n a g a n  J L ,  M c K i n n o n  K J ,  N i g h t i n g a l e  B N .  1988. 
P a p i l o m a v i r u s  s c r e e n i n g  o f  c e r v i c a l  l a v a g e s  b y  p o l y m e r a s e  c h a i n  
r e a c t i o n .  L a n c e t ;ii; 1368
86 Pao CC, Lin C-Y, Maa J-S, Lai C-H, Wu S-Y, Soong Y-K. 1990: 
Detection of human papillomaviruses in cervicovaginal cells using 
polymerase chain reaction. J Inf Dis;161; 113-15
87 Shibata DK, Fu YS, Gupta JW, Shah KV, Arnheim N, Martin WJ. 1988: 
Detection of human papillomavirus in normal and dysplastic tissue by 
the polymerase chain reaction. Lab Invest; 59; 4; 555-559
262
88 Snijders PJF, van de Brule, Schrijnemakers HFJ, Snow G, Meijer 
CULM, Walboomers JMM. 1990 . The use of general primers in the 
polymerase chain reaction permits the detection of a broad spectrum of 
human papillomavirus genotypes. J Gen Virol; 71; 173-181.
89 Tidy JA, Vousden KH, Farrell PJ. 1989 . Relation between infection 
with a subtype of HPV16 and cervical neoplasia. Lancet; i; 1225-1227
90 Ting Y, Manos M. Detection and typing of genital human 
papillomaviruses. 1990. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ 
(eds): PCR protocols: a guide to methods and applications. San Diego: 
Academic press; 356-67.
91 Ward P, Parry GN, Yule R, Coleman DV, Malcolm ADB.1989 . Human 
papillomavirus subtype 16a.Lancet;ii; 170
92 X i a o  X ,  C a o  M ,  M i l l e r  TR, C a o  Z - Y ,  Y e n  TSB. 1988. P a p i l l o m a v i r u s  
D N A  i n  c e r v i c a l  c a r c i n o m a  s p e c i m e n s  f r o m  c e n t r a l  C h i n a .  L a n c e t ; i i ;
902.
93 Johnson MA, Blomfield PI, Bevan IS, Woodman CBJ, Young LS. 1990. 
Analysis of human papillomavirus type 16 E6-E7 transcription in 
cervical carcinomas and normal cervical epithelium using polymerase 
chain reaction. J Gen Virol; 71; 1473-79
94 M a n o s  M M ,  L e e  K, G r e e r  C, W a l d m a n  J, K i v i a t  N, H o l m e s  K ,  W h e e l e r  C.
1990. L o o k i n g  f o r  H u m a n  p a p i l l o m a v i r u s  t y p e  16 b y  PCR; L a n c e t ;  i; 734
95 W a r d  P ,  P a r r y  G N ,  Y u l e  R, C o l e m a n  DV, M a l c o l m  ADB. 1990. 
b e t w e e n  p o l y m e r a s e  c h a i n  r e a c t i o n  a n d  s l o t  b l o t
hybridisation for the detection of HPV sequences in cervical scrapes. 
Cytopathology; 1; 19-23
96 Evans BA, Bond RA, Macrae KD. 1988. Sexual behaviour in women 
attending a genitourinary clinic. Genitourin Med; 64; 43-48.
97 Wickendon C, Hanna N ,  Taylor-Robinson D et al; Sexual transmission 
of human papillomaviruses in heterosexual and male homosexual couples, 
studied by DNA hybridisation: Genitourinary medicine; 1988 64; 34-38
98 Schneider A, Kitchmayr R, de Villiers EM, Gissmann L. 1988. 
Subclinical human papillomavirus infections in male sexual partners of 
female carriers. J Urol; 140; 1431-34
99 Grusendorf-Conen E-I, Meinhof W, de Villiers E-M, Gissman L. 
Occurrence of HPV genomes in penile smears of healthy men. Arch 
Dermatol Res 1987 279; S73-S75
100 O s t r o w  R S ,  Z a c h o w  K R ,  N i m u r a  M ,  O k a g a k i  T ,  M u l l e r  S ,  B e n d e r  M ,  
F a r a s  A J .  1986. D e t e c t i o n  o f  p a p i l l o m a v i r u s  D N A  i n  s e m e n .  S c i e n c e ;  
231 ; 731-33
101 McNicol PJ, Dodd JG. 1990. Detection of human papillomavirus DNA 
in prostate gland tissue by using the polymerase chain reaction 
amplification assay. 1990. J Clin Microbiol; 28; 3; 409-412
102 McNicol PJ, Dodd JG. 1990. Detection of papillomavirus DNA in 
human prostatic tissue by Southern blot analysis. Can J microbiol;36; 
359-362.
103 Green J, Monteiro E, Gibson P .  1989. Detection of human 
papillomavirus DNA in semen from patients with intrameatal penile 
warts. Genitourin Med; 65; 357-60
104 Selvey L, Buntine DW, Kennedy L, Frazer IH. 1989. Male partners 
of women with genital human papillomavirus infection: An assessment of 
colposcopic abnormalities by histological examination and human 
papillomavirus hybridisation. Med J Aust; 150; 479-481
105 Pustell J, Kafatos FC. 1986. A convenient and adaptable 
microcomputer enviroment for DNA and protein manipulation and 
analysis. NAR; 14; 479-88
106 Innis MA, Gelfand DH. 1990. Optimisation of PCRs. In: Innis MA, 
Gelfand DH, Sninsky JJ, White TJ (eds). PCR protocols; a guide to 
methods and applications, pps 3-12. Academic Press, London
107 Durst M ,  Scharwz E, Gissman L .  1986. Integration and 
persistence of human papillomavirus DNA in genital tumours. In: Viral 
etiology of cervical cancer. Banbury Report 21. Peto R, zur Hausen H 
(Eds). Cold Spring Harbor. NY
108 Awady MK, Kaplan JB, O'Brien SJ, Burk RD. 1989. Molecular 
analysis of integrated human papillomavirus 16 sequences in the 
cervical cancer cell line SiHa. Virology; 159; 389-98
109 B a k e r  CC. 1987. S e q u e n c e  a n a l y s i s  o f  p a p i l l o m a v i r u s  g e n o m e s .  I n :  
T h e  p a p o v a v i r i d a e ;  t h e  p a p i l l o m a v i r u s e s .  S a l z m a n  N P ,  H o w l e y  P M  ( E d s ) .  
321-385. P l e n u m  P r e s s ,  N e w  Y o r k .
110 Chan S - Y ,  Ho L, Ong C-K, Chow V, Drescher B, Durst M, Ter Meulen 
J, Villa L, Luande J, Mgaya HN, Bernard H-U. 1992. Molecular 
variants of human papillomavirus type 16 from four continents suggest 
ancient pandemic spread of the virus and its coevolution with 
humankind. J Virol;66;(4); 2057-2066
264
111 de Franchis R, Cross NCP, Foulkes NS, Cox TM. 1988. A potent 
inhibitor of Taq polymerase copurifies with human genomic DNA. N A R:
16; 10355
112 Wilde J, Eiden J, Yolken R. 1990. Removal of inhibitory 
substances from human fecal specimens for detection of group A 
rotaviruses by reverse transcriptase and polymerase chain reactions.
J Clin Microbiol; 28; 1300-1307
113 Boom R ,  Sol CJA, Salismans MMM, Jansen CL, Wertheim-van Dillen 
P M E ,  van der Noordaa J. A rapid and simple method for purification of 
nucleic acids. J Clin Microbiol; 28;(3);495-503
114 Mercier B, Gaucher C, Feugeas 0, Mazurier C.1990. Direct PCR from 
whole blood without DNA extraction. N A R : 18; (19); 5908
115 Skryabin BV, Khalchitsky SE, Kuzjmin AI, Kaboev OK, Kalilnin VN, 
Schwartz El. 1990. A crude lysate of cells immobilised on solid 
support can serve as a matrix for enzymatic DNA amplification. NAR;
18; (14); 4289
116 Arthur R R ,  Dagostin S, Shah K V .  1989. Detection of B K  virus and 
JC virus in urine and brain tissue by the polymerase chain reaction.
J Clin Microbiol; 27; (6); 1174-79
117 Taylor-Robinson D. 1990. Clinical significance of genital 
chlamydial and mycoplasma infections, pps 19-39. In: Csonka GW, Oates 
JK (eds). Sexually transmitted diseases; a textbook of genitourinary 
medicine. Balliere Tindall; London England
118 Doble A, Taylor-Robinson D, Thomas BJ, Jalil N, Witherow RO'N.
1989. Acute epididymitis ; a microbiological and ultrasonic study. B J 
Urol; 63; 90-94
119 Cates W Jr, Rolfs RT, Aral SO. 1990. Sexually transmitted 
diseases, pelvic inflammatory disease and infertility; an 
epidemiologic update. Epidemiological Reviews; 12; 199-220
120 Kane JL, Woodland RM, Forsy T, Daringer S, Elder MG. 1984.
Evidence of Chlamydial infection in infertile women with or without 
fallopian tube obstruction. Fertil Steril; 42; 843-48
121 Gorini G, Milano F, Olliaro P, Regazetti A, Rondanelli EG. 1990. 
European J Epidemiol; 6; (3); 335-338
122 Kennedy L, Buntine DW, O'Connor D, Frazer IH. 1988. Human 
papillomaviruses - a study of male sexual partners. Med J Aust; 149; 
309-311
265
123 Campion MJ, McCance DJ, Mitchell HS, Jenkins D/ Singer A. 1988. 
Subclinical penile human papillomavirus infection and dysplasia in 
consorts of women with cervical neoplasia. Genitourin Med; 64; 90-99
124 Mascola L, Guinan ME. 1987. Semen donors as the source of 
sexually transmitted diseases in artificially inseminated women; the 
saga unfolds. J Amer Med Assoc; 257; (8); 1093-1094
125 B o o n e  ME, D e n g  Z, B a o w e n  G, R y d  W. 1986. K o i l o c y t e  f r e q u e n c y  i n  
p o s i t i v e  c e r v i c a l  s m e a r s  a s  i n d i c a t o r  o f  s e x u a l  p r o m i s c u i t y .  L a n c e t ;  
i; 205
126 Hallam N, Gibson P, Green J, Charnock M. 1989. Detection and 
typing of human papillomavirus infection of the uterine cervix by dot 
blot hybridisation; Comparison of scrapes and biopsies. J Med Virol:
27; 317-321
127 Munoz N, Bosch X, Kaldor JW. 1988. Does human papillomavirus 
cause cervical cancer? The state of the epidemiological evidence. Br 
J Cancer ; 57; 1-5
128 Sedlacek TV, Lindheim S, Eder C. 1989. Mechanisms for human 
papillomavirus transmission at birth. Am J Obstet Gynecol: 161; 55-59
129 J e n i s o n  S A ,  Y u  XP, V a l e n t i n e  J M ,  K o u t s k y  L A ,  C h r i s t i a n s e n  A E ,  
B e c k m a n n  A M ,  G a l l o w a y  D .  1990. E v i d e n c e  o f  p r e v a l e n t  g e n i t a l - t y p e  
h u m a n  p a p i l l o m a i r u s  i n f e c t i o n s  i n  a d u l t s  a n d  c h i l d r e n .  J  I n f  D i s ;
162: 60-69
130 Pao CC, Tsai PL, Chang Y-L, Hsieh T-T, Jin JY. 1992. non-sexual 
papillomavirus transmission routes. Lancet; 339; 1479-1480
131 stoler MH, Whitbeck A, Wolinsky SM, Broker TR, Chow LT, Howett 
MK, Kreider JW. 1990. Infectious cycle of human papillomavirus type 
11 in human foreskin xenografts in nude mice. J Virol; 64; (4); 
3310-3318
132 S t e r l i n g  J, S t a n l e y  M ,  G a t w a r d  G ,  M i n s o n  T. P r o d u c t i o n  o f  h u m a n  
p a p i l l o m a v i r u s  t y p e  16 v i r i o n s  i n  a  k e r a t i n o c y t e  c e l l  l i n e .  J V i r o l ;  
64; (12) 6305-6307
133 Morrison EA, Goldberg GL, Kadish AS, Burk RD. 1992. Polymerase 
chain reaction detection of human papillomavirus: quantitation may 
improve clinical utility. J Clin Microbiol; 30; (10); 2539-43
266
Acknowledgment
I  w i s h  t o  t h a n k  D r  P G  S a n d e r s ,  D r  P E  G i b s o n ,  D r  J  D a l e  a n d  D r  S  
G a r d n e r  f o r  t h e i r  h e l p f u l  s u p e r v i s i o n  a n d  a d v i c e ,  p a r t i c u l a r l y  D r  
S a n d e r s  f o r  t h e  c o n s i d e r a b l e  t i m e  a n d  e f f o r t  h e  h a s  i n v e s t e d  i n  t h i s  
T h e s i s .
I  w i s h  t o  t h a n k  m y  c o l l a b o r a t o r s  i n  t h e  v a r i o u s  s t u d i e s ;  D r  N F  
H a l l a m ,  D r  E  M o n t e i r o  a n d  D r  V N  B o l t o n .  I  a l s o  w i s h  t o  t h a n k  D R  N F  
H a l l a m  f o r  h e l p f u l  a d v i c e  t h r o u g h o u t  t h i s  w o r k .
I  t h a n k  D R  P P  M o r t i m e r  a n d  D R  D W G  B r o w n  f o r  t h e i r  e n c o u r a g e m e n t  
p a r t i c u l a r l y  d u r i n g  t h e  l a t t e r  s t a g e s  o f  p r e p a r i n g  t h i s  t h e s i s .  I  
a l s o  g r e a t l y  a p p r e c i a t e  t h e  h e l p  o f  M r  J o n  W h i t e  f o r  h i s  h e l p  w i t h  
t h e  a r t w o r k .
L a s t l y ,  I  w i s h  t o  t h a n k  f r i e n d s ,  c o l l e a g u e s ,  a n d  m e m b e r s  o f  m y  f a m i l y ,  
p a r t i c u l a r l y  m y  w i f e ,  w h o  h a v e  h e l p e d  a n d  e n c o u r a g e d  m e  t h r o u g h o u t  
t h i s  w o r k .
267
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
